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FoxO transcription factors:  Master regulators of the biology of aging 
Aging is the leading risk factor for cancer and heart disease, as well as the majority of 
adult diseases.  By improving our understanding of the biology of aging, we hope to 
uncover strategies to interfere with the underlying aging process, and as a result prevent 
or mitigate the effects of age-associated diseases.    
FoxO transcription factors play important roles in the biology of aging; understanding the 
regulation of these factors promises to shed light on the aging process and illuminate new 
therapeutic targets for the treatment of age-associated diseases.  FoxO transcription 
factors were first implicated as regulators of longevity in the round worm C. elegans. 
Reducing insulin/insulin-like growth factor signaling (ILS) or ablating the germline 
extends C. elegans lifespan in a manner dependent on the FoxO transcription factor DAF-
16.  The reduction of ILS is also known to enhance mammalian longevity, suggesting 
potential conservation of the lifespan-promoting role of FoxO transcription factors. 
Recent evidence supports this hypothesis, as studies in multiple independent human 
cohorts have found that specific FoxO polymorphisms are associated with extreme 
longevity.  Additionally, evidence supports roles for FoxO in modulating age-associated 
diseases in humans, including cancer, Type 2 diabetes, and osteoporosis. Increasing 
FoxO activity protects against tumor development and osteoporosis, but is also sufficient 
to induce metabolic dysregulation.  The ability to modulate FoxO activity is therefore 
desirable as a potential therapeutic strategy to combat the progression of cancer, Type 2 
diabetes, and potentially other age-associated diseases.  Moreover, understanding the 
regulatory mechanisms controlling FoxO activity will likely contribute to our broader 
understanding of the biology of aging. 
The current paradigm for the regulation of the FoxO family of transcription factors is that 
activity is dependent on subcellular localization of the factor; when FoxO is in the 
cytoplasm, its function as a transcription factor is inhibited.  When it is in the nucleus, 
FoxO is active and can initiate transcriptional programs controlling cell cycle 
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progression, stress resistance and apoptosis.  In C. elegans and in mammals, insulin 
activation of the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway causes 
phosphorylation of FoxO by Akt, resulting in cytoplasmic sequestration and consequent 
inhibition of the transcription factor.   In worms, ILS reduction or germline removal 
causes DAF-16/FoxO to translocate to the nucleus, increasing its activity.  Nuclear DAF-
16/FoxO induces transcriptional programs that promote longevity.   
Nuclear localization is necessary for DAF-16/FoxO activity, however, evidence indicates 
that it is not sufficient for full activation of the transcription factor, suggesting the 
existence of a second pathway controlling DAF-16/FoxO.  Our lab has recently 
discovered the EAK pathway, a conserved pathway which inhibits the C. elegans DAF-
16/FoxO by a novel mechanism.   
The EAK pathway was identified in a genetic screen for enhancers of an akt-1 mutant 
phenotype.  In animals deficient in AKT-1, DAF-16/FoxO accumulates in the nucleus but 
is not fully active.  The akt-1 mutation therefore provides a sensitized background to 
identify molecules that, when mutated, further activate DAF-16/FoxO.  Genes identified 
by the eak screen encode molecules that normally function in parallel to AKT-1 to inhibit 
DAF-16/FoxO.  Twenty-one independent alleles defining seven eak genes were isolated 
by the screen.  My thesis involves characterizing the EAK pathway and elucidating the 
mechanism by which it controls DAF-16/FoxO.  I describe my thesis in the following 
three parts. 
Part I: Characterization of EAK-2/HSD-1, a conserved FoxO regulator 
The first aim of my thesis, corresponding to Chapter 2, was to characterize one of two 
conserved eak genes, eak-2/hsd-1.  The human ortholog of eak-2/hsd-1, SDR42E1, is 
highly expressed in the liver but its function is unknown.  It is a member of the 3-beta 
hydroxysteroid dehydrogenase family of enzymes, which are involved in steroid hormone 
and bile acid synthesis.  In C. elegans, EAK-2/HSD-1 is predicted to play a role in the 
biosynthesis of steroid hormones known as dafachronic acids (DAs).  DAs have a 
structure similar to that of bile acids, and act as ligands for an important nuclear hormone 
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receptor in the worm, DAF-12.  DAF-12 is orthologous to human Liver X Receptor, 
which is a key regulator of lipid homeostasis.  In the worm, DAF-12 regulates the 
transition into a developmental state known as dauer diapause.  Importantly, DAF-16 is 
also required for this transition.   
I determined that EAK-2/HSD-1 acts with the other eaks in parallel to PI3K/Akt to 
inhibit DAF-16/FoxO activity, independent of controlling its subcellular localization.  
Loss of EAK-2/HSD-1 activity increases DAF-16/FoxO activation during larval 
development.  Interestingly, deletion of eak-2/hsd-1 reduces longevity that is induced by 
ILS abrogation, suggesting eak-2/hsd-1 mutation has the opposite impact on DAF-
16/FoxO in the context of aging.  It is noteworthy that all eak genes characterized to date 
act in one genetic pathway.  Moreover, eak-2/hsd-1 and all but one of the other 
characterized eak genes are expressed only in two endocrine cells in the worm.  
Importantly, DAF-16 is not expressed in these cells, suggesting the eaks exert their 
function on DAF-16 non-autonomously, possibly through steroid hormone/DAF-12 
signaling.  
Part II: Characterization of convergence of steroid hormone signaling and 
insulin signaling in the control of DAF-16-dependent longevity 
Given its ability to both potentiate and antagonize the activity of DAF-16/FoxO, I sought 
to further understand the mechanistic underpinnings of DAF-16/FoxO control by eak-
2/hsd-1 and steroid hormone/DAF-12 signaling.  DAF-12 and DAs we previously known 
to impinge on DAF-16/FoxO in longevity control, however the nature of the interaction 
was unclear.  My second aim, corresponding to Chapter 3, was to unravel the intersection 
of these two signaling axes in longevity control.  Using animals with mutations in key 
DA synthetic enzymes, I tested the role of DAs and DAF-12 in regulating longevity via 
DAF-16/FoxO.  I found that in animals with reduced ILS, mutations that reduce DA 
biosynthesis or abrogate DAF-12 activity shorten life span, suggesting that liganded 
DAF-12 promotes longevity.  In animals with weakly reduced ILS, unliganded DAF-12 
also promotes longevity.  However, with a greater reduction in ILS, as conferred by 
insulin/IGF-1 receptor mutation, and in germline-ablated animals, unliganded DAF-12 
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shortens life span. Thus, multiple DAF-12 activities influence life span in a context-
dependent manner. These findings highlight the complexity of interactions among DA 
biosynthetic pathways, DAF-12, and DAF-16/FoxO in aging.  
Part III: Genetic screen to identify DAF-16/FoxO activators  
My work in parts I and II helped to reveal that all characterized eak genes act in one 
genetic pathway to control the nuclear pool of DAF-16/FoxO.  The pathway is endocrine; 
all EAKs but one, eak-7 (the other conserved eak), act in cells distant from those which 
express DAF-16/FoxO and are the important sites for influencing development and aging.  
EAK-7, which is active in the same cells as DAF-16/FoxO and DAF-12, is anchored to 
the plasma membrane while it acts on the nuclear pool of DAF-16/FoxO.  Given its 
expression pattern, EAK-7 is likely the most downstream EAK, yet how it transduces 
signals to DAF-16/FoxO is not known.   
My final aim was to illuminate the mechanism underlying EAK pathway inhibition of 
DAF-16/FoxO activity.  To accomplish this, I designed an approach to identify molecules 
which may relay EAK pathway signals to DAF-16/FoxO.  I reasoned that by using akt-1 
mutant animals, we could move DAF-16 into the nucleus, and via the addition of an eak-
7 mutation, we could induce activation of nuclear DAF-16/FoxO.  In this sensitized 
background, we could then ask for components which, when mutated, suppress the 
activation of DAF-16/FoxO.  As such, I sought to identify suppressors of an eak-7;akt-1 
mutant phenotype (seak mutants).  We hypothesize that seak genes will encode molecules 
that activate DAF-16/FoxO by acting in the PI3K/Akt or EAK pathways, or that exert 
their function in parallel to both pathways. 
We took two approaches to identifying seak mutants.  The first approach, described in 
Chapter 4, was to take advantage of the fact that we isolated a strain of eak-7;akt-1 
mutant animals that spontaneously lost its dauer arrest phenotype.  Dauer arrest delays 
the onset of the reproductive period in C. elegans.  Because of this delay in reaching 
sexual maturity, there is selection pressure on the population that favors the accumulation 
of spontaneous mutations which promote bypass of the dauer stage.  Thus, isolation of a 
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strain that lost its arrest phenotype suggested to us that the strain acquired a de novo 
mutation that suppressed dauer, potentially in a gene whose activity was normally 
required to activate DAF-16/FoxO.  We therefore pursued identification of the 
spontaneous seak mutations in the strain via whole-genome DNA sequencing.  This 
analysis revealed a point mutation in the gene gap-3, a conserved Ras GTPase activating 
protein (RasGAP) orthologous to human RASA1, which is associated with the seak 
phenotype.  
My studies of GAP-3 revealed that reducing its function suppresses phenotypes 
associated with DAF-16 activity, including dauer arrest and longevity.  Interestingly, this 
trait is specific to gap-3, as mutation of neither gap-1 nor gap-2 (the other C. elegans 
RasGAPs) suppresses dauer or longevity.  Moreover, gap-3 loss-of-function is not 
phenocopied by a let-60/Ras gain-of-function mutation, which renders Ras insensitive to 
inactivation by GAP.  Together, this suggests GAP-3 regulates DAF-16 independently of 
LET-60/Ras, potentially through a distinct small GTPase.  
Our second approach to identifying novel DAF-16/FoxO activators (seak genes) was a 
forward genetic screen, described in Chapter 5.  Based on the utility of our first approach 
which implicated gap-3 as a seak gene, I pursued a pilot mutagenesis screen to uncover 
more seak genes.  I screened approximately 1,200 haploid genomes and isolated sixteen 
independent seak mutants.  Using whole-genome DNA sequencing, we identified all 
lesions in each mutant strain, and I used SNP mapping to rapidly locate the causative 
seak mutation in each.  To date, I have characterized one seak mutant from the genetic 
screen, dpy-21, which encodes a conserved component of the C. elegans dosage 
compensation machinery.   
Like gap-3, dpy-21 is a bona fide seak gene as its mutation suppresses dauer arrest of 
eak-7;akt-1 mutants.  DPY-21 is a component of the dosage compensation complex 
(DCC) which functions to equate sex chromosome gene dosage between the sexes.  Via 
RNAi-mediated knockdown of individual DCC components in hermaphrodite and male 
animals, I demonstrated that the dauer suppression phenotype of dpy-21 mutants is due to 
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a defect in dosage compensation per se.  Expression of several X-linked dauer regulatory 
genes that promote dauer bypass is elevated in dpy-21 null animals, including four genes 
encoding components of the ILS pathway that antagonize DAF-16/FoxO activity.  
Accordingly, dpy-21 mutation reduced the expression of DAF-16/FoxO target genes.  
This work establishes a post-embryonic function for dosage compensation and 
demonstrates that chromosome-wide regulation of gene expression can influence the 
developmental response of an organism to environmental cues.  
The causative mutation remains to be identified in thirteen of the seak mutant strains; we 
believe seak gene identity and characterization will illuminate regulatory mechanisms 
controlling FoxO transcription factors that might be implicated in the pathogenesis of 
aging and age-associated disease. 
Summary 
In summary, little is known about the regulation of FoxO factors by components outside 
of the PI3kinase/Akt pathway.  My thesis research provides important insights into 
alternative regulatory paradigms of FoxO control with the characterization of the eak 
genes and discovery of novel seak genes.  These new paradigms may represent avenues 
amenable to pharmacologic intervention, providing potential therapeutic benefit for aging 
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Chapter 1: Introduction 
FoxO transcription factors 
FoxO transcription factors translate environmental stimuli into gene expression programs 
that result in control of stress resistance, metabolism, and cell growth and proliferation.  
Thus, they play a key role in enabling the appropriate physiological response of an 
organism to its environment.     
FoxO transcription factors belong to the conserved forkhead transcription superfamily; all 
members of this family are characterized by their forkhead box DNA binding domain 
(Kaestner et al., 2000). Forkhead transcription factors are conserved across animal 
phylogeny and are also present in fungi and yeast, but they are absent in plants (Mazet et 
al., 2003).  In mammals, the FoxO subgroup of forkhead transcription factors has four 
members, FOXO1, FOXO3, FOXO4, and FOX6.  Caenorhabditis elegans has only one 
FoxO ortholog, DAF-16. Likewise, Drosophila also has a single FoxO ortholog, dFOXO.   
FoxO factors typically act as transcriptional activators but they can also repress 
transcription.  FoxOs interact with DNA via their winged-helix DNA binding domain in 
the forkhead box of the protein.  Specificity and targeting of FoxO factors to target genes 
occurs via presence of the core recognition motif, TTGTTTAC (Furuyama et al., 2000; 
Greer and Brunet, 2008).  By controlling expression of many target genes, FoxO 
transcription factors promote a range of cellular responses including apoptosis, 
differentiation, cell cycle arrest, and resistance to oxidative stress.  At an organismal 
level, the integration of FoxO-dependent cellular responses results in promotion of 
development, metabolism, tumor suppression, and longevity.  
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Regulation of FoxO by insulin/insulin-like signaling 
Mammalian FoxO transcription factors are negatively regulated by insulin and insulin-
like growth factor signaling (ILS), via signaling through the phosphoinositide 3-kinase 
(PI3kinase)/protein kinase B (Akt) pathway.  Insulin and insulin-like growth factor exert 
their effects by binding to their respective receptor tyrosine kinase, the insulin receptor or 
the insulin-like growth factor receptor (Ullrich et al., 1985, 1986).  In response to 
engagement of receptor by ligand, the intrinsic tyrosine kinase activity of the receptor is 
activated, triggering a phosphorylation cascade.  The active receptor phosphorylates its 
substrate proteins, which include insulin receptor substrate (IRS) proteins and 
subsequently PI3kinase.  Activated PI3kinase phosphorylates phosphatidylinositol (4,5)-
bisphosphate (PIP2) in the plasma membrane, converting it to phosphatidylinositol 
(3,4,5)-trisphosphate (PIP3) (Vanhaesebroeck and Alessi, 2000).  PIP3 serves as a 
recruitment signal for other downstream kinases.  The pleckstrin homology domains of 
phosphoinositide-dependent kinase (PDK) and Akt cause their recruitment to PIP3 in the 
plasma membrane.  Once co-located at the plasma membrane, PDK phosphorylates Akt 
on threonine 308 which resides within the activation loop.  Subsequently other kinases 
phosphorylate Akt on a second site, serine 473 in the C-terminal hydrophobic motif of 
the protein.  Phosphorylation of Akt on both residues results in maximal activation of the 
kinase.  Activated Akt translocates through the cytosol to the nucleus, allowing it to 
phosphorylate its substrate proteins in both compartments (Andjelković et al., 1997).  Akt 
has numerous substrate proteins whose activities collectively allow Akt to promote cell 
survival, proliferation, and growth; FoxO transcription factors are substrates of Akt.   
Active Akt promotes the phosphorylation of FoxO on three consensus phosphorylation 
sites that are conserved from nematodes to mammals (Greer and Brunet, 2009).  Akt 
directly phosphorylates FoxO on a gatekeeper phosphorylation site, thereby promoting 
phosphorylation of the other two sites.   This phosphorylation results in recognition of 
FoxO by 14-3-3 chaperone proteins, which then bind to FoxO.  14-3-3 binding to FoxO 
both exposes a nuclear export sequence (Brunet et al., 2002) and obscures a nuclear 
localization sequence on FoxO (Obsilova et al., 2005).  As a result, phosphorylated FoxO 
and associated 14-3-3 are exported from the nucleus and FoxO is sequestered in the 
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cytoplasm. Moreover, ubiquitin-mediated proteasomal degradation of FoxO protein is 
triggered by Akt phosphorylation (Huang et al., 2005; Calnan and Brunet, 2008), 
reinforcing the inhibition of FoxO by ILS.  Signaling through InsR/PI3kinase/Akt is 
inhibited by the activity of phosphatase and tensin homolog (PTEN) (Stambolic et al., 
1998).  PTEN converts PIP3 back to PIP2, thereby reversing the effect of PI3kinase.  In 
this way, PTEN activity promotes the activation of FoxO.   
In summary, activation of ILS results in phosphorylation of FoxO and subsequent 
redistribution of the transcription factor to the cytoplasm.  Once sequestered in the 
cytosol, FoxOs are unable to carry out transactivation of gene expression and the 
cytoplasmic pool of the protein is degraded. Thus, signaling through PI3kinase and Akt 
inhibits FoxO activity principally through its nuclear exclusion, but also by promoting 
degradation of FoxO protein.   
Discovery of FoxO as a longevity promoting factor 
Work in C. elegans first revealed that FoxO is a critical longevity factor.  Investigation of 
a panel of mutants that constitutively entered an alternative, long-lived larval stage 
known as dauer arrest facilitated the discovery that mutations in the gene daf-2 increase 
adult life span two-fold.  Moreover, this daf-2 mutant longevity completely required the 
activity of a second gene, daf-16 (Kenyon et al., 1993).  It was subsequently discovered 
that daf-2 encodes the C. elegans ortholog of the insulin and insulin-like growth factor 
receptor (InsR) (Kimura et al., 1997), and daf-16 encodes the C. elegans FoxO ortholog 
(Lin et al., 1997; Ogg et al., 1997).  Ensuing studies illustrated that over-expression of 
wild-type FoxO can extend life span in both worms and flies (Henderson and Johnson, 
2001; Giannakou et al., 2004; Hwangbo et al., 2004).  Collectively, this work 
demonstrated that a mutation in a single gene, the insulin/insulin-like growth factor 
receptor, was capable of extending organismal life span. Moreover, it revealed that FoxO 
is a key regulator of the transcriptional outputs of ILS.  These discoveries suggested for 
the first time that the insulin signaling axis, through its interaction with FoxO 
transcription factors, might play a role in regulating the aging process in higher 
organisms.   
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FoxO in the control of mammalian aging 
It remains an open question as to whether FoxO transcription factors regulate life span in 
humans.  As in model organisms, the reduction of ILS also promotes longevity in 
mammals (Blüher et al., 2003; Holzenberger et al., 2003; Taguchi et al., 2007), but it is 
not yet known whether this life span extension requires FoxO transcription factors. 
Interestingly, recent studies have identified specific FoxO polymorphisms that are 
associated with extreme longevity in multiple cohorts of humans (Lunetta, 2007; Willcox 
et al., 2008; Anselmi, 2009; Flachsbart et al., 2009; Li, 2009; Pawlikowska, 2009).  
Together, this evidence is suggestive of the possibility that FoxO transcription factors 
might in fact play a role in longevity control in humans, as is the case in worms and flies.   
FoxO controls mammalian age-associated disease 
While a direct connection between mammalian FoxO transcription factors and life span 
control has not been established experimentally, recent work in conditional knockout 
mice supports a role for FoxO in modulating phenotypes that are reminiscent of aging-
associated diseases in humans, including cancer, osteoporosis, and diabetes.  Studies in 
mice illustrate that mammalian FoxOs function as tumor suppressors with the finding that 
loss of FoxO1, FoxO3, and FoxO4 in adults results in a cancer-prone phenotype 
characterized by thymic lymphomas and hemangiomas (Paik et al., 2007).  Furthermore, 
deletion of FoxO factors in mouse osteoblasts results in reduced bone mass secondary to 
increased osteoblast apoptosis (Ambrogini et al., 2010; Rached et al., 2010), suggesting 
that FoxO transcription factors are protective against osteoporosis. In contrast to these 
apparent beneficial effects of FoxO, FoxO1 can contribute to metabolic dysregulation 
similar to that observed in Type 2 diabetes; FoxO1 haploinsufficiency protects mice 
against insulin resistance induced by a high-fat diet (Nakae et al., 2003), and both liver-
specific and osteoblast-specific FoxO1 deletion ameliorate glucose intolerance in mouse 
models of insulin resistance (Matsumoto et al., 2007; Dong et al., 2008; Rached et al., 
2010). Thus, in mammals, FoxO transcription factors have context-dependent effects on 
the development of phenotypes associated with age-related disease. Elucidating the 
regulatory mechanisms that maintain the balance of FoxO transcription factor activity 
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may prove to be crucial for understanding and combating the progression of age-related 
disease. 
Caenorhabditis elegans as a model to study FoxO 
Caenorhabditis elegans is an excellent model system for revealing and dissecting the 
signaling networks that control the activity of FoxO transcription factors.  In addition to 
being the system in which the life span promoting function of FoxO was first discovered, 
there are several advantages to using C. elegans as a model system.  First, the key 
molecules and pathways implicated in mammalian FoxO regulation have orthologs in C. 
elegans (Taniguchi et al., 2006).  Secondly, the C. elegans system is simplified in that 
there is only one FoxO transcription factor, DAF-16, compared to four FoxO factors in 
mammals, as well as one InsR, in contrast to multiple mammalian insulin and insulin-like 
receptors.  Importantly, in contrast to early embryonic lethality of total FoxO deletion in 
mice (Greer and Brunet, 2008), the C. elegans daf-16 null mutant is viable, facilitating 
genetic analysis.  Moreover, in addition to regulating longevity, the C. elegans ILS 
pathway and DAF-16/FoxO control a well characterized, easily observable 
developmental phenotype known as dauer arrest. These facts, combined with the 
experimental manipulability and relatively short, approximately two-week life span of the 
organism, make C. elegans a well suited tool for the rapid identification and 
characterization of novel regulators of FoxO transcription factors. 
Dauer arrest 
In favorable environments, C. elegans larvae develop through four larval stages, 
becoming reproductively competent adults in approximately two days.  When faced with 
adverse environmental conditions such as high population density, elevated temperatures 
or food scarcity, larvae undergo an alternative developmental pathway and enter a 
persistent larval stage known as dauer arrest (Figure 1.1). Dauer larvae are 
morphologically distinct from their non-arrested L3 counterparts and have undergone a 
series of physiologic changes that make them extremely stress resistant and long lived. 
Animals can remain in the dauer stage for several months. When dauer larvae encounter a 
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favorable environment, they rapidly exit the dauer stage and resume reproductive 
development at the L4 stage.   
 
Dissection of the genetics of the dauer formation phenotype led to the identification of 
many genes responsible for regulating dauer formation, known as daf genes (abnormal 
DAuer Formation). Characterization of daf genes revealed four conserved signaling 
pathways which control dauer formation (Figure 1.2); a guanylyl cyclase/cGMP sensing 
pathway defined by dauer-constitutive (daf-c) mutants daf-11 and daf-21 (Figure 1.2A); a 
TGFβ-like pathway defined by daf-c mutants daf-1, daf-4, daf-7, daf-8, and daf-14 
(Figure 1.2B); the ILS pathway defined by daf-c mutant, InsR ortholog daf-2, and dauer-
defective (daf-d) mutants PTEN ortholog daf-18 and daf-16/FoxO (Figure 1.2C); and a 
hormonal signaling pathway defined by daf-c mutants daf-36 and daf-9, each encoding 
enzymes involved in biosynthesis of steroid hormones known as dafachronic acids 
(DAs), and daf-d mutant daf-12, which encodes a nuclear hormone receptor that is the 
target of the DAs (Figure 1.2D) (Riddle et al., 1981; Vowels and Thomas, 1992; Gottlieb 
and Ruvkun, 1994; Gerisch et al., 2001; Jia et al., 2002; Motola et al., 2006).  Genetic 
analysis of the dauer pathways indicate that DAF-16 acts downstream of the ILS 
pathway, and this pathway functions in parallel to the guanylyl cyclase/TGFβ pathways 
(Thomas et al., 1993; Gottlieb and Ruvkun, 1994).  The hormonal DA/DAF-12 pathway 
functions downstream of all other dauer pathways; however there is some evidence to 
suggest that DAF-12 may also function in parallel to the ILS pathway and DAF-16/FoxO 
(Vowels and Thomas, 1992; Larsen et al., 1995; Dumas et al., 2010). Together, the dauer 
signaling pathways integrate environmental stimuli and coordinate an appropriate 
organism-wide physiologic response, promoting reproductive development when 
conditions are replete and triggering arrest when conditions are adverse.   
 
The elucidation of daf genes led to the first identification of the ILS pathway in C. 
elegans and facilitated the discovery of DAF-2/InsR and DAF-16/FoxO as longevity 
regulators.  Because of the enhanced longevity of dauer animals, the daf genes were used 
for the initial life span extension screens, resulting in the previously mentioned discovery 
that daf-2 mutation extends life span.  Investigation of dauer arrest in C. elegans therefore 
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directly facilitated the discovery DAF-16/FoxO as a key longevity promoting factor.  
Building on this initial work, dauer arrest remains a convenient phenotype for dissection 
of DAF-16/FoxO regulation.  Loss-of-function mutation of daf-16 renders animals dauer-
defective, indicating DAF-16/FoxO activity is required for arrest.  Because of this, dauer 
arrest can be used as a surrogate phenotype for DAF-16/FoxO activation, providing an 
experimental avenue for identification of novel FoxO regulators.  It is noteworthy that 
each of the signaling pathways controlling dauer also impinges on adult longevity 
regulation in C. elegans, suggesting that novel DAF-16/FoxO regulators uncovered in the 









Figure 1.2: Signaling pathways controlling dauer arrest. 
(A.) A guanylyl cyclase pathway, (B.) TGFβ-like pathway, (C.) Insulin/insulin-like 
signaling pathway, and (D.) a steroid hormone pathway regulate dauer arrest.   
 
 
Known inputs to C. elegans DAF-16/FoxO regulation  
Since its initial discovery as a critical longevity promoting factor, much work has focused 
on identifying and characterizing the regulatory inputs controlling the activity of DAF-
16/FoxO, resulting in the elucidation of a network of factors involved in controlling 
activity of the transcription factor.  In C. elegans, as in mammals, DAF-16/FoxO is 
regulated canonically by the insulin/insulin-like signaling pathway. Activation of DAF-
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2/InsR triggers a PI3kinase/PDK/Akt signaling cascade resulting in the phosphorylation 
of DAF-16/FoxO (Lee et al., 2001; Lin et al., 2001), which causes the cytoplasmic 
sequestration of DAF-16/FoxO through its direct association with the 14-3-3 protein, 
FTT-2 (Berdichevsky et al., 2006; Li et al., 2007). PI3kinase is encoded by C. elegans 
age-1, the catalytic subunit, and aap-1, which encodes the adaptor subunit.  Two Akt 
orthologs are responsible for inhibitory phosphorylation of DAF-16/FoxO, AKT-1 and 
AKT-2.  Both AKT-1 and AKT-2 are widely expressed in C. elegans and they are 
activated by phosphorylation on sites corresponding to threonine 308 and serine 473 in 
mammalian Akt (Paradis and Ruvkun, 1998).  AKT-2 appears to play a lesser role in 
DAF-16/FoxO regulation than AKT-1, as phenotypes associated with akt-2 loss-of-
function mutation are weaker than those associated with akt-1 loss-of-function mutation 
(Paradis and Ruvkun, 1998; Hertweck et al., 2004; Quevedo et al., 2007).  Additionally, 
ablation of akt-1 is sufficient to drive GFP tagged DAF-16 into the nucleus; however 
AKT-2 does not significantly influence DAF-16 localization (Hertweck et al., 2004).   
In addition to the ILS pathway, a second pathway in C. elegans governs longevity via 
regulation of DAF-16 nuclear localization.  Building on the finding that DAF-2/InsR 
mutation significantly extends C. elegans life span, subsequent work showed that 
removing the germline also results in life span extension in a DAF-16/FoxO dependent 
manner (Hsin and Kenyon, 1999).  When the germline is ablated, DAF-16/FoxO 
translocates to the nucleus of intestinal cells (Lin et al., 2001), suggesting the germline 
normally produces an endocrine signal that promotes the cytoplasmic sequestration of 
intestinal DAF-16/FoxO.  Interestingly, the somatic gonad is required for germline 
removal to extend life span, as animals lacking both the somatic gonad and the germline 
are not long lived (Hsin and Kenyon, 1999).  This suggests that in addition to the FoxO-
inhibitory signal from the germline, there is also a life span-promoting signal emanating 
from the somatic gonad.  The nature of the endocrine signals deriving from the germline 
and the somatic gonad is not well understood; however, dafachronic acids (DAs), sterol 




The mechanisms by which the ILS pathway and the germline control DAF-16/FoxO 
subcellular localization are distinct. The germline signal likely acts in parallel to ILS 
pathway activity, as germline removal further extends life span of animals with reduced 
ILS (Hsin and Kenyon, 1999).  However, the consequence of germline removal in the 
context of daf-2/InsR null mutation is unknown; daf-2 null mutants arrest non-
conditionally and do not reach adulthood, precluding the assessment of adult life span in 
the total absence of DAF-2/InsR. In contrast to ILS, DAF-16/FoxO nuclear localization 
as a result of germline removal requires activity of the nuclear hormone receptor DAF-12 
and the presence of its ligands, DAs (Berman and Kenyon, 2006; Motola et al., 2006; 
Yamawaki et al., 2010). DAF-16/FoxO nuclear localization in the absence of the 
germline also requires the conserved protein KRI-1; however KRI-1 is dispensable for 
DAF-16/FoxO nuclear accumulation in the absence of ILS (Berman and Kenyon, 2006).   
Together, this evidence supports the paradigm of endocrine regulation of DAF-16/FoxO 
by controlling its subcellular localization. Nuclear exclusion inhibits the activity of the 
transcription factor whereas, in the absence of an inhibitory signal (either ILS or signals 
from the germline), DAF-16/FoxO translocates to the nucleus where it can activate its 
transcriptional programs.   
Paradigm shift:  What controls nuclear DAF-16/FoxO? 
Although nuclear localization of DAF-16/FoxO is clearly necessary for DAF-16/FoxO-
dependent life span extension, multiple lines of evidence indicate that it is not sufficient 
for full DAF-16/FoxO activation.  For example, reducing the activity of the 14-3-3 
protein FTT-2 by RNAi mediated knock-down  results in nuclear accumulation of DAF-
16/FoxO but does not cause dauer arrest in wild-type animals (Li et al., 2007; Alam et al., 
2010).  Moreover, mutation of the consensus AKT phosphorylation sites on DAF-
16/FoxO results in protein that is constitutively nuclear, but is not fully active (Lin et al., 
2001).   
In addition to nuclear localization being insufficient for full activation of DAF-16/FoxO, 
at least two findings support the existence of DAF-16/FoxO regulatory components 
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distinct from PI3kinase/Akt.  First, partial loss-of-function mutation in daf-18/PTEN 
suppresses dauer arrest of age-1/PI3kinase mutants but does not suppress arrest of daf-
2/InsR loss-of-function mutants (Gil et al., 1999).  Second, pdk-1 and akt-1 activating 
mutations suppress age-1/PI3kinase mutant dauer arrest to a greater extent than they 
suppress daf-2/InsR mutant dauer arrest (Paradis and Ruvkun, 1998; Paradis et al., 1999).   
Together, this evidence suggests that there is likely a signal that controls DAF-16/FoxO 
activity independently of PI3kinase, perhaps acting on the nuclear pool of the protein.  
The biologic importance of FoxO, together with the dearth of knowledge regarding what 
might control its activity once in the nucleus, prompted an attempt to uncover 
components of this parallel regulatory pathway.   
A genetic screen for molecules that regulate nuclear DAF-16/FoxO 
activity 
To identify components of the regulatory pathway acting on the nuclear pool of DAF-
16/FoxO, a genetic screen was undertaken that exploited the fact that DAF-16/FoxO 
activity promotes dauer arrest. The screen was designed to uncover mutants that enhance 
the weak dauer-constitutive phenotype of an akt-1 null mutant (eak screen, enhancer of 
akt-1).  As mentioned previously, akt-1 null mutation promotes nuclear localization of 
DAF-16/FoxO, potentiating its activation.  However, akt-1 null mutant animals develop 
reproductively at the elevated temperature of 25°C and do not arrest as dauer larvae, 
indicating DAF-16/FoxO is not fully active in the context of AKT-1 absence.  akt-1 null 
animals were subjected to mutagenesis and animals that subsequently arrested as a dauer 
larvae at 25°C in a daf-16-dependent manner were selected as harboring an eak mutation, 
as they likely acquired a mutation that causes the activation of DAF-16/FoxO.  eak genes 
therefore encode molecules that normally function to inhibit the activity of nuclear DAF-
16/FoxO.   
Characterization of the EAK pathway 
The eak screen identified twenty-one independent mutants that define seven eak genes, 
five of which have been cloned prior to this work (see Table 1.1) (Hu et al., 2006; Zhang 
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et al., 2008; Alam et al., 2010).  The phenotypic similarity of all eak single mutants and 
the observation that no eak;eak double mutant combination tested to date exhibits 
phenotypic enhancement compared to eak single mutants indicate that the EAK proteins 
are components of a single pathway.  EAK proteins and AKT-1 both control DAF-
16/FoxO target gene expression. However, in contrast to AKT-1, EAK proteins inhibit 
nuclear DAF-16/FoxO activity without influencing its subcellular localization (Zhang et 
al., 2008; Alam et al., 2010). The precise mechanism by which EAK proteins inhibit 
nuclear DAF-16/FoxO remains elusive.   




eak-1  ?  ? ?  
eak-2  ?  ? XXX cells  
eak-3  N-myristoylated protein  ? XXX cells  
eak-4  N-myristoylated protein  ? XXX cells  
eak-5  sdf-9  ? XXX cells  
eak-6  Protein tyrosine phosphatase ? XXX cells
1
  
eak-7  N-myristoylated TLDc protein  KIAA1609 
XXX cells, neurons, 
intestine, other tissues 
 
Table 1.1: Seven EAK proteins were identified from the eak screen.  
1
eak-6 is also expressed in the M1 pharyngeal motor neuron. 
 
The expression pattern of the eak genes provides some clues as to their function.  
Strikingly, of the cloned eak genes, all but eak-7 are expressed exclusively in the two 
neuroendocrine XXX cells (Hu et al., 2006; Zhang et al., 2008; Alam et al., 2010).  
Interestingly, the XXX cells do not express DAF-16/FoxO (Hu et al., 2006), suggesting 
the eak genes encode molecules with endocrine activity.  The XXX cells play a known 
role in dauer arrest; laser ablation of both XXX cells results in dauer arrest (Ohkura et al., 
2003), and the cells are the site of synthesis of DAs, the steroid hormone ligands for the 
nuclear hormone receptor DAF-12 (Ohkura et al., 2003; Motola et al., 2006).  In the 
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presence of DAs, DAF-12 promotes bypass of dauer arrest (Motola et al., 2006).  
Collectively, this indicates the XXX cells normally function to inhibit dauer, likely 
through the production of DAs.  Based on their expression in the XXX cells and epistasis 
to DA biosynthesis enzyme daf-9, the XXX-specific EAKs are thought to potentiate DA 
synthesis or secretion (Hu et al., 2006; Zhang et al., 2008).   
In contrast to other eak genes, eak-7 is expressed in multiple tissues in the worm, 
including tissues which also express daf-16/FoxO (Alam et al., 2010).  Additionally, 
unlike the other eak genes, eak-7 loss-of-function mutation results in a longevity 
phenotype.  eak-7 mutants live approximately 25% longer than wild-type animals, and 
this life span extension requires DAF-16/FoxO as well as the DAF-16/FoxO cofactors 
HSF-1 and SMK-1 (Alam et al., 2010). eak-7 mutation strongly enhances life span 
extension in animals lacking a germline (Alam et al., 2010), indicating that EAK-7 
functions in parallel to signals from the reproductive system to regulate DAF-16/FoxO 
and longevity. 
Based on its presence in the same cells as DAF-16/FoxO and the strength of its 
phenotypes, EAK-7 is likely the most downstream component of the known EAK 
pathway proteins. Nevertheless, how EAK-7 controls nuclear DAF-16/FoxO activity 
remains unclear.  The structure of EAK-7 provides few clues as to its function; it contains 
a consensus N-myristoylation (N-myr) motif and a TLDc (TBC- and LysM-domain-
containing) domain, the function of which is poorly understood. The N-myr motif likely 
targets EAK-7 to the plasma membrane, as a functional EAK-7::GFP fusion protein 
localizes to the plasma membrane and does not appear to translocate in adult animals 
(Alam et al., 2010). Thus, EAK-7 likely regulates nuclear DAF-16/FoxO activity 
indirectly.  Interestingly, eak-7 mutation increases steady-state DAF-16/FoxO protein 
levels in akt-1 mutants without altering daf-16/FoxO transcript levels (Alam et al., 2010), 
suggesting that EAK-7 may modulate DAF-16/FoxO synthesis or turnover. 
Collectively, the EAK proteins define a novel, conserved endocrine pathway that acts in 
parallel to PI3kinase/Akt and the germline to regulate the activity of nuclear DAF-
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16/FoxO. Continued investigation of the C. elegans EAK pathway promises to reveal 
new insights into mechanisms of FoxO regulation. In light of the potential role of FoxO 
transcription factors in mammalian aging and the pathogenesis of aging-associated 
diseases, EAK proteins could emerge as promising targets for the development of new 
drugs to treat Type 2 diabetes, cancer, and osteoporosis.  
Outstanding questions 
The following unresolved question provides the raison d'être of this dissertation: How 
does the EAK pathway inhibit the activity DAF-16/FoxO? Several independent lines of 
inquiry address this question and comprise the subsequent chapters of this dissertation.  
First, elucidation of the uncloned eaks may shed light on the function of the entire 
pathway; as such, in Chapter 2, this dissertation takes up the question, what is the nature 
of eak-2, and by what mechanism does it inhibit DAF-16 FoxO?  Second, the evidence 
outlined above indicates the steroid hormone pathway defined by DA and DAF-12 
influence DAF-16/FoxO phenotypes and might represent a mechanism of action of the 
EAKs.  This dissertation pursues this hypothesis by investigating the role of the steroid 
hormone pathway in the control of DAF-16/FoxO-dependent longevity, as described in 
Chapter 3. Lastly, an approach to uncover new molecules required to confer EAK 
inhibitory signal to DAF-16/FoxO is described, along with preliminary findings, in 
Chapter 4 and Chapter 5.  In sum, this work sheds light on novel regulators of FoxO 
transcription factors, and expands our understanding of FoxO regulation beyond its 
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Chapter 2: Functional divergence of 
dafachronic acid pathways in the control of 
Caenorhabditis elegans development and life 
span1 
Abstract 
Steroid hormone and insulin/insulin-like growth factor signaling (ILS) pathways control 
development and life span in the nematode Caenorhabditis elegans by regulating the 
activity of the nuclear receptor DAF-12 and the FoxO transcription factor DAF-16, 




-dafachronic acid (DA) promote bypass of 
the dauer diapause and proper gonadal migration during larval development; in adults, 




-DA have unique biological functions is not 
known. We identified the 3--hydroxysteroid dehydrogenase (3HSD) family member 
HSD-1, which participates in 
4
-DA biosynthesis, as an inhibitor of DAF-16/FoxO 
activity. Whereas ILS promotes the cytoplasmic sequestration of DAF-16/FoxO, HSD-1 
inhibits nuclear DAF-16/FoxO activity without affecting DAF-16/FoxO subcellular 
localization. Thus, HSD-1 and ILS inhibit DAF-16/FoxO activity via distinct and 
complementary mechanisms. In adults, HSD-1 was required for full life span extension in 
ILS mutants, indicating that HSD-1 interactions with ILS are context-dependent. In 
contrast to the 
7
-DA biosynthetic enzyme DAF-36, HSD-1 is dispensable for proper 
gonadal migration and life span extension induced by germline ablation. These findings 





-DA pathways have unique as well as overlapping biological functions in 
the control of development and life span.  
                                                 
1
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In replete environments, Caenorhabditis elegans larvae undergo four molts during 
reproductive development. When faced with unfavorable conditions, they enter diapause, 
arresting in an alternative third larval stage known as dauer. Dauers are adapted for 
survival and dispersal and resume development to adulthood once ambient conditions 
improve (Riddle, 1988). 
The elucidation of signal transduction pathways that regulate dauer arrest has provided a 
glimpse into how organisms integrate environmental cues with developmental programs. 
Genetic analysis has defined an intricate signaling network that controls the transition to 
diapause (Hu, 2007; Fielenbach and Antebi, 2008). A pathway regulated by the DAF-11 
guanylyl cyclase (Birnby et al., 2000) acts in sensory neurons to promote reproductive 
development by potentiating the expression of insulin-like (Pierce et al., 2001; Li et al., 
2003) and transforming growth factor-beta (TGF)-like (Ren et al., 1996; Schackwitz et 
al., 1996; Murakami et al., 2001) ligands. These ligands regulate gene expression by 
activating conserved insulin-like and TGF-like signal transduction pathways in target 
tissues. 
A hormone biosynthetic pathway also regulates dauer arrest by synthesizing dafachronic 
acids (DAs), which are steroid ligands for the nuclear receptor DAF-12 (Motola et al., 
2006). The cytochrome P450 DAF-9 (Gerisch et al., 2001; Jia et al., 2002) acts on 









-DA are thought to be synthesized by the 3--hydroxysteroid 
dehydrogenase (3HSD) family member HSD-1 (Patel et al., 2008) and the Rieske 
oxygenase DAF-36 (Rottiers et al., 2006), respectively (Figure 2.1). DA binding to DAF-
12 promotes reproductive development, whereas unliganded DAF-12 promotes dauer 
arrest (Motola et al., 2006). Although synthetic 
7
-DA is more potent than synthetic 
4
-
DA in dauer rescue bioassays (Sharma et al., 2009), exogenous 
4
-DA rescues daf-36 





compensate for a reduction in 
7




-DA have distinct 




Figure 2.1. Hypothetical model of dafachronic acid (DA) biosynthetic pathways.  




daf-12 mutations suppress dauer arrest in daf-11 and daf-7/TGF pathway mutants 
(Thomas et al., 1993), indicating that DAF-12 is required for dauer arrest in these 
mutants and suggesting that DAF-12 acts downstream of DAF-11 and DAF-7/TGF 
pathways. In contrast, the relationship between the DA pathway and the insulin-like 
pathway appears to be complex. Whereas reduced insulin-like signaling results in 
constitutive dauer arrest, daf-12 mutations cause a synthetic non-dauer larval arrest 
phenotype in the context of reduced insulin-like signaling (Vowels and Thomas, 1992; 
Larsen et al., 1995). Furthermore, exogenous 
4
-DA fully rescues dauer arrest in daf-9 
and daf-7/TGF mutants but causes non-dauer larval arrest in some strains harboring 
mutations in the insulin receptor (InsR) ortholog DAF-2 (Motola et al., 2006). The 
molecular basis for these interactions between DA and insulin-like signaling remains 
poorly understood.  
Upon engagement by insulin-like ligands, DAF-2/InsR promotes reproductive 
development by activating a conserved phosphoinositide 3-kinase (PI3K)/Akt pathway 
(Morris et al., 1996; Paradis and Ruvkun, 1998; Paradis et al., 1999). Dauer arrest caused 
by reductions in DAF-2/InsR signaling is fully suppressed by mutations in the FoxO 
transcription factor DAF-16 (Vowels and Thomas, 1992; Gottlieb and Ruvkun, 1994), 
indicating that DAF-16/FoxO is the major target of DAF-2/InsR pathway signaling and 
that DAF-2/InsR antagonizes DAF-16/FoxO. DAF-2/InsR activation of PI3K/Akt 
signaling results in DAF-16/FoxO phosphorylation by Akt and its subsequent 
cytoplasmic sequestration via binding to 14-3-3 proteins (Berdichevsky et al., 2006; 
Hertweck et al., 2004; Lee et al., 2001; Li et al., 2007; Lin et al., 2001). 
Although the inhibition of FoxO transcription factors by Akt in both C. elegans and 
mammals is well established, multiple lines of evidence support the existence of a second 
pathway that acts in parallel to PI3K/Akt signaling to inhibit FoxO. DAF-16/FoxO that is 
constitutively nuclear by virtue of either mutation of its consensus Akt/PKB 
phosphorylation sites or inactivation of either AKT-1 or the 14-3-3 protein FTT-2 is not 
fully active (Lin et al., 2001; Hertweck et al., 2004; Berdichevsky et al., 2006; Zhang et 
al., 2008), suggesting that a pathway acting in parallel to AKT-1 inhibits the activity of 
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nuclear DAF-16/FoxO. To identify components of this pathway, we performed a genetic 
screen for enhancers of the dauer arrest phenotype seen in akt-1 null mutants (eak 
mutants) (Hu et al., 2006; Zhang et al., 2008). Here we report the cloning and 
characterization of eak-2. Surprisingly, eak-2 is allelic to hsd-1 (Patel et al., 2008). This 
finding provided us with an opportunity to examine the interface between C. elegans 
insulin-like and DA pathways in dauer regulation and life span control.  
Materials and Methods 
Strains 
The following alleles were used, in the N2 Bristol wild-type background, hsd-1(mg345), 
hsd-1(mg433) (Patel et al., 2008), daf-9(k182) (Gerisch et al., 2001), daf-36(k114) 
(Rottiers et al., 2006), glp-1(e2141) (Priess et al., 1987), daf-16(mgDf47) (Ogg et al., 
1997), daf-12(rh61rh411) (Antebi et al., 2000), akt-1(mg306) (Hu et al., 2006), eak-
3(mg344) (Zhang et al., 2008), daf-2(e1370) (Kimura et al., 1997), sqt-1(sc13) age-
1(hx546) (Morris et al., 1996), pdk-1(sa709) (Paradis et al., 1999), eak-4(mg348) (Hu et 
al., 2006), and sdf-9(mg337) (Hu et al., 2006). DAF-16::GFP localization was assayed 
using strain TJ356 (zIs356) IV, which contains an integrated C-terminal translational 
fusion of the DAF-16A isoform in-frame to GFP (Henderson and Johnson, 2001). Strains 
CF1330 and CF1371 harbor extrachromosomal arrays encoding wild-type GFP::DAF-
16/FoxO and a constitutively nuclear GFP::DAF-16/FoxO mutant lacking all AKT 
phosphorylation sites, respectively (Lin et al., 2001). 
eak-2 mutant isolation, mapping, and sequencing 
Isolation, mapping, and sequencing of eak-2 alleles were performed as described for eak-
3 (Zhang et al., 2008).   
hsd-1 cDNA isolation 
hsd-1 cDNA isolation was performed as described for eak-3 (Zhang et al., 2008), except 
that total RNA was isolated from fluorescent XXX cells that had been FACS-purified 
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from cultured embryonic cells containing an integrated sdf-9p::RFP transgene (Hu et al., 
2006).  
hsd-1p::GFP construction and analysis 
The hsd-1 promoter (corresponding to nucleotides 24173-24413 of YAC Y6B3B, as 
annotated by the National Center for Biotechnology Information, was amplified from 
genomic DNA, a fragment containing GFP and the unc-54 3’ UTR was amplified using 
pPD95.75 as a template, and the two PCR products were fused using overlap extension 
PCR to create hsd-1p::GFP. hsd-1p::GFP and the transformation marker plasmid pRF4 
were coinjected at concentrations of 40 ng/l and 60 ng/l respectively into animals 
containing an integrated sdf-9p::RFP transgene. Transgenic animals were generated, 
animals were visualized using an Olympus BX61 upright microscope, and fluorescence 
was analyzed using SlideBook 4.1 digital microscopy software (Intelligent Imaging 
Innovations, Inc., Denver, CO, USA) as described (Hu et al., 2006).  
Gonadal migration assays 
Egg lays were performed on standard NGM plates at 20°C, and L4 larvae were scored for 
gonadal migration defects (Mig phenotype) using a Nikon SMZ800 stereomicroscope. 
Mig phenotypes were confirmed by visualization on an Olympus BX61 upright 
microscope at 200X magnification. 
Life span assays 
Life span assays were performed as described (Hu et al., 2006), except that the 5-
fluorodeoxyuridine (FUDR) concentration used in life span assays was 0.025 mg/ml. For 
life span assays on glp-1(e2141) strains, animals were cultured at 25°C after egg lay, and 
L4 animals were picked to NGM plates containing nystatin but lacking FUDR and 




Dauer assays were performed as described (Hu et al., 2006). To test rescue of dauer arrest 
by various sterols, 10l of 100M sterol stock solution was mixed with 90l of 
concentrated E. coli OP50 suspension, and the mix was aliquotted onto 6-cm NGM plates 
and allowed to dry overnight at room temperature. These plates were then used for 
standard dauer assays on hsd-1;akt-1 double mutant animals at 25°C. Final concentration 
of exogenous sterols was 111nM. For assays of strains harboring extrachromosomal 
DAF-16/FoxO transgenes, gravid transgenic animals were picked for egg lays based on 
the Rol phenotype. Progeny were incubated at 25°C and assayed for dauer arrest 48-60 
hours after egg lay. Animals that bypassed dauer arrest were scored as Rol or non-Rol. 
Only Rol bypassors were included in calculations of dauer arrest penetrance. 
Quantitative real-time reverse transcriptase PCR  
After four-hour egg lay, animals were grown at 25°C for 24 hours prior to harvesting. 
Total RNA isolation, cDNA synthesis, and quantitative real-time reverse transcriptase 
PCR were performed using gene-specific primers as described (Zhang et al., 2008). 
DAF-16::GFP localization 
Animals harboring an integrated DAF-16::GFP transgene were grown at 25°C and 
analyzed as described (Zhang et al., 2008). To obtain a distribution of DAF-16::GFP 
localization patterns in a population of animals, single animals were categorized as 
exhibiting nuclear, nuclear and cytoplasmic, or cytoplasmic fluorescence, and 
percentages of animals exhibiting each pattern were calculated for each strain. 
Results 
Animals harboring the akt-1(mg306) null mutation arrest as dauers at 27°C but develop 
reproductively at 25°C (Hu et al., 2006). To identify mutations that enhance the akt-
1(mg306) dauer arrest phenotype, we mutagenized akt-1(mg306) animals and screened 
for rare F2 dauers at 25°C. After excluding mutants whose dauer arrest phenotype was 
either not suppressed by daf-16/FoxO RNAi or did not require the presence of the akt-
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1(mg306) mutation, we identified 21 independent mutants that define seven eak genes. 
Four eak genes have been cloned: eak-3, eak-4, sdf-9 (which is allelic to eak-5), and eak-
6. They encode plasma membrane-associated proteins that function in a single pathway to 
promote reproductive development by acting in parallel to AKT-1 to inhibit DAF-
16/FoxO activity nonautonomously (Hu et al., 2006; Zhang et al., 2008). 
eak-2 is defined by two independent alleles, mg334 and mg345. We cloned eak-2 and 
found that it is allelic to the 3HSD family member hsd-1 (see Supporting Information 
for details), which was originally identified in a screen for enhancers of the ncr-1 dauer 
arrest phenotype (Patel et al., 2008). HSD-1 is thought to participate in the biosynthesis 
of DAs. DAF-9, which is expressed in the XXX cells, the hypodermis, and the 
hermaphrodite spermatheca (Gerisch et al., 2001; Jia et al., 2002), catalyzes the final 




-DA, from the precursors 4-
cholesten-3-one and lathosterone (Motola et al., 2006) (Figure 2.1). The predicted 
biochemical activity of HSD-1 and the expression pattern of hsd-1p::GFP (Supplemental 
Figure 2.3; (Patel et al., 2008) suggest that HSD-1 and DAF-9 participate in 
4
-DA 
biosynthesis in the XXX cells, whereas DAF-36 and hypodermal DAF-9 synthesize 
7
-
DA (Figure 2.1). 
hsd-1 mutants undergo dauer arrest in a DAF-16/FoxO- and DAF-12-
dependent manner 
hsd-1 single mutants do not have a strong dauer arrest phenotype at 25°C (Figures 2.2B 
and 2.2C). However, they do undergo dauer arrest at 27°C when cultured on NGM plates 
lacking supplemental cholesterol (Figure 2.2A). Dauer arrest in these conditions required 
both DAF-16/FoxO and DAF-12, indicating that HSD-1 promotes reproductive 
development by antagonizing DAF-16/FoxO and DAF-12. hsd-1 mutation also enhanced 
the dauer arrest phenotype of other DA biosynthetic mutants (Figure 2.2B). As previously 




-DA rescued the hsd-1 dauer 
arrest phenotype (Supplemental Figure 2.4). 
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Since hsd-1 mutations strongly enhance the dauer arrest phenotype of akt-1 mutants 
(Figures 2.2B and 2.2C), we tested the interactions of hsd-1 with other daf-2/InsR 
pathway mutants. hsd-1 mutations also enhanced the dauer arrest phenotypes of age-
1/PI3K and pdk-1 mutants, consistent with HSD-1 acting in parallel to the PI3K/Akt 
pathway (Figure 2.2C). The strong dauer arrest phenotype of hsd-1;akt-1 double mutants 
also required both DAF-16/FoxO and DAF-12 function (Figure 2.2C). hsd-1 mutation 
also enhanced the dauer arrest phenotype of daf-2(e1370) mutants; whereas daf-2(e1370) 
animals develop reproductively at 15°C, a significant fraction of hsd-1;daf-2 double 
mutant animals arrested as dauers at 15°C (Figure 2.2D). daf-2 mutants harboring the 
hsd-1(mg433) molecular null mutation had a stronger dauer arrest phenotype than daf-2 
mutants harboring the hsd-1(mg345) missense mutation (Figure 2.2D), suggesting that 
hsd-1(mg345) is a non-null allele. 
Since HSD-1 likely functions in DA biosynthesis, we tested other DA biosynthetic 
mutants for their ability to enhance the dauer arrest phenotype of akt-1(mg306). The daf-
9(k182) partial loss-of-function mutation (Gerisch et al., 2001) also enhanced the dauer 
arrest phenotype of akt-1 mutants (Figure 2.2B). The daf-36 gene is located on the same 
cosmid as akt-1, hindering the construction of a daf-36 akt-1 double mutant. However, 
we previously showed that RNAi of akt-1 enhances dauer arrest in a daf-36 mutant 





-DA or both DAs enhance the dauer arrest phenotype of akt-1 mutants. 
These findings indicate that DAs act in parallel to AKT-1 to inhibit dauer arrest. Taken 




-DA rescue dauer arrest 





DA act redundantly to promote reproductive development. 
hsd-1 mutation did not enhance the dauer arrest phenotype of other eak mutants (Figures 
2.2B and 2.2C), suggesting that HSD-1 and the other EAK proteins act in the same 





Figure 2.2: HSD-1 regulation of dauer arrest.  
(A.) hsd-1(mg433) animals arrest as dauers at 27°C on NGM plates lacking supplemental 
cholesterol in a DAF-16/FoxO- and DAF-12-dependent manner. (B.) Synthetic dauer 
arrest phenotypes at 25°C in combinations of hsd-1 and akt-1 mutations with mutations in 
DA biosynthetic pathway components. (C.) The hsd-1(mg433) mutation enhances dauer 
arrest at 25°C in PI3K/Akt pathway mutants but not in other eak mutants. (D.) hsd-1 





HSD-1 regulates DAF-16/FoxO target gene expression in a DAF-16/FoxO and 
DAF-12-dependent manner 
The requirement of DAF-16/FoxO for dauer arrest in hsd-1 mutants suggests that hsd-1 
mutation increases DAF-16/FoxO activity. To test this, we used quantitative real-time 
reverse transcriptase PCR (qPCR) to measure endogenous mRNA levels of three direct 
DAF-16/FoxO target genes: sod-3 (Oh et al., 2006), mtl-1 (Murphy et al., 2003), and dod-
3 (Murphy et al., 2003) (Figure 2.3). As previously observed (Zhang et al., 2008), akt-1 
mutation increases transcript levels of all three genes. This is consistent with the 
increased nuclear localization of DAF-16/FoxO caused by reduction of AKT-1 activity 
(Hertweck et al., 2004; Zhang et al., 2008). Intriguingly, hsd-1 mutation had divergent 
effects on different transcripts. hsd-1 mutation modestly increased sod-3 transcript levels 
and synergized with akt-1 mutation to further increase sod-3 mRNA levels (Figure 2.3A). 
This increase in sod-3 expression required both DAF-12 and DAF-16/FoxO activity, 
consistent with what we have previously observed with eak-3 mutation (Zhang et al., 
2008). Thus, HSD-1 inhibits sod-3 expression in a DAF-12- and DAF-16/FoxO-
dependent manner. Since DAF-16/FoxO activates sod-3 transcription directly (Oh et al., 
2006), this result suggests that in this context, DAF-12 acts either upstream of or in 
parallel to DAF-16/FoxO to promote sod-3 expression. 
In contrast, hsd-1 mutation reduced the expression of mtl-1 and dod-3 in both wild-type 
and akt-1 mutant backgrounds (Figures 2.3B and 2.3C). Thus, HSD-1 promotes the 
expression of mtl-1 and dod-3. akt-1 mutation increased mtl-1 and dod-3 expression in an 
hsd-1 mutant background, and this increase required both DAF-12 and DAF-16/FoxO 
activity (Figures 2.3B and 2.3C). These results indicate that HSD-1 has distinct effects on 
the expression of subsets of DAF-16/FoxO target genes and that both DAF-12 and DAF-





Figure 2.3. HSD-1 regulation of DAF-16/FoxO target gene expression.  
Quantification of endogenous transcripts corresponding to the DAF-16/FoxO target genes 





HSD-1 inhibits nuclear DAF-16/FoxO activity without influencing DAF-16/ 
FoxO subcellular localization 
To gain further insight into how HSD-1 regulates DAF-16/FoxO activity, we examined 
the localization of a functional DAF-16::GFP fusion protein (Henderson and Johnson, 
2001) in wild-type, akt-1 mutant, and hsd-1 mutant animals (Figures 2.4A and 2.4B). As 
previously reported, most wild-type animals exhibited diffuse fluorescence corresponding 
to cytoplasmic localization (Henderson and Johnson, 2001; Zhang et al., 2008). akt-1 
mutation promoted nuclear localization of DAF-16::GFP, as shown by the increase in 
percentage of animals exhibiting nuclear or nuclear and cytoplasmic fluorescence 
compared to wild-type (two-sided t-test: p = 0.017; Figure 2.4B). In contrast, the 
distribution of DAF-16::GFP fluorescence patterns in hsd-1 single mutants was 
indistinguishable from that of wild-type animals (two-sided t-test: p = 0.562; Figure 
2.4B). Thus, in contrast to AKT-1, which inhibits DAF-16/FoxO by promoting its 
translocation from the nucleus to the cytoplasm, HSD-1 inhibits DAF-16/FoxO activity 
without influencing its subcellular localization. Multiple efforts to construct an hsd-1;akt-
1 double mutant strain harboring DAF-16::GFP were unsuccessful, preventing us from 
determining whether hsd-1 mutation promotes the nuclear localization of DAF-16::GFP 
in an akt-1 mutant background. 
To directly test the hypothesis that HSD-1 inhibits nuclear DAF-16/FoxO activity, we 
assayed the ability of hsd-1 mutation to activate a constitutively nuclear GFP::DAF-16 
fusion protein that lacks all Akt phosphorylation sites (DAF-16
AM
) (Lin et al., 2001). 
Transgenic animals expressing DAF-16
AM
 exhibit constitutive nuclear fluorescence but 
do not arrest as dauers or live long (Lin et al., 2001), suggesting that in wild-type 
animals, nuclear DAF-16/FoxO is inhibited by a pathway that does not promote its 
relocalization to the cytoplasm. As previously reported, DAF-16
AM
 animals did not arrest 
as dauers at 25°C in a wild-type background (Figure 2.4B). hsd-1 mutation strongly 
enhanced the 25°C dauer arrest phenotype of animals harboring DAF-16
AM
 but did not 
promote dauer arrest in animals harboring a wild-type GFP::DAF-16 transgene (Figure 
2.4B). Thus, the effect of hsd-1 mutation on dauer arrest is greatly enhanced in contexts 
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Figure 2.4 HSD-1 inhibits nuclear DAF-16/FoxO activity without promoting its 
translocation from the nucleus to the cytoplasm.  
(A.) Percentage of animals exhibiting cytoplasmic, nuclear and cytoplasmic, or nuclear 
DAF-16::GFP localization. Error bars: s.d. N = 62 (wild-type), 77 (akt-1(mg306)), and 62 
(hsd-1(mg433)). (B.) The hsd-1(mg433) mutation enhances dauer arrest at 25°C in 
animals harboring a constitutively nuclear GFP::DAF-16/FoxO mutant lacking all Akt 
phosphorylation sites (DAF-16
AM
) but not in animals harboring wild-type GFP::DAF-16. 
Error bars indicate standard deviation. 
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HSD-1 is required for life span extension in DAF-2/InsR mutants 
To determine whether HSD-1 plays a role in life span control, we assayed the life span of 
hsd-1 mutants (Figure 2.5). The life spans of hsd-1 single mutants were comparable to 
that of wild-type animals. We previously showed that akt-1 mutants exhibit a slight 
increase in mean and median life span (Hu et al., 2006; Zhang et al., 2008); upon 
reduction of the FUDR concentration by 75%, we now observe significant life span 
extension in akt-1 mutants compared to wild-type or hsd-1 mutants (Figure 2.5A; P < 
0.0001 by the log-rank test). Two independent hsd-1 mutant alleles modestly suppressed 
the life span extension of akt-1 mutants, and this was of borderline statistical significance 
(P = 0.0128 for akt-1 vs. hsd-1(mg345);akt-1 and 0.0548 for akt-1 vs. hsd-1(mg433);akt-
1). This result contrasts with the strong enhancement of dauer arrest in akt-1 mutants by 
hsd-1 mutation (Figures 2.2B and 2.2C). 
In light of the trend toward suppression of life span extension of akt-1 mutants by hsd-1 
mutation, we determined the effect of hsd-1 mutation on the life span of daf-2/InsR 
mutants. Surprisingly, hsd-1 mutation significantly reduced the life span of daf-2(e1370) 
mutants (Figure 2.5B; P < 0.0001). This effect is unlikely to be a consequence of general 
frailty due to hsd-1 mutation, as hsd-1 single mutants have life spans that are comparable 
to wild-type (Figure 2.5). Thus, although HSD-1 does not influence life span 
substantially in wild-type animals, it is required for maximal life span extension when 
insulin-like signaling is reduced. The suppression of daf-2(e1370) life span extension by 
hsd-1 mutation contrasts with its enhancement of daf-2(e1370) dauer arrest (Figure 2.2D) 
and suggests that HSD-1 can either antagonize or potentiate DAF-16/FoxO activity, 






Figure 2.5. Impact of hsd-1 mutation on life span and gonadal migration.  
(A.) Effect of hsd-1 mutations on life span at 20°C in various genetic backgrounds. (B.) 
Effect of the hsd-1(mg433) mutation on life span extension in daf-2(e1370) mutants at 
20°C. (C.) Percentage of wild-type and mutant populations exhibiting the Mig phenotype 
at 20°C. Error bars indicate standard deviation. (D.) Life span extension in glp-1(e2141) 
mutant animals does not require hsd-1. 
 
HSD-1 is not required for proper gonadal migration or life span extension in 
animals lacking a germline 
In addition to their dauer-constitutive phenotypes, daf-9 and daf-36 loss-of-function 
mutants and daf-12 ligand binding domain mutants exhibit developmental abnormalities 
in gonadal migration (Mig phenotype) (Antebi et al., 2000; Gerisch et al., 2001; Jia et al., 
2002; Rottiers et al., 2006). In these mutants, the gonadal leader cells fail to turn dorsally 
and continue to migrate away from the primordial vulva (Figures 2.6A and 2.6B). Since 
exogenous 
4
-DA rescues the Mig phenotype of daf-9 mutants (Motola et al., 2006) and 
HSD-1 is thought to participate in 
4
-DA biosynthesis (Patel et al., 2008), we examined 
hsd-1 mutant animals for the Mig phenotype. Surprisingly, in contrast to daf-9 and daf-36 
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mutants, which exhibited high penetrance Mig phenotypes (Figures 2.6A and 2.6C), hsd-
1 null mutants did not have discernible gonadal migration abnormalities (Figures 2.6B 
and 2.6C). Thus, unlike DAF-9 and DAF-36, HSD-1 is not required for proper gonadal 
migration during larval development. 
DAF-9, DAF-36, and DAF-12 are also required for life span extension in animals lacking 
a germline (Berman and Kenyon, 2006; Rottiers et al., 2006). Since HSD-1 is required 
for full life span extension in daf-2(e1370) mutant animals (Figure 2.5B), we tested the 
role of HSD-1 in life span extension caused by germline ablation. As previously shown 
(Rottiers et al., 2006), DAF-36 was required for life span extension in glp-1(e2141) 
mutants lacking a germline (Figure 2.6D). In contrast, HSD-1 was completely 
dispensable for life span extension in glp-1 mutants. Thus, whereas HSD-1 and DAF-36 
play similar roles in dauer regulation (Figures 2.2B), they have distinct functions in the 
control of gonadal migration and life span.  
Discussion 
We have shown that the 3HSD family member HSD-1 acts in parallel to AKT-1 to 
regulate dauer arrest via DAF-16/FoxO and DAF-12. This is supported by three major 
lines of evidence. First, hsd-1 mutation strongly enhances the dauer arrest phenotype of 
an akt-1 null mutant in a DAF-16/FoxO- and DAF-12-dependent manner (Figure 2.2C). 
hsd-1 mutation also synergizes with akt-1 mutation to enhance expression of the DAF-
16/FoxO target gene sod-3 in a DAF-16/FoxO- and DAF-12-dependent manner (Figure 
2.3A). Finally, hsd-1 mutation enhances dauer arrest in animals expressing a 
constitutively nuclear DAF-16/FoxO mutant that lacks all Akt phosphorylation sites 
(Figure 2.4C). The observations that daf-9 mutation also enhances dauer arrest in an akt-1 
null mutant (Figure 2.2B) and that akt-1 RNAi induces dauer arrest and DAF-16/FoxO 
target gene expression in a daf-36 mutant (Zhang et al., 2008) are consistent with the 
postulated role of HSD-1 in synthesizing the 
4
-DA precursor 4-cholesten-3-one (Patel et 
al., 2008) (Figure 2.1). Taken together, these data suggest that DAs act in parallel to 
AKT-1 to promote reproductive development via DAF-16/FoxO and DAF-12. 
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Based on their observation that DAF-16::GFP localizes to the nucleus in hsd-1;ncr-1 
double mutants, Patel et al. have proposed that steroid signaling promotes reproductive 
development by inhibiting DAF-16/FoxO nuclear localization (Patel et al., 2008). 
However, they did not address the question of how HSD-1 itself regulates DAF-16/FoxO 
activity. We find that, in contrast to akt-1 mutation, which promotes the translocation of a 
functional DAF-16::GFP fusion protein from the cytoplasm to the nucleus, hsd-1 
mutation does not influence DAF-16::GFP localization (Figures 2.4A and 2.4B). 
Furthermore, hsd-1 mutation strongly promotes dauer arrest in animals expressing a 
constitutively nuclear DAF-16/FoxO mutant that lacks all of its Akt phosphorylation sites 
while having no effect on animals expressing wild-type DAF-16/FoxO (Figure 2.4C). 
HSD-1 also acts in the same dauer regulatory pathway as other EAK proteins (Figures 
2.2B and 2.2C), none of which influences DAF-16/FoxO localization (Zhang et al., 
2008). Based on these data, we favor a model whereby HSD-1 inhibits the activity of 
nuclear-localized DAF-16/FoxO without promoting its translocation from the nucleus to 
the cytoplasm. It is possible that hsd-1 mutation has indirect effects on other signaling 
pathways that may promote DAF-16/FoxO nuclear translocation in an ncr-1 mutant 
background (Patel et al., 2008). 
Surprisingly, whereas hsd-1 mutation enhanced the dauer arrest phenotype of DAF-
2/InsR pathway mutants, including daf-2(e1370) (Figures 2.2B-D), it suppressed the life 
span extension phenotype of daf-2(e1370) (Figure 2.5B). Thus, HSD-1 can either 
potentiate or antagonize DAF-2/InsR signaling depending upon the biological context 
(Figure 2.6). This could be due to context-dependent effects of the 
4
-DA/DAF-12 
interaction, the interaction of 
4
-DA with nuclear receptors other than DAF-12 during 
adulthood, or a possible role for HSD-1 in the biosynthesis of distinct steroid hormones 
during larval development and adulthood. 
Whereas mutations in hsd-1 and daf-36 have similar effects on dauer arrest (Figure 2.2B; 
(Rottiers et al., 2006), they differ in their impact on life span extension and gonadal 
migration (Figures 2.5C, D and Supplemental Figure 2.6, (Antebi et al., 2000; Gerisch et 
al., 2001; Rottiers et al., 2006)). In contrast to daf-36 mutation, hsd-1 mutation does not 
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cause defects in gonadal migration and does not suppress life span extension caused by 




-DA pathways may have 
overlapping and distinct functions in the control of development and life span. Since 
HSD-1 is the only putative DA biosynthetic enzyme that is specifically expressed in the 
XXX cells (Supplemental Figure 2.3, (Gerisch et al., 2001; Rottiers et al., 2006; Patel et 
al., 2008)), this result suggests that 
4
-DA synthesized in the XXX cells does not 
influence gonadal migration or life span in the context of germline ablation. This could 
be due to the presence of DAs synthesized in other tissues that suffice to promote normal 
gonadal migration in hsd-1 mutants and life span extension in hsd-1;glp-1 double 
mutants. Indeed, the ability of exogenous 
4
-DA to rescue both the gonadal migration 
phenotype as well as the suppression of glp-1(e2141) life span extension caused by daf-9 
mutation (Motola et al., 2006; Gerisch et al., 2007) indicates that 
4
-DA can regulate 
these processes. However, the partial suppression of life span extension in daf-2(e1370) 
mutants by hsd-1 mutation suggests that other DAs that may compensate for loss of 
HSD-1 activity to promote normal gonadal migration and life span in germline-ablated 
animals are not sufficient to do so in the context of reduced insulin-like signaling. 
 
Figure 2.6. Hypothetical models of insulin-like and DA pathways in the control of 
diapause, longevity, and gonadal migration.   
(A.) HSD-1 and DAF-36 act in canonical DA biosynthetic pathways to promote 
reproductive development. (B.) HSD-1 does not participate in life span control by the 
germline pathway but promotes life span extension in animals with reduced insulin-like 
signaling. (C.) Regulation of gonadal migration does not require HSD-1. 
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In aggregate, our data support distinct roles for DA pathways in dauer regulation, the 
control of life span, and gonadal migration (Figure 2.6). In dauer regulation, HSD-1 and 
DAF-36 act in parallel to AKT-1 to promote reproductive development via DAF-12 and 
DAF-16/FoxO (Figure 2.6A). During adulthood, DAF-36 is required for life span 
extension in animals lacking a germline. In contrast, HSD-1 is dispensable for life span 
extension caused by germline ablation but required for life span extension in animals 
with reduced insulin-like signaling (Figure 2.6B). HSD-1 has no apparent role in the 
regulation of gonadal migration by DAs (Figure 6C). Since neither the biochemical 
activities of HSD-1 and DAF-36 nor the steroid profiles of hsd-1 and daf-36 mutants 
have been characterized, the caveat must be considered that differences in levels of 
and/or the anatomical site of DA synthesis could contribute to differences in hsd-1 and 
daf-36 mutant phenotypes. 
Our model of HSD-1 as a regulator of nuclear DAF-16/FoxO activity suggests that 
human SDR42E1, the putative HSD-1 ortholog, could play an important role in the 
regulation of FoxO transcription factor activity in physiological or pathophysiological 
states in which PI3K/Akt pathway activity is low. For example, FoxO1 localizes to 
hepatocyte nuclei in fasted wild-type as well as diabetic mice (Aoyama et al., 2006). In 
light of recent reports highlighting the role of hepatic FoxO1 in glucose homeostasis 
(Matsumoto et al., 2007; Dong et al., 2008), SDR42E1 could be a critical regulator of 
nuclear FoxO1 activity and glucose metabolism in the liver. FoxO1 also localizes to the 
nucleus in response to dietary restriction in tumors lacking activating PI3K/Akt pathway 
mutations, and FoxO1 overexpression sensitizes such tumors to dietary-restriction-
induced apoptosis (Kalaany and Sabatini, 2009); in this context, SDR42E1 could 
modulate the apoptotic response of tumors to dietary restriction. Finally, the association 
of FoxO3 polymorphisms with extreme human longevity (Willcox et al., 2008; 
Flachsbart et al., 2009) suggests the possibility that HSD-1 control of life span may also 
be phylogenetically conserved. 
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Supplemental Material  
Cloning of eak-2 
We used single nucleotide polymorphism mapping to localize eak-2 to the right arm of 
chromosome I. The hsd-1 gene lies within this interval. The hsd-1 null allele mg433 
(Patel et al., 2008) did not complement eak-2(mg334) or eak-2(mg345), and sequencing 
of predicted exons and splice junctions in the hsd- open reading frame identified distinct 
point mutations in both eak-2 alleles. Injection of a genomic fragment containing the 
putative hsd-1 promoter, open reading frame, and 3’untranslated region rescued the dauer 
arrest phenotype of hsd-1;akt-1 double mutants. Therefore, eak-2 is allelic to hsd-1.  
Comparative sequence analysis indicates that HSD-1 is most closely related to human 
SDR42E1, which is one of six human 3βHSD family members (Supplemental Figure 
2.1). Both hsd-1 alleles that emerged from the eak screen contain missense mutations that 
are predicted to alter amino acid residues that are conserved in mammalian SDR42E1; 
the mg334 mutation is a G-to-A transition predicted to change alanine 387 to valine 
(A387V), and the mg345 mutation is a C-to-T transition predicted to change glycine 200 
in the 3βHSD catalytic domain to glutamate (G200E; Supplemental Figure 2.2). 
Although 3βHSDs are known to participate in sterol biosynthesis (Simard et al., 2005), 




















Supplemental Figure 2.1: Phylogenetic relationship among C. elegans and human 
3βHSD family members. 
A phylogeny tree was constructed based on amino acid sequences using the neighbor-
joining method (Saitou and Nei, 1987). C. elegans and human sequences are denoted in 
red and black font, respectively. Numbers on the internal branches indicate bootstrap 






Supplemental Figure 2.2: hsd-1 cDNA structures. 
Structures of three hsd-1 cDNAs are shown. Exons are depicted as rectangles and introns 
as lines. Open reading frame sequences are shaded. Asterisks indicate the location of 
mutations in mutant alleles mg433 (Patel et al., 2008), mg345, and mg334. The region of 





We identified three distinct cDNA isoforms using reverse transcriptase PCR, 5’ RACE, 
and 3’ RACE (Supplemental Figure 2.2). hsd-1L corresponds to the predicted hsd-
1cDNA structure in WormBase and encodes a protein of 462 amino acids containing both 
the 3βHSD domain and a C-terminal transmembrane domain. hsd-1M is generated by 
lack of splicing of the sixth intron and encodes a 414-amino-acid protein that diverges 
from HSD-1L in its 12 C-terminal amino acids and lacks the C-terminal transmembrane 
domain. 
In contrast to hsd-1L and hsd-1M, the structures of which were confirmed with multiple 
independent cDNA isolates, a single hsd-1S clone was isolated that is generated by lack 
of splicing of the third intron and encodes a 164-amino-acid protein diverging from the 
longer HSD-1 isoforms in its 5 C-terminal amino acids. The biological significance of 
hsd-1S is not clear, as hsd-1S is predicted to encode a protein that would be missing most 
of the 3βHSD domain (Supplemental Figure 2.2). Furthermore, the molecular lesions in 
mg334 and mg345 do not affect the predicted amino acid sequence of HSD-1S. If HSD-
1S is a biologically relevant isoform, its activity is not sufficient to compensate for the 
loss of HSD-1M and HSD-1L. The previously identified nonsense mutation mg433 is 
predicted to affect all three HSD-1 isoforms (Supplemental Figure 2.2), consistent with it 
being a candidate null allele (Patel et al., 2008). 
hsd-1 promoter analysis 
 
The predicted hsd-1 initiation codon is only 217 nucleotides downstream of the predicted 
translation termination codon of the immediate upstream gene lagr-1, suggesting that 
lagr-1 and hsd-1 may be cotranscribed in an operon. However, whereas the genomic 
structure of the vast majority of C. elegans operons is conserved in C. briggsae, the C. 
briggsae lagr-1 and hsd-1 genes are not contiguous (Stein et al., 2003). Furthermore, the 
single clone we isolated that corresponded to the 5’ end of the hsd-1 cDNA contained an 
SL1 leader sequence, suggesting that hsd-1 may be transcribed from a promoter that lies 
between lagr-1 and hsd-1 (Blumenthal, 2005). To determine whether the hsd-1-lagr-1 
intergenic fragment has promoter activity, we injected an hsd-1 genomic fragment 
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containing the 217-bp sequence between hsd-1 and lagr-1, the hsd-1 open reading frame, 
and the hsd-1 3’untranslated region into hsd-1;akt-1 double mutant animals. This 
transgene rescued hsd-1;akt-1 dauer arrest in six of six independent transgenic lines, 
indicating that the 217-bp promoter contiguous with the hsd-1 gene is sufficient to drive 
hsd-1 expression in a physiologically relevant manner. Taken together with the 
pharyngeal expression of a lagr-1p::GFP fusion (Henricson et al., 2004), this result 
suggests that hsd-1 and lagr-1 are transcribed from distinct promoters and do not 
comprise an operon. 
A GFP fusion containing the putative lagr-1 promoter, the lagr-1 open reading frame, 
and the lagr-1-hsd-1 intergenic region drives expression specifically in the XXX cells 
(Patel et al., 2008) To determine where the hsd-1 promoter is active, we constructed an 
hsd-1p::GFP promoter fusion in which GFP expression is controlled solely by the 217-bp 
lagr-1-hsd-1 intergenic region and assayed transgenic animals for green fluorescence. 
The hsd-1 promoter was active specifically in the endocrine XXX cells (Supplemental 





Supplemental Figure 2.3: The hsd-1 promoter drives expression specifically in the 
XXX cells. 
A representative late L1 larva harboring hsd-1p::GFP and sdf-9p::RFP (Hu et al., 2006) 




Supplemental Figure 2.4: Dafachronic acid precursors rescue the dauer arrest 
phenotype of hsd-1;akt-1 double mutants. 







Supplemental Figure 2.5:  Subcellular DAF-16::GFP localization. 
Examples of animals exhibiting nuclear (nuc.; upper left panel), cytoplasmic (cyto.; lower 








Supplemental Figure 2.6: hsd-1 mutants do not exhibit the gonadal migration (Mig) 
phenotype characteristic of other DA biosynthetic mutants. 
(A.) Gonadal migration (Mig) phenotype. A schematic of the Mig defect is shown in the 
upper panel. The vulva is denoted by a black dot. Examples of the Mig phenotype in 
representative daf-9(k182) (middle panel) and daf-36(k114) (lower panel) animals are 
shown. (B.) Normal gonadal migration. A schematic (upper panel) and normal gonadal 
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Chapter 3: The influence of steroid hormone 
signaling on life span control by 
Caenorhabditis elegans insulin-like signaling2 
Abstract 
Sterol-sensing nuclear receptors and insulin-like growth factor signaling play 
evolutionarily conserved roles in the control of aging. In the nematode Caenorhabditis 
elegans, bile-acid-like steroid hormones known as dafachronic acids (DAs) influence 
longevity by binding to and regulating the activity of the conserved nuclear receptor 
DAF-12, and the insulin receptor (InsR) ortholog DAF-2 controls life span by inhibiting 
the FoxO transcription factor DAF-16. How the DA/DAF-12 pathway interacts with 
DAF-2/InsR signaling to control life span is poorly understood. Here we specifically 
interrogate the roles of liganded and unliganded DAF-12 in life span control in the 
context of reduced DAF-2/InsR signaling. In animals with reduced DAF-2/InsR activity, 
mutations that either reduce DA biosynthesis or fully abrogate DAF-12 activity shorten 
life span, suggesting that liganded DAF-12 promotes longevity. In animals with reduced 
DAF-2/InsR activity induced by daf-2/InsR RNAi, both liganded and unliganded DAF-
12 promote longevity. However, in daf-2/InsR mutants, liganded and unliganded DAF-12 
act in opposition to control life span. Thus, multiple DAF-12 activities influence life span 
in distinct ways in contexts of reduced DAF-2/InsR signaling. Our findings establish new 
roles for a conserved steroid signaling pathway in life span control and elucidate 
interactions among DA biosynthetic pathways, DAF-12, and DAF-2/InsR signaling in 
aging.  
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Steroid hormones have critical functions in development and the maintenance of 
homeostasis throughout metazoan phylogeny. They exert their effects largely by binding 
to and regulating the activity of transcription factors of the nuclear receptor superfamily 
(Wollam and Antebi, 2011). In the nematode C. elegans, bile-acid-like steroid hormones 
known as dafachronic acids (DAs) are nuclear receptor ligands that control development 
and life span by binding to and regulating the activity of the nuclear receptor DAF-12 




-DA, differ in potency but 
appear to have similar functions in regulating larval development (Sharma et al., 2009). 
Genetic analyses and rescue experiments with presumed DA biosynthetic intermediates 




-DA are synthesized from cholesterol via 
distinct pathways [Figure 3.1A; (Wollam et al., 2012)]. The Rieske oxygenase family 
member DAF-36 catalyzes the first step of 
7
-DA biosynthesis by synthesizing 7-
dehydrocholesterol [7-DHC; (Rottiers et al., 2006; Wollam et al., 2011; Yoshiyama-
Yanagawa et al., 2011)]. 7-DHC is thought to be converted into lathosterol, the 3-OH 
group of which is subsequently oxidized by the 3-hydroxysteroid dehydrogenase DHS-16 
to create lathosterone (Rottiers et al., 2006; Wollam et al., 2012). Lathosterone is a direct 

7
-DA precursor which is a substrate for the cytochrome P450 family member DAF-9 
(Motola et al., 2006). The enzyme that catalyzes the conversion of 7-DHC into lathosterol 
has not been identified.  
DAF-9 catalyzes the final common step of DA biosynthesis, converting lathosterone into 

7
-DA and 4-cholesten-3-one into 
4
-DA (Motola et al., 2006). Whereas 
7
-DA is 
detectable in lipid extracts from wild-type C. elegans, it is not detectable in extracts from 
daf-36 or daf-9 mutants, indicating that both DAF-36 and DAF-9 are required for 
7
-DA 
synthesis in vivo (Motola et al., 2006; Wollam et al., 2011). 
4
-DA has not been 




Figure 3.1: Models of dafachronic acid (DA) biosynthetic pathways and DAF-12 
complexes in the control of dauer arrest and life span. 
(A.) Hypothetical model of DA biosynthesis, adapted from WOLLAM et al. 2012. (B.) 
Liganded DAF-12 promotes reproductive development, whereas unliganded DAF-12 acts 
with DIN-1S to promote dauer arrest. (C.) Liganded DAF-12 promotes longevity in 
animals lacking a germline. Unliganded DAF-12 acts with DIN-1S to promote longevity 
at low temperatures (15°) but shortens life span at higher temperatures (20°-25°). The 





































DAs and DAF-12 have multiple functions during larval development. In conditions of 
high population density, food scarcity, and high temperature, wild-type C. elegans larvae 
undergo developmental arrest in an alternative third larval stage known as dauer. Dauers 
are long-lived and resistant to environmental insults (Hu, 2007). daf-9 mutants, which 
lack endogenous DAs (Motola et al., 2006), arrest as dauers constitutively, even when 
ambient conditions favor reproductive development (Gerisch et al., 2001; Jia et al., 
2002). This dauer-constitutive phenotype is fully suppressed by exogenous DA (Motola 
et al., 2006; Giroux et al., 2008; Sharma et al., 2009) as well as by null mutations in daf-
12 (Gerisch et al., 2001). daf-12 ligand binding domain mutants also have a dauer-
constitutive phenotype (Antebi et al., 1998, 2000). Therefore, unliganded DAF-12 
promotes dauer arrest. The dauer-constitutive phenotype of daf-9 mutants and daf-12 
ligand binding domain mutants is also suppressed by mutations in din-1S, which encodes 
a transcriptional coregulator that binds to DAF-12 (Ludewig et al., 2004).  
Taken together, these results support a model whereby unliganded DAF-12 acts together 
with DIN-1S to promote dauer arrest; DAs permit reproductive development by binding 
to DAF-12, thereby preventing its interaction with DIN-1S [Figure 3.1B; (Fielenbach and 
Antebi, 2008)]. DAs are also required during larval development for proper gonadal 
migration (Gerisch et al., 2001; Motola et al., 2006) and expression of let-7-family 
microRNAs that coordinate the timing of cell divisions (Bethke et al., 2009; Hammell et 
al., 2009). In adult males, DAs are required for normal mate searching behavior 
(Kleemann et al., 2008). 
The roles of DAs and DAF-12 in the control of adult life span are complex. daf-9 mutants 
are long-lived when cultured at 15° (Jia et al., 2002; Gerisch et al., 2007) but short-lived 
when cultured at temperatures between 20° and 25° (Gerisch et al., 2001, 2007; Jia et al., 
2002; Lee and Kenyon, 2009). These temperature-dependent phenotypes are suppressed 
by daf-12 loss-of-function mutations (Jia et al., 2002; Lee and Kenyon, 2009) and 
exogenous DA (Gerisch et al., 2007), suggesting that unliganded DAF-12 promotes 
longevity at low temperatures but shortens life span at higher temperatures (Figure 3.1C). 
din-1S mutation suppresses the life span extension conferred by daf-9 mutation at low 
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temperatures (Ludewig et al., 2004), indicating that at 15°, unliganded DAF-12 and DIN-
1S act together to extend life span (Figure 3.1C). 
DAs and DAF-12 have a profound influence on life span in animals lacking a germline. 
Ablation of the germline extends adult life span at 20° by ~60%, and this life span 
extension requires DAF-9, DAF-36, DAF-12, and the FoxO transcription factor DAF-16 
(Hsin and Kenyon, 1999; Gerisch et al., 2001, 2007). Exogenous DA restores life span 
extension in germline-ablated animals harboring daf-9 or daf-36 mutations (Gerisch et 
al., 2007), indicating that liganded DAF-12 promotes longevity in this context (Figure 
3.1C). 
Similar to germline ablation, loss-of-function mutations in daf-2, which encodes the sole 
C. elegans insulin/insulin-like growth factor receptor family member (InsR) (Kimura et 
al., 1997), extend C. elegans life span in a DAF-16/FoxO-dependent manner (Kenyon et 
al., 1993). Both DAF-2/InsR and the germline inhibit DAF-16/FoxO activity by 
promoting its translocation from the nucleus to the cytoplasm (Henderson and Johnson, 
2001; Lee et al., 2001; Lin et al., 2001). In mutants that either lack a germline or have 
reduced DAF-2/InsR signaling, DAF-16/FoxO enters the nucleus, activating a gene 
regulatory program that promotes longevity (Murphy et al., 2003; McCormick et al., 
2012).  
How DAs and DAF-12 influence life span in the context of reduced DAF-2/InsR 
signaling is poorly understood. The daf-9 missense allele rh50 has distinct effects on life 
span in the context of specific daf-2 mutant alleles. At 15°, daf-9(rh50) shortens the life 
span of both daf-2(e1368) (harboring a missense mutation in the DAF-2 ligand binding 
domain) and daf-2(e1370) (harboring a missense mutation in the tyrosine kinase domain) 
mutant animals. However, at 22.5°, daf-9(rh50) shortens daf-2(e1368) life span but 
lengthens daf-2(e1370) life span (Gerisch et al., 2001). Accordingly, exogenous 
4
-DA 
prolongs the life span of daf-2(e1368) animals but does not significantly influence the life 
span of daf-2(e1370) animals (Gerisch et al., 2007). Furthermore, daf-12 mutant alleles 
influence the life span of daf-2/InsR mutants in an allele-specific manner. For example, 
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the non-null allele daf-12(m20) [Supplemental Figure 3.1; (Antebi et al., 2000; Snow and 
Larsen, 2000)] suppresses the extended life span phenotype of daf-2(e1365) [harboring a 
mutation in the ligand binding domain; (Patel et al., 2008)] at all temperatures tested 
(Gems et al., 1998), whereas it enhances daf-2(e1370) life span extension at high 
temperatures (Larsen et al., 1995; Gems et al., 1998). In aggregate, these data underscore 
the need for further investigation into how steroid hormone signaling and DAF-2/InsR 
signaling interact in life span control. Specifically, the relative contributions of liganded 
and unliganded DAF-12 to life span control have not been defined. Prior studies on the 
interactions of daf-12 and daf-2/InsR mutants in life span control were performed with 
non-null alleles of daf-12 (Larsen et al., 1995; Gems et al., 1998), complicating the 
interpretation of these experiments. 
Here we use null alleles of daf-36 and daf-12 to explore the relationship between DA 
pathways and DAF-2/InsR signaling in life span regulation. Our results are consistent 
with a model whereby both liganded and unliganded DAF-12 influence life span. 
Liganded DAF-12 promotes longevity in animals with reduced DAF-2/InsR signaling. 
Unliganded DAF-12 also extends life span in animals subjected to daf-2/InsR RNAi but 
shortens life span in daf-2/InsR mutants and in animals lacking a germline. These 
findings establish that distinct DAF-12 activities interact with DAF-2/InsR signaling to 
control life span. 
Materials and Methods 
C. elegans strains 
The wild-type N2 Bristol strain was used. Mutant alleles used in this study are described 
in Supplemental Table 3.1. Compound mutants were constructed using standard 
techniques.  
Dauer arrest assays 
Dauer arrest assays were performed at the indicated temperatures in Percival I-36NL 
incubators (Percival Scientific, Inc., Perry, IA) as described (Hu et al., 2006).  P-values 
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were calculated using Student’s t-Test.  Statistical analysis of all data is presented in 
Supplemental Table 3.2. 
Life span assays 
Life span assays were performed in Percival I-36NL incubators at the indicated 
temperatures.  After alkaline hypochlorite treatment and two generations of growth, 
young adult animals were placed onto NGM plates containing 25 g/ml (100 M) 5-
fluoro-2’-deoxyuridine (FUDR; Sigma) and 10 g/ml nystatin (Sigma) that had been 
seeded with 20X concentrated E. coli OP50.  Assays were conducted at 20˚ unless 
otherwise noted.  Viability was assessed visually or with gentle prodding.  For life span 
assays of strains carrying glp-1(e2141), animals were raised at 25˚, and sterile young 
adult animals were placed onto NGM plates containing nystatin but lacking FUDR as 
described above. GraphPad Prism (GraphPad Software, La Jolla, CA) was used for data 
representation and statistical analysis.  P-values were calculated using the Log-rank Test.  
Statistical analysis of all data is presented in Supplemental Table 3.2. 
RNAi 
Feeding RNAi was performed using variations of standard procedures (Boulton et al., 
2002).  For dauer assays, NGM plates containing 5 mM IPTG and 25 μg/ml carbenicillin 
were seeded with 500 μl of overnight culture of E. coli HT115 harboring either control 
L4440 vector or daf-2 RNAi plasmid. Gravid animals cultured on control or daf-2 RNAi 
plates were picked to assay plates for six-hour egg lays. Dauers were scored after 
progeny had been incubated at 25˚ for 48–60 hours.  For life span assays, NGM plates 
containing 5 mM IPTG, 25 μg/ml carbenicillin, 25 μg/ml FUDR, and 10 μg/ml nystatin 
were seeded with 500 μl of 5X concentrated overnight culture of E. coli HT115 harboring 
either control L4440 vector or daf-2 RNAi plasmid. Young adult animals cultured on 
standard NGM plates seeded with E. coli OP50 were picked to RNAi plates and scored 




Modulation of DAF-2/InsR signaling by DAF-12 
Two classes of daf-2 mutants have distinct interactions with the non-null daf-12(m20) 
allele (Gems et al., 1998). The dauer-constitutive phenotype of Class 1 daf-2 alleles (e.g., 
the ligand binding domain mutant e1368), which are also long-lived and thermotolerant 
(Gems et al., 1998), is suppressed by daf-12(m20). In contrast, Class 2 daf-2 alleles (e.g., 
the tyrosine kinase domain mutant e1370), which have pleiotropies in addition to the 
aforementioned Class 1 phenotypes, have a synthetic non-dauer larval arrest phenotype in 
combination with daf-12(m20) (Vowels and Thomas, 1992; Larsen et al., 1995; Gems et 
al., 1998).  
Notably, daf-12(m20) is a nonsense mutation that specifically affects DAF-12A isoforms; 
it is predicted to truncate DAF-12A upstream of the C-terminal ligand binding domain, 
potentially resulting in a DAF-12A polypeptide that contains an intact zinc finger in the 
N-terminal DNA binding domain. The DAF-12B isoform, which contains the ligand 
binding domain but lacks the DNA binding domain, is not affected by m20 
[Supplemental Figure 3.1; (Antebi et al., 2000; Snow and Larsen, 2000)]. The influence 
of a daf-12 null allele on the dauer-constitutive phenotype of daf-2 mutants has not been 
explored. 
To clarify the epistatic relationship between daf-2 and daf-12, we constructed daf-2;daf-
12 double mutants using the daf-12(rh61rh411) null allele [Supplemental Figure 3.1 and 
Supplemental Table 3.1; heretofore referred to as “daf-12 null”; (Antebi et al., 2000; 
Snow and Larsen, 2000)] and performed dauer arrest assays at 25°. As expected, both the 
Class 1 daf-2(e1368) ligand binding domain mutant as well as the Class 2 daf-2(e1370) 
tyrosine kinase domain mutant had strong dauer-constitutive phenotypes (Supplemental 
Figure 3.2). The dauer-constitutive phenotype of daf-2(e1368) was completely 
suppressed by daf-12(null), consistent with the effect of daf-12(m20) on other Class 1 
daf-2 alleles (Gems et al., 1998). At 15°, daf-2(e1370);daf-12(null) double mutants 
developed reproductively into adults (data not shown). At 25°, they arrested as larvae that 
59 
 
were longer and wider than dauers and that lacked both dauer alae and pharyngeal 
remodeling (Supplemental Figure 3.2 and data not shown). This phenotype is comparable 
to that previously described for daf-2(e1370);daf-12(m20) double mutants (Vowels and 
Thomas, 1992; Larsen et al., 1995; Gems et al., 1998) and suggests that the DAF-12A 
isoforms that are affected by the m20 mutation are the isoforms that prevent non-dauer 
larval arrest in daf-2(e1370) mutants at 25°.  
daf-12(m20) also has disparate effects on the longevity of Class 1 and Class 2 daf-2 
mutants (Larsen et al., 1995; Gems et al., 1998). To gain insight into how DAF-12 
influences life span in animals with reduced DAF-2/InsR signaling, we measured life 
spans of daf-12(null) animals in three contexts of reduced DAF-2/InsR activity. First, we 
performed daf-2 RNAi in wild-type and daf-12(null) animals. daf-2 RNAi does not 
induce dauer arrest in wild-type animals at 25° but enhances dauer arrest at 27° (Dillin et 
al., 2002a), suggesting that the extent to which RNAi reduces DAF-2 activity is less than 
that caused by Class 1 and Class 2 daf-2 mutant alleles, which all have strong dauer-
constitutive phenotypes at 25° (Gems et al., 1998). As previously observed (Dillin et al., 
2002b), daf-2 RNAi extended life span to an degree comparable to daf-2 mutation 
(Figures 3.2A-C). Life span extension induced by daf-2 RNAi was significantly 
attenuated in daf-12(null) animals (Figure 3.2A, 3.2D, and Supplemental Table 3.2: daf-
12(null) animals subjected to daf-2 RNAi exhibited a 34.5% decrease in median survival 
compared to wild-type animals on daf-2 RNAi, p < 0.0001 by the Log-rank Test), 
suggesting that DAF-12 is required for life span extension in animals with reduced DAF-
2/InsR activity.  At 25°, daf-12(null) mutants live approximately as long as wild-type 
animals do (Figure 3.2A, p = 0.0018; Figure 3.2B, p = 0.1787; Figure 3.2C, p = 0.0678; 
Supplemental Table 3.2), indicating that the effect of daf-12(null) on the life span of 
animals subjected to daf-2 RNAi is unlikely to be due to general frailty. Furthermore, 
RNAi of three unrelated genes in wild-type and daf-12(null) animals revealed that daf-
12(null) animals do not have an Rde (RNAi-defective) phenotype (Supplemental Figure 
3.3). This indicates that the relative reduction in life span extension caused by daf-2 
RNAi in daf-12(null) animals is unlikely to be due to reduced inactivation of daf-2.  
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We also assayed the life spans of daf-2;daf-12(null) double mutants. Interestingly, 
although daf-2(e1368);daf-12(null) animals had a shorter life span than Class 1 daf-
2(e1368) single mutants, the effect of daf-12(null) on life span extension in the context of 
the Class 1 daf-2(e1368) mutation was significantly smaller than its effect in the context 
of daf-2 RNAi (Figure 3.2B, 3.2D, and Supplemental Table 3.2: daf-2(e1368);daf-
12(null) exhibited a 10.3% decrease in median survival compared to daf-2(1368) alone, p 
< 0.0001). Furthermore, daf-2(e1370);daf-12(null) animals lived as long as Class 2 daf-
2(e1370) single mutants (Figure 3.2C, 3.2D, and Supplemental Table 3.2: 0% change in 
median survival of daf-2(e1370);daf-12(null) compared to daf-2(e1370), p = 0.4275). 
Taken together, these results suggest that DAF-12 is required for life span extension in 
the context of RNAi knock-down of daf-2, but is largely dispensable for longevity in the 
context of Class I daf-2(e1368) and Class II daf-2(e1370) mutants (see comparison of 
replicate experiments in Figure 3.2D).   
A possible explanation for the differences in the influence of DAF-12 on life span 
between the contexts of daf-2 RNAi and mutational reduction of DAF-2/InsR activity are 
the distinct food sources employed in each experimental condition. RNAi by feeding, as 
used to reduce daf-2/InsR activity, involves the use of an E. coli strain, HT115, which is 
distinct from standard lab food source, E. coli OP50. It has been shown that using HT115 
in place of OP50 as a food source is sufficient to impact C. elegans longevity (Maier et 
al., 2010). To test whether E. coli strain differences influence the effect of daf-12(null) on 
life span in the context of reduced DAF-2/InsR activity, we performed life span assays on 
daf-2(e1368) and daf-2(e1370) mutant animals grown on E. coli HT115 (expressing 
empty vector control RNAi) as the food source. Under these conditions, daf-
2(e1368);daf-12 double mutants were not shorter lived than daf-2(e1368) single mutants 
(Figures 3.2D, 3.2E, and Supplemental Table 3.2: daf-2(e1368);daf-12 animals exhibited 
a 0% change in median life span compared to daf-2(e1368), p = 0.1989).  daf-
2(e1370);daf-12 double mutants grown on HT115 were shorter lived than daf-2(e1370) 
single mutants, but the difference in median life span was not statistically significant 
(Figures 3.2D, 3.2F, and Supplemental Table 3.2: 12.1% decrease in median life span 
compared to daf-2(e1370), p = 0.1439).  These results suggest that the food source does 
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not account for the differential effects of daf-12(null) on longevity in the three contexts of 
reduced daf-2/InsR activity that we examined.  
Figure 3.2: Modulation of life span by daf-12(null) mutation in animals with 
reduced DAF-2/InsR activity. 
(A.) In the context of DAF-2/InsR activity reduction by daf-2 RNAi, daf-12(null) 
mutation shortened median life span [daf-12(null) v. wild-type, p < 0.0001].  (B.) In the 
context of the Class 1 daf-2(e1368) allele, daf-12(null) shortened median life span [daf-
2(e1368);daf-12(null) v. daf-2(e1368), p < 0.0001].  (C.) daf-12(null) mutation did not 
shorten median life span of animals with DAF-2/InsR activity reduction via the Class 2 
daf-2(e1370) allele [daf-2(e1370);daf-12(null) v. daf-2(e1370), p = 0.4275].  (D.) Scatter 
plot of median survival of daf-12(null) animals normalized to daf-12 wild-type animals in 
the three contexts of reduced DAF-2/InsR activity, separated by assay food source. Error 
bars indicate SEM.  (E.-F.) Food source control experiments for (B.) and (C.), 
respectively. E. coli HT115 expressing vector control RNAi was used as the assay food 
source as opposed to E. coli OP50. For each experiment, greater than 60 animals were 
scored per genotype, and at least two experimental replicates were performed.  See 



































































Modulation of DAF-2/InsR signaling by DA biosynthetic components 
Since DAF-12 is regulated by DA ligands (Motola et al., 2006), we explored the 
influence of mutations in DA biosynthetic pathway components on dauer arrest and life 
span in animals with reduced DAF-2 activity. Mutations in two genes encoding 
components of DA biosynthetic pathways, daf-36 and daf-9, cause a dauer-constitutive 
phenotype (Gerisch et al., 2001; Jia et al., 2002; Rottiers et al., 2006). The null allele daf-
36(k114)(Rottiers et al., 2006) (heretofore referred to as “daf-36(null)”) and the partial 
loss-of-function allele daf-9(k182) enhanced the dauer-constitutive phenotype induced by 
daf-2 RNAi at 25°C (Figure 3.3A). They also enhanced the dauer-constitutive phenotype 
of the Class 1 daf-2(e1368) ligand binding domain mutant at 20° (Figure 3.3B) and 15° 
(Supplemental Figure 3.4).  
To elucidate interactions between DA biosynthetic pathways and DAF-2/InsR signaling 
in life span control, we performed life span assays in daf-36(null) and daf-9(k182) 
mutants in two contexts of reduced DAF-2/InsR activity: daf-2 RNAi and daf-2(e1368).  
daf-36(null) and daf-9(k182) mutations both reduced life span extension induced by daf-2 
RNAi (Figure 3.3C: daf-36(null) exhibited a 25.8% decrease in life span compared to 
wild-type animals on daf-2 RNAi, p < 0.0001; Figure 3.3D: daf-9(k182) exhibited a 
28.1% decrease in median life span compared to wild-type, p < 0.0001; Supplemental 




-DA is detectable in daf-36 null mutants (Wollam et 
al., 2011), these results suggest that DAs are required for maximal life span extension in 
animals subjected to daf-2 RNAi. Similar to the case for DAF-12 (Figure 3.2), the 
requirement for DA biosynthesis in life span extension induced by reduced DAF-2/InsR 
activity is dependent on the context of InsR activity reduction, as the magnitude of life 
span reduction caused by daf-36 and daf-9 mutations was smaller in animals harboring 
the Class 1 daf-2(e1368) allele than in animals subjected to daf-2 RNAi (Figure 3.3E: 
daf-2(e1368);daf-36(null) median life span was 10.3% less than that of daf-2(e1368), p < 
0.0001; Figure 3.3F: daf-2(e1368);daf-9(k182) median life span was 10.3% less than that 
of daf-2(e1368), p < 0.0001; compare to Figures 3.3C-D; Supplemental Table 3.2; results 
summarized in Table 3.1).   
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The difference in response on daf-2 RNAi compared to daf-2/InsR genetic mutation was 
not due to differences in the E. coli strain used as a food source, as daf-2(e1368) mutant 
animals had similar life spans when assayed on E. coli HT115 (with vector control 
RNAi) and E. coli OP50 (Figure 3.3G: on HT115, median life span of daf-2(e1368);daf-
36(null) animals was 7.4% shorter than daf-2(e1368), p = 0.4328; Figure 3.3H: on 
HT115, median life span of daf-2(e1368);daf-9(k182) animals was 7.4% shorter than daf-
2(e1368), p = 0.2991; Supplemental Table 3.2). Collectively, these data suggest that both 





































































Figure 3.3: Mutations that reduce DA biosynthesis promote dauer arrest and 
shorten life span in animals with reduced DAF-2/InsR signaling.  
(A.-B.) daf-36(null) and daf-9(k182) mutations enhance dauer arrest of animals subjected 
to daf-2 RNAi, (A.), [wild-type on daf-2 RNAi v. daf-36(null) on daf-2 RNAi, p = 
0.0009; wild-type on daf-2 RNAi v. daf-9(k182) on daf-2 RNAi, p = 0.0689], or 
harboring the Class I daf-2(e1368) allele, (B.), [daf-2(e1368) v. daf-2(e1368);daf-
36(null), p = 0.0017; daf-2(e1368) v. daf-2(e1368);daf-9(k182), p =  0.0072].  Data 
represent the average of three replicate experiments, with a minimum of 400 animals 
scored per genotype.  Error bars indicate SEM. (C.-D.) daf-36(null) or daf-9(k182) 
mutations reduce life span of animals subjected to daf-2 RNAi [p < 0.0001] or (E.-F.) 
harboring the Class I daf-2(e1368) allele [p < 0.0001].  (G.-H.) Food source control 
experiments for (E.) and (F.), respectively. E. coli HT115 expressing vector control 
RNAi was used as the assay food source as opposed to E. coli OP50.  For each life span 
experiment, greater than 60 animals were assayed per genotype.  All raw data and 
statistics are presented in Supplemental Table 3.2.   
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Role of unliganded DAF-12 in life span control by DAF-2/InsR signaling 
To elucidate the relative contributions of liganded and unliganded DAF-12 to life span 
control in animals with reduced DAF-2/InsR signaling, we determined the influence of 
daf-12(null) mutation on the life spans of daf-36(null) animals with reduced DAF-2/InsR 
activity. Since daf-36(null) animals do not make 
4
- or 7-DA (Wollam et al., 2011), 
DAF-12 activity in the context of daf-36(null) is largely attributable to unliganded DAF-
12. 
In animals subjected to daf-2 RNAi, daf-36(null) mutation reduced life span (Figures 
3.3C and 3.4A), as did the hypomorphic daf-9(k182) mutation (Figure 3.3D). daf-
36(null);daf-12(null) animals subjected to daf-2 RNAi had even shorter life spans than 
daf-36(null) single mutants subjected to daf-2 RNAi (Figure 3.4A and Supplemental 
Table 3.2: daf-36(null);daf-12(null) had a 25.9% decrease in median life span compared 
to daf-36(null) on daf-2 RNAi, p < 0.0001).  From this finding, we infer that unliganded 
DAF-12 promotes longevity in the context of daf-2 RNAi. 
In the daf-2(e1368) background, daf-36(null) and daf-9(k182) mutations also reduced life 
span (Figures 3.3E, 3.3F, and 3.4B). However, in contrast to our findings with daf-2 
RNAi, daf-12(null) mutation did not further shorten the life spans of daf-2(e1368);daf-
36(null) double mutant animals. Whereas daf-12(null) mutation shortened the life span of 
daf-36(null) animals subjected to daf-2 RNAi (Figure 3.4A, 25.9% decrease in median 
life span, p < 0.0001), it extended the life span of daf-2(e1368);daf-36(null) animals fed 
E. coli OP50 (Figure 3.4B and Supplemental Table 3.2: 29.2% increase in median life 
span of daf-2(e1368);daf-36(null);daf-12(null) compared to daf-2(e1368);daf-36(null), p 
< 0.0001). The food source does not account for this difference; in contrast to the context 
of daf-2 RNAi, daf-12(null) mutation did not shorten the life spans of daf-2(e1368);daf-
36(null) mutant animals when animals were grown on E. coli HT115 (Figure 3.4C and 
Supplemental Table 3.2; 0% change in median life span comparing daf-2(e1368);daf-
36(null);daf-12(null) to daf-2(e1368);daf-36(null), p = 0.6097). Because daf-12 null 
mutation in the context of daf-2(e1368) mutation and the absence of DA is either 
beneficial or neutral to life span (Figures 3.4B-C), we conclude that unliganded DAF-12 
66 
 
shortens life span in daf-2(e1368) mutant animals. We were unsuccessful in our efforts to 
construct daf-2(e1370);daf-36(null) double mutants; this precluded an assessment of the 
influence of daf-36(null) mutation on life span in the daf-2(e1370) mutant background.  
In aggregate, our results (summarized in Table 3.1) support roles for both liganded and 
unliganded DAF-12 in life span control in animals with reduced DAF-2/InsR signaling. 
Liganded DAF-12 promotes longevity in all contexts tested, whereas unliganded DAF-12 
modulates life span in a context-dependent manner; in the context of reduced DAF-
2/InsR signaling via daf-2 RNAi, unliganded DAF-12 promotes longevity.  In contrast, in 
the context of DAF-2/InsR signaling reduction via daf-2(e1368) mutation, unliganded 
DAF-12 is detrimental to life span.   
Role of unliganded DAF-12 in life span control by the germline 
Although both DAF-2/InsR and the germline control life span by regulating DAF-
16/FoxO activity, they do so through distinct molecular pathways (Hsin and Kenyon, 
1999; Berman and Kenyon, 2006; Ghazi et al., 2009). DA biosynthetic enzymes and 
DAF-12 are required for life span extension induced by germline ablation (Hsin and 
Kenyon, 1999; Gerisch et al., 2001, 2007; Yamawaki et al., 2010), suggesting that 
liganded DAF-12 is important in promoting longevity in animals lacking a germline. In 
light of our finding that unliganded DAF-12 can shorten life span in daf-2 mutants 
(Figure 3.4B), we sought to determine whether unliganded DAF-12 also shortens life 
span in animals lacking a germline. 
We confirmed previously established requirements for daf-36 and daf-12 in life span 
extension induced by germline ablation [Figure 3.4C; (Hsin and Kenyon, 1999; Gerisch 
et al., 2007; Yamawaki et al., 2010)]. Notably, in three of five replicate experiments, we 
found that glp-1;daf-12(null) animals lived longer than glp-1;daf-36(null) animals 





-DA (Wollam et al., 2011), this result suggested the possibility that unliganded DAF-
12 shortens life span in animals lacking a germline. To determine whether this was the 
case, we examined the influence of daf-12(null) mutation on life span in germline-ablated 
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daf-36(null) animals. glp-1;daf-36(null);daf-12(null) triple mutant animals lived 
significantly longer than glp-1;daf-36(null) double mutant animals (Figure 3.4D and 
Supplemental Table 3.2: 27.3% increase in median life span of glp-1;daf-36(null);daf-
12(null) compared to glp-1;daf-36(null), p < 0.0001), indicating that unliganded DAF-12 
also shortens life span in germline-ablated animals. This result was recapitulated by 
control experiments performed on E. coli HT115 as the food source (Figure 3.4E and 
Supplemental Table 3.2: 18.2% increase in median life span of glp-1;daf-36(null);daf-
12(null) compared to glp-1;daf-36(null), p < 0.0001).  Thus, DAF-12 has at least two 
distinct activities that control life span in germline-ablated animals: liganded DAF-12 
promotes longevity, whereas unliganded DAF-12 shortens life span.  These findings are 
summarized in Table 3.1.   
Role of the transcriptional coregulator DIN-1S in life span control by the 
germline 
In animals lacking DAs, DIN-1S, the short isoform of the transcriptional coregulator 
DIN-1, acts in a complex with unliganded DAF-12 to promote dauer arrest [Figure 3.1B; 
(Ludewig et al., 2004)]. Since unliganded DAF-12 shortens life span in germline-ablated 
animals (Figure 3.4D), we examined the role of DIN-1S in life span control in animals 
lacking a germline by determining the impact of the din-1S null mutation dh127 
(Ludewig et al., 2004) (heretofore referred to as “din-1S(null)”) on the life span of glp-
1;daf-36(null) double mutant animals. din-1S(null) animals have life spans comparable to 
wild-type animals at 15° (Ludewig et al., 2004).   Surprisingly, din-1S(null) completely 
suppressed the life span shortening effect of daf-36(null) on germline-ablated animals fed 
E. coli OP50 (Figure 3.4D and Supplemental Table 3.2: p = 0.8829 for the comparison of 
din-1S(null);glp-1;daf-36(null) to glp-1 single mutant; din-1S(null);glp-1;daf-36(null) 
median life span was between 35.3% and 118.2% longer than that of glp-1;daf-36(null) 
in four replicate experiments, p <0.0001 for each experiment).  This result was replicated 
with E. coli HT115 as the food source (Figure 3.4E and Supplemental Table 3.2: p = 
0.0389 for the comparison of din-1S(null);glp-1;daf-36(null) to glp-1 single mutant; din-
1S(null);glp-1;daf-36(null) median life span was 54.4% longer than that of glp-1;daf-
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36(null), p <0.0001). Thus, in daf-36(null) animals lacking a germline, DIN-1S plays a 
major role in shortening life span. 
 
Figure 3.4: Unliganded DAF-12 influences life span in a context-dependent manner. 
daf-12(null) mutation further decreased median life span of daf-36(null) animals on daf-2 
RNAi [daf-36(null);daf-12(null) v. daf-36(null), p < 0.0001]. (B., D.) In contrast, daf-
12(null) mutation increased median life span of daf-36(null) in the context of daf-
2(e1368), (B.), and germline ablation (glp-1 mutation), (D.) [daf-2(e1368);daf-
36(null);daf-12(null) v. daf-2(e1368);daf-36(null), p < 0.0001; glp-1;daf-36(null);daf-
12(null) v. glp-1;daf-36(null), p < 0.0001]. (D.) din-1S(null) abrogated life span 
shortening induced by daf-36(null) in the context of germline ablation [din-1S(null);glp-
1;daf-36(null) v. glp-1;daf-36(null), p < 0.0001]. (C., E.) Food source control 
experiments for (B.) and (D.), respectively. E. coli HT115 expressing vector control 
RNAi was used as the assay food source as opposed to E. coli OP50. For each 
experiment, greater than 60 animals were assayed per genotype, and at least two 
experimental replicates were performed.  Raw data and statistics are presented in 
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DAF-12 on  
life span 
daf-2 RNAi 
34.5 (< 0.0001) 
[Fig. 3.2A] 
10.0 (< 0.0001) 
[Fig. 3.4A] 
25.9 (< 0.0001)   
[Fig. 3.4A]   
daf-2(e1368) 
10.3 (< 0.0001) 
[Fig. 3.2B] 
29.4 (< 0.0001) 
[Fig. 3.4B] 
29.2 (< 0.0001)  
[Fig. 3.4B]   
glp-1(e2141) 
60.7 (< 0.0001) 
[Fig. 3.4D] 
60.7 (< 0.0001) 
[Fig. 3.4D] 
27.3 (< 0.0001)  
[Fig. 3.4D]   
 
Table 3.1: Summary of effects of daf-12 and daf-36 null mutations on life span in 
three contexts of DAF-16 activation.  
daf-2 RNAi, daf-2(e1368) mutation, and germline ablation (glp-1(e2141) animals raised 
at the restrictive temperature) were used to induce DAF-16-dependent life span 
extension. Percent change in median life span vs. the comparator (p value) are shown for 
each indicated experiment. Refer to Supplemental Table 3.2 for replicate experiments. 
Arrows indicate the direction of effect on life span ( decrease,  increase). The two 





Although the interface between C. elegans hormonal signaling and the DAF-2/InsR 
pathway has been explored previously (Larsen et al., 1995; Gems et al., 1998), how these 
pathways interact to influence longevity remains obscure. Our work provides novel 
insights into the genetic interactions of liganded and unliganded DAF-12 with DAF-
2/InsR signaling in life span control. 
70 
 
Liganded DAF-12 promotes longevity in animals with reduced DAF-2/InsR 
activity 
Ambiguity about the role of DAF-12 in determining longevity is due at least in part to the 
use of the non-null daf-12(m20) allele in previous investigations (Larsen et al., 1995; 
Gems et al., 1998). We now show that the daf-12(rh61rh411) null allele and the non-null 
daf-12(m20) allele have distinct effects on the life spans of animals with reduced DAF-
2/InsR signaling [Figure 3.2; (Larsen et al., 1995; Gems et al., 1998; McCulloch and 
Gems, 2007)]. Our results indicate that at high temperatures, DAF-12 promotes longevity 
in animals with reduced DAF-2/InsR signaling (Figure 3.2). The magnitude of this life-
span-extending effect of DAF-12 is greater in animals subjected to daf-2 RNAi than in 
animals harboring daf-2 mutation, indicating that the specific context of reduced DAF-
2/InsR activity influences the role of DAF-12 in life span control (Table 3.1). The 
disparity between our results and those obtained with the non-null daf-12(m20) allele 
(Larsen et al., 1995; Gems et al., 1998) suggests that the longevity-promoting effect of 
daf-12(m20) and other non-null daf-12 mutations (that specifically affect DAF-12A 
isoforms) on the life span of daf-2(e1370) and other Class 2 daf-2 mutants (Larsen et al., 
1995; Gems et al., 1998; Antebi et al., 2000; McCulloch and Gems, 2007) may be 
attributable to a life-span-extending activity of either the DAF-12B isoform, which 
contains a ligand binding domain but no DNA binding domain, or truncated DAF-12A 
polypeptides containing most of the DNA binding domain but lacking the ligand binding 
domain (Antebi et al., 2000; Snow and Larsen, 2000). These DAF-12 polypeptides do not 
play a significant role in dauer regulation by DAF-2/InsR, as daf-12(null) and daf-
12(m20) have similar effects on the dauer-constitutive phenotypes of daf-2 mutants 
(Supplemental Figure 3.1). 
The observation that mutations in either daf-12 (Figure 3.2) or genes encoding DA 
biosynthetic components (Figure 3.2) reduce life span in animals with reduced DAF-
2/InsR signaling is consistent with a model whereby liganded DAF-12 promotes 
longevity when DAF-2/InsR signaling is reduced (Figure 3.5A). Similar results indicate 
that liganded DAF-12 also promotes longevity in germline-ablated animals [Figure 3.4D; 
(Hsin and Kenyon, 1999; Gerisch et al., 2001, 2007; Yamawaki et al., 2010)]. The 
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magnitude of the effect of reducing the activity of DA biosynthetic components or DAF-
12 on life span is greater in animals lacking a germline than in animals with reduced 
DAF-2/InsR activity [Figures 3.2-3.4 (Hsin and Kenyon, 1999; Gerisch et al., 2001, 
2007; Yamawaki et al., 2010)]. The molecular basis for this observation is not known.  
Unliganded DAF-12 has context-dependent influences on life span in animals 
with reduced DAF-2/InsR activity 
Unliganded DAF-12 promotes longevity in animals cultured at low temperatures (Gerisch 
et al., 2001; Jia et al., 2002) but shortens life span in animals that are cultured at high 
temperatures (Lee and Kenyon, 2009). Here we show that in the context of reduced DAF-
2/InsR signaling, unliganded DAF-12 can either extend or shorten life span. In daf-




-DA (Wollam and Antebi, 2011), DAF-12 
extends life span in the context of daf-2 RNAi (Figure 3.4A) but shortens life span in the 
contexts of the Class 1 daf-2(e1368) allele (Figure 3.4B) and germline ablation (Figure 
3.4D). Since DAF-16/FoxO is a major target of both DAF-2/InsR signaling and germline 
signaling in life span control (Kenyon et al., 1993; Hsin and Kenyon, 1999), it is likely 
that the impact of unliganded DAF-12 on longevity is strongly influenced by relative 
levels of DAF-16/FoxO activity. This notion is supported by a recent report 
demonstrating that DAF-12 and DAF-16/FoxO mutually influence target gene expression 
in animals lacking a germline (McCormick et al., 2012). 
The transcriptional coregulator DIN-1S shortens life span in animals lacking a 
germline 
DIN-1S acts together with unliganded DAF-12 at 15° to promote longevity (Ludewig et 
al., 2004). Here we show for the first time that the DAF-12 coregulator DIN-1S plays a 
major role in life span control in germline-ablated animals. Both daf-12(null) and din-
1S(null) suppressed the life-span-shortening effect of daf-36(null) on animals lacking a 
germline (Figure 3.4D-E). This is consistent with a model whereby unliganded DAF-12 
and DIN-1S act together to shorten life span. The role of DIN-1S in life span control by 
unliganded DAF-12 in the context of reduced DAF-2/InsR signaling is not known. 
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Context-dependent life span control by DAF-12 complexes 
Our results define new functions for DAF-12 complexes in life span control and 
underscore the context-dependence of these activities (Figure 3.5).  As summarized in 
Table 3.1, liganded DAF-12 promotes longevity both in animals with reduced DAF-
2/InsR activity (Figures 3.2A-C, E-F and 3.3C-H) as well as in animals lacking a 
germline (Figure 3.4D-E; (Gerisch et al., 2007; Yamawaki et al., 2010)). Unliganded 
DAF-12 also promotes longevity in animals subjected to daf-2 RNAi (Figure 3.4A) but 
shortens life span in animals harboring daf-2 mutations or lacking a germline (Figure 
3.4B-E). The basis for the context-dependent influence of unliganded DAF-12 on life 
span may involve context-specific proteins and/or undiscovered DAF-12 ligands present 
in daf-36(null) animals that influence the transcriptional regulatory activity of DAF-12 


















Figure 3.5: New functions of DAF-12 complexes in life span control.  
(A.) Liganded DAF-12 promotes longevity in animals with reduced DAF-2 activity. (B.-
C.) Unliganded DAF-12 promotes longevity in animals subjected to daf-2 RNAi (B.) but 
shortens life span in daf-2 mutant animals (C.). (D.) Unliganded DAF-12 acts together 






























































Supplemental Information  
  
Supplemental Figure 3.1: daf-12 gene structure, transcripts, and relevant mutations. 
The structure of daf-12 transcripts is adapted from WormBase (WBGene00000908). 
Transcripts corresponding to DAF-12A and DAF-12B isoforms as first described in 
Antebi et al. 2000 and Snow and Larsen 2000 are shown. The location of molecular 
lesions is taken from Antebi et al. 2000 and Snow and Larsen 2000. The m20 mutation is 
indicated by a caret, and the rh411 mutation is indicated by an asterisk in the DNA 
binding domain. rh411 is a small deletion/duplication after the first Zn finger in the DNA 
binding domain that results in an in-frame stop (Antebi et al., 2000). Abbreviations: 








Supplemental Figure 3.2: Larval arrest phenotypes of daf-2;daf-12(null) mutants.  
daf-12(null) suppresses dauer arrest of daf-2(e1368) mutant animals [daf-2(e1368) v. daf-
2(e1368);daf-12(null), p < 0.0001].  daf-2(e1370);daf-12(null) animals arrest as non-
dauer larvae, see text for details.  Data represent the average of at least two replicate 
experiments, with a minimum of 495 animals scored per genotype.  Error bars represent 


























Supplemental Figure 3.3: daf-12(null) does not cause an RNAi-defective phenotype.  
Phenotypes of animals subjected to RNAi of lir-1, unc-22, and pos-1 are shown. As 
controls, the enhanced-RNAi strain eri-1(mg366) and the RNAi-defective strain rde-4 





Supplemental Figure 3.4: Enhancement of the dauer-constitutive phenotype daf-
2(e1368) by mutations in genes encoding DA biosynthetic pathway components. 
 daf-36(null) and daf-9(k182) mutations enhance dauer arrest of animals harboring the 
Class I daf-2(e1368) allele [daf-2(e1368) v. daf-2(e1368);daf-36(null), p = 0.0388; daf-
2(e1368) v. daf-2(e1368);daf-9(k182), p =  0.0561].  Data represent the average of three 
replicate experiments, with a minimum of 700 animals scored per genotype.  Error bars 









Supplemental Table 3.2: Life span and dauer statistics.  
















P value      
(Log-rank)  
(comparison 1) 
P value v. (comparison 1)
P value       
(Log-rank) 
(comparison 2) 
P value v. (comparison 2) 
wild-type (vector) 15.11 2.68 61(0) 15 n/a wild-type (vector) n/a n/a n/a n/a n/a n/a
daf-12 (vector) 15.00 1.59 58(0) 15 0.0018 wild-type (vector) 0.0 no change n/a n/a n/a n/a
wild-type (daf-2 RNAi) 30.05 3.61 60(0) 29 < 0.0001 wild-type (vector) 93.3 increase n/a n/a n/a n/a
daf-12 (daf-2 RNAi) 20.03 4.55 59(0) 19 < 0.0001 wild-type (daf-2 RNAi) 34.5 decrease n/a n/a n/a n/a
wild-type (vector) 14.10 1.46 58(1) 14 n/a wild-type (vector) n/a n/a n/a n/a n/a n/a
daf-12 (vector) 12.74 1.52 53(6) 13 < 0.0001 wild-type (vector) 7.1 decrease n/a n/a n/a n/a
wild-type (daf-2 RNAi) 30.62 4.09 60(0) 32 < 0.0001 wild-type (vector) 128.6 increase n/a n/a n/a n/a
daf-12 (daf-2 RNAi) 19.65 3.95 57(1) 19 < 0.0001 wild-type (daf-2 RNAi) 40.6 decrease n/a n/a n/a n/a
wild-type (vector) 14.88 2.17 73(0) 16 n/a wild-type (vector) n/a n/a n/a n/a n/a n/a
daf-12 (vector) 14.15 1.72 72(0) 14 0.0038 wild-type (vector) 12.5 decrease n/a n/a n/a n/a
wild-type (daf-2 RNAi) 29.35 4.29 75(0) 30 < 0.0001 wild-type (vector) 87.5 increase n/a n/a n/a n/a
daf-12 (daf-2 RNAi) 20.14 4.11 65(2) 20 < 0.0001 wild-type (daf-2 RNAi) 33.3 decrease n/a n/a n/a n/a
Figure 2B wild-type 14.23 1.81 106(0) 15 n/a wild-type n/a n/a n/a n/a n/a n/a
daf-12 13.86 1.84 72(0) 15 0.1787 wild-type 0.0 n/a n/a n/a n/a n/a
daf-2(e1368) 28.24 5.39 76(0) 29 < 0.0001 wild-type 93.3 increase n/a n/a n/a n/a
daf-2(e1368);daf-12 25.56 3.95 75(0) 26 < 0.0001 daf-2(e1368) 10.3 decrease n/a n/a n/a n/a
wild-type 15.38 2.11 91(0) 17 n/a wild-type n/a n/a n/a n/a n/a n/a
daf-12 14.59 1.89 86(5) 14 0.0039 wild-type 17.6 decrease n/a n/a n/a n/a
daf-2(e1368) 24.67 5.17 81(0) 26 < 0.0001 wild-type 52.9 increase n/a n/a n/a n/a
daf-2(e1368);daf-12 23.53 5.54 78(4) 26 0.2228 daf-2(e1368) 0.0 no change n/a n/a n/a n/a
wild-type 14.29 1.10 102(0) 14 n/a wild-type n/a n/a n/a n/a n/a n/a
daf-2(e1368) 24.16 5.43 74(1) 25 < 0.0001 wild-type 78.6 increase n/a n/a n/a n/a
daf-2(e1368);daf-12 19.66 3.96 56(15) 22 < 0.0001 daf-2(e1368) 12.0 decrease n/a n/a n/a n/a
Figure 2E wild-type 15.07 2.74 87(2) 15 n/a wild-type n/a n/a n/a n/a n/a n/a
daf-12 13.77 2.26 86(3) 13 0.0002 wild-type 13.3 decrease n/a n/a n/a n/a
daf-2(e1368) 24.93 4.37 86(4) 27 < 0.0001 wild-type 80.0 increase n/a n/a n/a n/a
daf-2(e1368);daf-12 24.61 5.81 88(1) 27 0.1989 daf-2(e1368) 0.0 no change n/a n/a n/a n/a
wild-type 12.89 2.62 85(3) 12 n/a wild-type n/a n/a n/a n/a n/a n/a
daf-12 11.60 2.27 86(1) 12 0.0004 wild-type 0.0 no change n/a n/a n/a n/a
daf-2(e1368) 23.02 5.26 83(4) 24 < 0.0001 wild-type 100.0 increase n/a n/a n/a n/a
daf-2(e1368);daf-12 24.18 5.74 87(1) 24 0.0257 daf-2(e1368) 0.0 no change n/a n/a n/a n/a
Figure 2C wild-type 15.31 2.70 77(2) 15 n/a wild-type n/a n/a n/a n/a n/a n/a
daf-12 14.76 1.81 84(0) 15 0.0678 wild-type 0.0 no change n/a n/a n/a n/a
daf-2(e1370) 32.34 11.39 77(0) 33 < 0.0001 wild-type 120.0 increase n/a n/a n/a n/a
daf-2(e1370);daf-12 31.77 9.86 82(0) 33 0.4275 daf-2(e1370) 0.0 no change n/a n/a n/a n/a
wild-type 13.49 2.33 77(23) 13.5 n/a wild-type n/a n/a n/a n/a n/a n/a
daf-12 13.56 1.96 56(44) 13.5 0.08576 wild-type 0.0 no change n/a n/a n/a n/a
daf-2(e1370) 39.46 8.71 97(3) 41.5 < 0.0001 wild-type 207.4 increase n/a n/a n/a n/a
daf-2(e1370);daf-12 34.82 9.60 97(3) 36.5 < 0.0001 daf-2(e1370) 12.0 decrease n/a n/a n/a n/a
wild-type 15.49 1.76 85(15) 15.5 n/a wild-type n/a n/a n/a n/a n/a n/a
daf-12 15.20 1.70 74(26) 15.5 0.3576 wild-type 0.0 no change n/a n/a n/a n/a
daf-2(e1370) 41.03 12.54 97(3) 43.5 < 0.0001 wild-type 180.6 increase n/a n/a n/a n/a
daf-2(e1370);daf-12 38.34 11.23 100(0) 39.5 0.0161 daf-2(e1370) 9.2 decrease n/a n/a n/a n/a
daf-2(e1370) 39.37 9.88 101(0) 40 n/a daf-2(e1370) n/a n/a n/a n/a n/a n/a
daf-2(e1370);daf-12 39.90 9.22 99(1) 39 0.9095 daf-2(e1370) 2.5 decrease n/a n/a n/a n/a
Figure 2F wild-type 12.89 2.62 85(3) 12 n/a wild-type n/a n/a n/a n/a n/a n/a
daf-12 11.60 2.27 86(1) 12 0.0004 wild-type 0.0 no change n/a n/a n/a n/a
daf-2(e1370) 27.60 8.85 87(1) 29 < 0.0001 wild-type 141.7 increase n/a n/a n/a n/a
daf-2(e1370);daf-12 25.23 9.17 86(0) 25.5 0.1439 daf-2(e1370) 12.1 decrease n/a n/a n/a n/a
wild-type 15.07 2.74 87(2) 15 n/a wild-type n/a n/a n/a n/a n/a n/a
daf-12 13.77 2.26 86(3) 13 0.0002 wild-type 13.3 decrease n/a n/a n/a n/a
daf-2(e1370) 29.01 8.01 89(1) 31 < 0.0001 wild-type 106.7 increase n/a n/a n/a n/a
daf-2(e1370);daf-12 24.82 10.14 83(8) 25 0.1719 daf-2(e1370) 19.4 decrease n/a n/a n/a n/a
wild-type (vector) 18.64 2.31 89(0) 18 n/a wild-type (vector) n/a n/a n/a n/a n/a n/a
daf-36 (vector) 17.55 3.34 73(1) 18 0.1054 wild-type (vector) 0.0 no change n/a n/a n/a n/a
wild-type (daf-2 RNAi) 29.62 3.79 82(5) 31 < 0.0001 wild-type (vector) 72.2 increase n/a n/a n/a n/a
daf-36 (daf-2 RNAi) 21.57 4.77 67(4) 23 < 0.0001 wild-type (daf-2 RNAi) 25.8 decrease n/a n/a n/a n/a
wild-type (vector) 14.10 1.46 58(1) 14 n/a wild-type (vector) n/a n/a n/a n/a n/a n/a
daf-36 (vector) 12.72 1.52 36(24) 13 < 0.0001 wild-type (vector) 7.1 decrease n/a n/a n/a n/a
wild-type (daf-2 RNAi) 30.62 4.09 60(0) 32 < 0.0001 wild-type (vector) 128.6 increase n/a n/a n/a n/a
daf-36 (daf-2 RNAi) 21.57 4.65 46(13) 23 < 0.0001 wild-type (daf-2 RNAi) 28.1 decrease n/a n/a n/a n/a
wild-type (vector) 15.11 2.68 61(0) 15 n/a wild-type (vector) n/a n/a n/a n/a n/a n/a
daf-36 (vector) 14.52 2.05 54(2) 15 < 0.0001 wild-type (vector) 0.0 no change n/a n/a n/a n/a
wild-type (daf-2 RNAi) 30.05 3.61 60(0) 29 < 0.0001 wild-type (vector) 93.3 increase n/a n/a n/a n/a
daf-36 (daf-2 RNAi) 23.04 4.57 49(4) 23 < 0.0001 wild-type (daf-2 RNAi) 20.7 decrease n/a n/a n/a n/a
wild-type (vector) 14.10 1.46 58(1) 14 n/a wild-type (vector) n/a n/a n/a n/a n/a n/a
daf-9 (vector) 13.29 1.73 49(10) 13 0.0153 wild-type (vector) 7.1 decrease n/a n/a n/a n/a
wild-type (daf-2 RNAi) 30.62 4.09 60(0) 32 < 0.0001 wild-type (vector) 128.6 increase n/a n/a n/a n/a
daf-9 (daf-2 RNAi) 21.34 5.20 53(6) 23 < 0.0001 wild-type (daf-2 RNAi) 28.1 decrease n/a n/a n/a n/a
Figure 3E wild-type 14.23 1.81 106(0) 15 n/a wild-type n/a n/a n/a n/a n/a n/a
daf-36 13.13 1.60 68(0) 12 < 0.0001 wild-type 20.0 decrease n/a n/a n/a n/a
daf-2(e1368) 28.24 5.39 76(0) 29 < 0.0001 wild-type 93.3 increase n/a n/a n/a n/a
daf-2(e1368);daf-36 22.84 4.94 69(0) 26 < 0.0001 daf-2(e1368) 10.3 decrease n/a n/a n/a n/a
wild-type 17.38 2.01 58(14) 17 n/a wild-type n/a n/a n/a n/a n/a n/a
daf-36 13.24 1.64 29(42) 14 < 0.0001 wild-type 17.6 decrease n/a n/a n/a n/a
daf-2(e1368) 34.88 5.50 64(7) 37 < 0.0001 wild-type 117.6 increase n/a n/a n/a n/a
daf-2(e1368);daf-36 28.70 5.06 66(4) 31 < 0.0001 daf-2(e1368) 16.2 decrease n/a n/a n/a n/a
wild-type 16.48 2.23 92(1) 17 n/a wild-type n/a n/a n/a n/a n/a n/a
daf-2(e1368) 31.82 5.13 102(0) 34 < 0.0001 wild-type 100.0 increase n/a n/a n/a n/a
daf-2(e1368);daf-36 23.60 5.39 84(4) 24 < 0.0001 daf-2(e1368) 29.4 decrease n/a n/a n/a n/a
wild-type 15.38 2.11 91(0) 17 n/a wild-type n/a n/a n/a n/a n/a n/a
daf-36 13.39 2.97 67(15) 14 < 0.0001 wild-type 17.6 decrease n/a n/a n/a n/a
daf-2(e1368) 24.67 5.17 81(0) 26 < 0.0001 wild-type 52.9 increase n/a n/a n/a n/a
daf-2(e1368);daf-36 23.52 5.51 85(0) 26 0.1956 daf-2(e1368) 0.0 no change n/a n/a n/a n/a
Figure 3G wild-type 15.07 2.74 87(2) 15 n/a wild-type n/a n/a n/a n/a n/a n/a
daf-36 9.58 2.54 45(45) 9 < 0.0001 wild-type 40.0 decrease n/a n/a n/a n/a
daf-2(e1368) 24.93 4.37 86(4) 27 < 0.0001 wild-type 80.0 increase n/a n/a n/a n/a
daf-2(e1368);daf-36 23.70 5.45 83(2) 25 0.4328 daf-2(e1368) 7.4 decrease n/a n/a n/a n/a
wild-type 12.89 2.62 85(3) 12 n/a wild-type n/a n/a n/a n/a n/a n/a
daf-36 10.58 1.97 52(37) 10 < 0.0001 wild-type 16.7 decrease n/a n/a n/a n/a
daf-2(e1368) 23.02 5.26 83(4) 24 < 0.0001 wild-type 100.0 increase n/a n/a n/a n/a
daf-2(e1368);daf-36 14.26 5.19 78(6) 15 < 0.0001 daf-2(e1368) 37.5 decrease n/a n/a n/a n/a
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Figure 2A 253F wild-type 14.23 1.81 106(0) 15 n/a wild-type n/a n/a n/a n/a n/a n/a
daf-9 13.24 1.79 88(0) 12 0.0002 wild-type 20.0 decrease n/a n/a n/a n/a
daf-2(e1368) 28.24 5.39 76(0) 29 < 0.0001 wild-type 93.3 increase n/a n/a n/a n/a
daf-2(e1368);daf-9 24.46 4.67 71(0) 26 < 0.0001 daf-2(e1368) 10.3 decrease n/a n/a n/a n/a
wild-type 17.38 2.01 58(14) 17 n/a wild-type n/a n/a n/a n/a n/a n/a
daf-9 14.60 1.91 63(10) 14 < 0.0001 wild-type 17.6 decrease n/a n/a n/a n/a
daf-2(e1368) 34.88 5.50 64(7) 37 < 0.0001 wild-type 117.6 increase n/a n/a n/a n/a
daf-2(e1368);daf-9 30.33 6.57 69(2) 31 < 0.0001 daf-2(e1368) 16.2 decrease n/a n/a n/a n/a
Figure 3H wild-type 15.07 2.74 87(2) 15 n/a wild-type n/a n/a n/a n/a n/a n/a
daf-9 11.80 2.32 90(0) 13 < 0.0001 wild-type 13.3 decrease n/a n/a n/a n/a
daf-2(e1368) 24.93 4.37 86(4) 27 < 0.0001 wild-type 80.0 increase n/a n/a n/a n/a
daf-2(e1368);daf-9 23.99 5.52 79(10) 25 0.2991 daf-2(e1368) 7.4 decrease n/a n/a n/a n/a
wild-type 12.89 2.62 85(3) 12 n/a wild-type n/a n/a n/a n/a n/a n/a
daf-9 11.24 1.80 84(3) 11 < 0.0001 wild-type 8.3 decrease n/a n/a n/a n/a
daf-2(e1368) 23.02 5.26 83(4) 24 < 0.0001 wild-type 100.0 increase n/a n/a n/a n/a
daf-2(e1368);daf-9 21.37 4.62 83(3) 22 0.0005 daf-2(e1368) 8.3 decrease n/a n/a n/a n/a
wild-type (vector) 14.88 2.17 73(0) 16 n/a wild-type (vector) n/a n/a n/a n/a n/a n/a
daf-36 (vector) 15.36 2.17 66(2) 16 0.1511 wild-type (vector) 0.0 no change n/a n/a n/a n/a
daf-36;daf-12 (vector) 13.95 1.61 74(0) 14 < 0.0001 wild-type (vector) 12.5 decrease n/a n/a n/a n/a
wild-type (daf-2 RNAi) 29.35 4.29 75(0) 30 < 0.0001 wild-type (vector) 87.5 increase n/a n/a n/a n/a
daf-36 (daf-2 RNAi) 26.11 4.52 64(5) 27 < 0.0001 wild-type (daf-2 RNAi) 10.0 decrease n/a n/a n/a n/a
daf-36;daf-12 (daf-2 RNAi) 20.28 3.36 71(6) 20 < 0.0001 wild-type (daf-2 RNAi) 33.3 decrease < 0.0001 daf-36 (daf-2 RNAi) 25.9 decrease
wild-type (vector) 18.64 2.31 89(0) 18 n/a wild-type (vector) n/a n/a n/a n/a n/a n/a
daf-36 (vector) 17.55 3.34 73(1) 18 0.1054 wild-type (vector) 0.0 no change n/a n/a n/a n/a
daf-36;daf-12 (vector) 16.10 2.35 77(1) 16 < 0.0001 wild-type (vector) 11.1 decrease n/a n/a n/a n/a
wild-type (daf-2 RNAi) 29.62 3.79 82(5) 31 < 0.0001 wild-type (vector) 72.2 increase n/a n/a n/a n/a
daf-36 (daf-2 RNAi) 21.57 4.77 67(4) 23 < 0.0001 wild-type (daf-2 RNAi) 25.8 decrease n/a n/a n/a n/a
daf-36;daf-12 (daf-2 RNAi) 19.40 2.78 65(2) 18 < 0.0001 wild-type (daf-2 RNAi) 41.9 decrease < 0.0001 daf-36 (daf-2 RNAi) 21.7 decrease
wild-type 16.48 2.23 92(1) 17 n/a wild-type n/a n/a n/a n/a n/a n/a
daf-2(e1368) 31.82 5.13 102(0) 34 < 0.0001 wild-type 100.0 increase n/a n/a n/a n/a
daf-2(e1368);daf-36 23.60 5.39 84(4) 24 < 0.0001 daf-2(e1368) 29.4 decrease n/a n/a n/a n/a
daf-2(e1368);daf-36;daf-12 28.52 5.12 88(0) 31 < 0.0001 daf-2(e1368) 8.8 decrease < 0.0001 daf-2(e1368);daf-36 29.2 increase
wild-type 13.73 2.06 88(2) 14 n/a wild-type n/a n/a n/a n/a n/a n/a
daf-2(e1368) 27.43 7.28 109(0) 30 < 0.0001 wild-type 114.3 increase n/a n/a n/a n/a
daf-2(e1368);daf-36;daf-12 24.73 5.57 87(0) 26 < 0.0001 daf-2(e1368) 13.3 decrease n/a n/a n/a n/a
wild-type 16.43 2.61 88(2) 17 n/a wild-type n/a n/a n/a n/a n/a n/a
daf-2(e1368) 29.07 4.17 109(0) 29 < 0.0001 wild-type 70.6 increase n/a n/a n/a n/a
daf-2(e1368);daf-36 21.85 6.66 13(4) 20 < 0.0001 daf-2(e1368) 31.0 decrease n/a n/a n/a n/a
daf-2(e1368);daf-36;daf-12 26.62 4.42 87(0) 29 < 0.0001 daf-2(e1368) 0.0 no change 0.0234 daf-2(e1368);daf-36 45 increase
wild-type 15.38 2.11 91(0) 17 n/a wild-type n/a n/a n/a n/a n/a n/a
daf-2(e1368) 24.67 5.17 81(0) 26 < 0.0001 wild-type 52.9 increase n/a n/a n/a n/a
daf-2(e1368);daf-36 23.52 5.51 85(0) 26 0.1956 daf-2(e1368) 0.0 no change n/a n/a n/a n/a
daf-2(e1368);daf-36;daf-12 23.18 5.48 82(7) 26 0.0712 daf-2(e1368) 0.0 no change 0.598 daf-2(e1368);daf-36 0.0 no change
wild-type 16.66 3.02 98(1) 16 n/a wild-type n/a n/a n/a n/a n/a n/a
daf-2(e1368) 31.89 6.30 95(2) 34 < 0.0001 wild-type 112.5 increase n/a n/a n/a n/a
daf-2(e1368);daf-36 26.04 7.11 96(2) 29 < 0.0001 daf-2(e1368) 14.7 decrease n/a n/a n/a n/a
daf-2(e1368);daf-36;daf-12 28.10 6.31 97(3) 31 < 0.0001 daf-2(e1368) 8.8 decrease 0.0706 daf-2(e1368);daf-36 6.9 increase
Figure 4C wild-type 15.07 2.74 87(2) 15 n/a wild-type n/a n/a n/a n/a n/a n/a
daf-2(e1368) 24.93 4.37 86(4) 27 < 0.0001 wild-type 80.0 increase n/a n/a n/a n/a
daf-2(e1368);daf-36 23.70 5.45 83(2) 25 0.4328 daf-2(e1368) 7.4 decrease n/a n/a n/a n/a
daf-2(e1368);daf-36;daf-12 22.69 6.47 85(0) 25 0.238 daf-2(e1368) 7.4 decrease 0.6097 daf-2(e1368);daf-36 0.0 no change
wild-type 12.89 2.62 85(3) 12 n/a wild-type n/a n/a n/a n/a n/a n/a
daf-2(e1368) 23.02 5.26 83(4) 24 < 0.0001 wild-type 100.0 increase n/a n/a n/a n/a
daf-2(e1368);daf-36 14.26 5.19 78(6) 15 < 0.0001 daf-2(e1368) 37.5 increase n/a n/a n/a n/a
daf-2(e1368);daf-36;daf-12 23.12 5.86 86(0) 24 0.2774 daf-2(e1368) 0.0 no change < 0.0001 daf-2(e1368);daf-36 60.0 increae
glp-1 20.50 11.97 72(25) 28 n/a glp-1 n/a n/a n/a n/a n/a n/a
glp-1;daf-36 11.73 3.57 91(8) 11 < 0.0001 glp-1 60.7 decrease n/a n/a n/a n/a
glp-1;daf-12 13.33 6.09 96(4) 11 < 0.0001 glp-1 60.7 decrease n/a n/a n/a n/a
glp-1;daf-36;daf-12 14.20 5.52 91(7) 14 < 0.0001 glp-1 50.0 decrease < 0.0001 glp-1;daf-36 27.3 increase
din-1;glp-1;daf-36 22.38 11.22 53(44) 24 0.8829 glp-1 14.3 decrease < 0.0001 glp-1;daf-36 118.2 increase
glp-1 23.34 9.83 90(0) 24 n/a glp-1 n/a n/a n/a n/a n/a n/a
glp-1;daf-36 11.59 1.95 78(2) 11 < 0.0001 glp-1 54.2 decrease n/a n/a n/a n/a
glp-1;daf-12 15.33 5.39 84(0) 14 < 0.0001 glp-1 41.7 decrease n/a n/a n/a n/a
glp-1;daf-36;daf-12 13.79 6.53 80(3) 11 < 0.0001 glp-1 54.2 decrease < 0.0001 glp-1;daf-36 0.0 n/a
din-1;glp-1;daf-36 19.32 8.95 78(1) 16 0.008 glp-1 33.3 decrease < 0.0001 glp-1;daf-36 45.5 increase
glp-1 26.54 8.66 93(6) 29 n/a glp-1 n/a n/a n/a n/a n/a n/a
glp-1;daf-36 13.53 2.67 89(13) 15 < 0.0001 glp-1 48.3 decrease n/a n/a n/a n/a
glp-1;daf-12 17.87 5.55 93(7) 17 < 0.0001 glp-1 41.4 decrease n/a n/a n/a n/a
glp-1;daf-36;daf-12 16.76 5.49 74(21) 17 < 0.0001 glp-1 41.4 decrease < 0.0001 glp-1;daf-36 13.3 increase
glp-1 27.46 9.23 67(16) 32 n/a glp-1 n/a n/a n/a n/a n/a n/a
glp-1;daf-36 15.00 2.89 19(65) 17 < 0.0001 glp-1 46.9 decrease n/a n/a n/a n/a
glp-1;daf-12 17.28 4.84 76(9) 17 < 0.0001 glp-1 46.9 decrease n/a n/a n/a n/a
din-1;glp-1;daf-36 23.14 8.58 139(21) 23 < 0.0001 glp-1 28.1 decrease < 0.0001 glp-1;daf-36 35.3 increase
glp-1 25.61 9.17 69(15) 28 n/a glp-1 n/a n/a n/a n/a n/a n/a
glp-1;daf-36 15.00 2.77 24(60) 17 < 0.0001 glp-1 39.3 decrease n/a n/a n/a n/a
glp-1;daf-12 18.84 6.48 77(6) 19 < 0.0001 glp-1 32.1 decrease n/a n/a n/a n/a
din-1;glp-1;daf-36 25.52 8.91 136(28) 26 0.7629 glp-1 7.1 decrease < 0.0001 glp-1;daf-36 52.9 increase
Figure 4E glp-1 18.63 8.34 91(1) 14 n/a glp-1 n/a n/a n/a n/a n/a n/a
glp-1;daf-36 11.57 1.90 53(35) 11 < 0.0001 glp-1 21.4 decrease n/a n/a n/a n/a
glp-1;daf-12 14.85 7.17 66(15) 13 0.0058 glp-1 7.1 decrease n/a n/a n/a n/a
glp-1;daf-36;daf-12 14.51 4.83 81(7) 13 0.0004 glp-1 7.1 decrease < 0.0001 glp-1;daf-36 18.2 increase
din-1;glp-1;daf-36 16.89 5.32 82(5) 17 0.0389 glp-1 21.4 increase < 0.0001 glp-1;daf-36 54.5 increase
glp-1 18.03 8.68 97(2) 15 n/a glp-1 n/a n/a n/a n/a n/a n/a
glp-1;daf-36 11.02 2.46 53(72) 11 < 0.0001 glp-1 26.7 decrease n/a n/a n/a n/a
glp-1;daf-12 14.80 6.22 96(2) 13 0.0004 glp-1 13.3 decrease n/a n/a n/a n/a
glp-1;daf-36;daf-12 16.08 6.16 95(5) 15 0.0163 glp-1 0.0 no change < 0.0001 glp-1;daf-36 36.4 increase
din-1;glp-1;daf-36 16.81 5.85 95(6) 18 0.0431 glp-1 20.0 increase < 0.0001 glp-1;daf-36 63.6 increase
*Bold typeface indicates replicate pictured in figure
HT115 control for 
Figure 4D
25
HT115 control for 
Figure 3F



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure S2 Percent arrest at 25°
Totals:
mean st. dev. n mean st. dev. n
wild-type 0 0 2474 0 0 2474
daf-12 0 0 1791 0 0 1791
daf-2 (e1368) 92.95 3.02 1503 0 0 1503
daf-2 (e1368);daf-12 0 0 495 0 0 495
daf-2 (e1370) 100 0 1216 0 0 1216
daf-2 (e1370);daf-12 0 0 1122 100 0 1122








1 wild-type 0 0 0 0 525
2 wild-type 0 0 0 0 549
3 wild-type 0 0 0 0 607
4 wild-type 0 0 0 0 793
1 daf-2(e1368) 94.53 1.55 0 0 693
2 daf-2(e1368) 91.37 3.59 0 0 810
1 daf-2(e1370) 100 0 0 0 437
2 daf-2(e1370) 100 0 0 0 362
3 daf-2(e1370) 100 0 0 0 417
1 daf-12 0 0 0 0 327
2 daf-12 0 0 0 0 471
3 daf-12 0 0 0 0 480
4 daf-12 0 0 0 0 513
1 daf-2(e1368);daf-12 0 0 0 0 318
2 daf-2(e1368);daf-12 0 0 0 0 177
1 daf-2(e1370);daf-12 0 0 100 0 299
2 daf-2(e1370);daf-12 0 0 100 0 421
3 daf-2(e1370);daf-12 0 0 100 0 402
Figre S2, significance tests
comparison: daf-2(e1368) v. daf-2(e1368);daf-12 daf-2(e1370) v. daf-2(e1370);daf-12, dauer
p < 0.0001 p < 0.0001
Student's t-Test (calculated using excel) Student's t-Test (calculated using excel)
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Chapter 4: The p120RasGAP family member 
GAP-3 is a novel regulator of dauer arrest and 
longevity in Caenorhabditis elegans3 
Abstract 
In C. elegans, reducing insulin/insulin-like growth factor signaling (ILS) promotes dauer 
arrest and extends life span by promoting the translocation of DAF-16/FoxO to the 
nucleus, where it can induce transcriptional programs that promote survival. The ILS 
pathway in C. elegans consists of conserved PI3K and Akt components that antagonize 
DAF-16/FoxO by promoting its cytoplasmic sequestration. We have discovered the EAK 
pathway, a novel, conserved pathway that inhibits DAF-16/FoxO in parallel to PI3K/Akt 
signaling. The EAK pathway inhibits nuclear DAF-16/FoxO activity without promoting 
its translocation to the cytoplasm. How the EAK pathway inhibits DAF-16/FoxO is not 
known. To illuminate the mechanism underlying EAK pathway inhibition of nuclear 
DAF-16/FoxO activity, we identified a suppressor of eak-7;akt-1 dauer arrest (seak 
gene).  In this study, we implicate gap-3 as a seak gene.  GAP-3 is homologous to human 
RASA1, which was first identified as a RasGAP that antagonizes Ras by promoting its 
GTPase activity, and is one of three putative RasGAPs encoded in the C. elegans 
genome. A spontaneous missense mutation in the RasGAP domain of gap-3 suppresses 
the dauer arrest and life span phenotypes of eak-7;akt-1 double mutant animals. Two 
independent loss-of-function alleles of gap-3 also suppress eak-7;akt-1 dauer arrest, 
confirming gap-3 as a seak gene. In contrast, mutations in gap-1 and gap-2 did not 
influence eak-7;akt-1 dauer arrest.  Notably, the let-60/Ras gain-of-function allele n1046 
suppresses eak-7;akt-1 dauer arrest to a lesser degree than gap-3 loss-of-function alleles, 
suggesting that GAP-3 may have Ras-independent functions in the control of dauer 
arrest. These results implicate GAP-3 as a novel regulator of dauer arrest and longevity.  
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In Caenorhabditis elegans, an insulin/insulin-like growth factor signaling (ILS) pathway, 
a TGF-β-like pathway, and a steroid hormone pathway function to control normal 
reproductive development in a manner that is appropriate for an organism’s given 
environment.  In unfavorable environments, signaling through these pathways is 
abrogated and normal reproductive development is aborted; animals instead undergo 
arrest in an alternative developmental stage known as dauer.  Dauer arrest requires the 
activity of the FoxO transcription factor DAF-16; in the absence of DAF-16/FoxO, 
animals develop reproductively, bypassing the dauer stage even in the absence of ILS 
activity.   
In mammals and in worms, ILS inhibits FoxO transcription factors via phosphorylation 
by Akt and subsequent nuclear export and cytoplasmic sequestration.  Nuclear 
localization, while necessary for FoxO activity, is not sufficient for its full activation (Lin 
et al., 2001; Tsai et al., 2003).  Once in the nucleus, C. elegans DAF-16/FoxO is 
regulated by the EAK pathway, a conserved pathway that functions in parallel to AKT-1 
to inhibit the activity of DAF-16/FoxO (Williams et al., 2010).    
EAK-7 and AKT-1 normally synergize to inhibit the activity of DAF-16/FoxO.  AKT-1 
inhibits DAF-16/FoxO by phosphorylating FoxO, triggering its nuclear export and 
cytoplasmic sequestration.  In the absence of akt-1, DAF-16/FoxO accumulates in the 
nucleus.  EAK-7, in contrast, regulates the activity of specifically the nuclear pool of 
DAF-16/FoxO.  eak-7 mutation has no effect on the subcellular localization of DAF-
16/FoxO, but it is able to enhance phenotypes associated with FoxO activity, including 
dauer arrest and longevity, doing so particularly in contexts which promote nuclear 
accumulation of DAF-16/FoxO (Alam et al., 2010).     
The exact mechanism by which the EAK pathway inhibits nuclear DAF-16/FoxO 
remains unknown.  EAK-7 is likely the most downstream component of the pathway 
based on the strength of its mutant phenotypes as well as its expression pattern; eak-7 is 
the only EAK that is expressed in the same cells as DAF-16/FoxO, and, in contrast to the 
87 
 
other EAKs, mutation of eak-7 alone is sufficient to promote longevity in otherwise wild-
type animals.  EAK-7 is conserved, yet the function of the protein is unknown.  EAK-7 
likely regulates DAF-16/FoxO indirectly, as it is tethered to the plasma membrane via a 
functional N-myristoylation motif. 
Because the mechanism of EAK inhibition of DAF-16/FoxO remains obscure, we are 
interested in uncovering molecules which might be required to relay EAK pathway 
signals to DAF-16/FoxO.  Here, we report the fortuitous identification of a conserved Ras 
GTPase activating protein, GAP-3, as a novel regulator of eak-7;akt-1 dauer arrest and 
longevity.  These findings define a novel function for gap-3 and inform the design of a 
broader approach to uncover new factors that mediate the EAK pathway signal. 
Materials and Methods 
Whole genome sequencing 
Genomic DNA was isolated from the seak strain and the non-suppressed eak-7;akt-1 
double mutant strain by phenol-chloroform extraction and subjected to whole genome 
sequencing using the Illumina HiSeq2000 platform. Approximately 30-40X genome 
coverage was obtained using 100-nucleotide paired-end reads. 
Sequence analysis  
Sequence reads were mapped to the WormBase reference genome build WS220 using the 
short read aligner BWA (Li and Durbin, 2009). Single nucleotide variants (SNVs) were 
identified with the help of the SAMtools toolbox (Li et al., 2009). Each SNV was 
annotated with a custom-made Perl script and gene information available from 
WormBase version WS220. Sequences of the seak mutant strain was compared to that of 
the non-suppressed eak-7;akt-1 parental strain.  All non-synonymous changes and 
predicted splice junction mutations were considered for subsequent analysis.   
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Dauer arrest assays 
Dauer arrest assays were performed at the indicated temperatures in Percival I-36NL 
incubators (Percival Scientific, Inc., Perry, IA) as described (Hu et al., 2006). 
Life span assays 
Life span assays were performed in Percival I-36NL incubators at 20°C.  After alkaline 
hypochlorite treatment and two generations of growth, young adult animals were placed 
onto NGM plates containing 25 g/ml (100 M) 5-fluoro-2’-deoxyuridine (FUDR; 
Sigma) and 10 g/ml nystatin (Sigma) that had been seeded with 20X concentrated E. 
coli OP50.  Assays were conducted at 20˚.  Viability was assessed visually or with gentle 
prodding.  GraphPad Prism (GraphPad Software, La Jolla, CA) was used for data 
representation and statistical analysis.   
RNAi  
Feeding RNAi was performed using variations of standard procedures (Kamath et al., 
2001).  NGM plates containing 5 mM IPTG and 25 μg/ml carbenicillin were seeded with 
500 μl of overnight culture of E. coli HT115 harboring either control L4440 vector or 
indicated RNAi plasmid. Gravid animals cultured on NGM plates seeded with E. coli 
OP50 were picked to assay plates for six-hour egg lays at 20°C. Dauers were scored after 
progeny had been incubated at the assay temperature for 48–60 hours.   
DAF-16A:GFP localization 
daf-16(mu86);zIs356;akt-1(mg306) animals (akt-1 mutants harboring a DAF-16A::GFP 
transgene as the only source of DAF-16) and  gap-3(ga139);daf-16(mu86);zIs356;akt-
1(mg306) were cultured on OP50 E. coli at 20°C. L3 or L4 larvae were mounted on glass 
slides using a thin pad of 2% agarose and 10 mM sodium azide to paralyze the animals.  
Images were captured using an Olympus BX61 epifluorescence compound microscope 
equipped with a Hamamatsu ORCA ER camera and Slidebook 4.0.1 digital microscopy 
software (Intelligent Imaging Innovations) and processed using ImageJ software. Images 
were captured within twenty minutes of mounting animals on slides to prevent variations 
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in DAF-16A::GFP localization due to prolonged stress induced by mounting.  Images 
were then blinded and animals sorted into categories 1 through 5 based on the extent of 
nuclear localization of DAF-16A::GFP. 1 indicates that all cells have only cytoplasmic 
GFP, and 5 indicates that all cells have exclusively nuclear GFP.  
Results 
Identification of a spontaneous dauer suppressor mutation  
Animals harboring a loss-of-function mutation in akt-1 have an increase in nuclear 
localization of DAF-16 (Hertweck et al., 2004), as AKT-1 is responsible for inhibitory 
phosphorylation of DAF-16 which leads to its cytoplasmic sequestration.  EAK-7 
functions to inhibit specifically the nuclear pool of DAF-16; in its absence, DAF-16 
activity increases, promoting enhanced dauer arrest and increased longevity (Alam et al., 
2010).  Together, loss-of-function mutations of both eak-7 and akt-1 synergize to increase 
DAF-16 activity (Alam et al., 2010).  Animals harboring both mutations arrest as dauers 
at elevated temperatures (e.g. 25°C) as a result of this DAF-16 activation.   The strong 
dauer-constitutive phenotype of eak-7;akt-1 double mutants is fully suppressed by daf-
16/FoxO loss-of-function mutations (Alam et al., 2010).  In the process of using eak-
7;akt-1 double mutant animals as a constitutive dauer control, we isolated a strain of 
animals that spontaneously lost its dauer arrest phenotype at 25°C, while maintaining the 
eak-7 and akt-1 loss-of-function mutations.   
Dauer arrest delays the onset of the reproductive period in C. elegans (Hu, 2007).  
Because of this delay in reaching sexual maturity, there is selection pressure on the 
population that favors the accumulation of spontaneous mutations which promote bypass 
of the dauer stage.  Thus, isolation of a strain that lost its arrest phenotype suggested to us 
that the strain acquired a de novo mutation that suppressed dauer, potentially in a gene 
whose activity was normally required to activate DAF-16.   
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Identification of gap-3 as a seak gene 
We therefore pursued identification of the spontaneous suppressor of eak-7;akt-1 (seak) 
mutation via whole-genome DNA sequencing. We isolated and sequenced genomic DNA 
from the eak-7;akt-1;seak strain and an eak-7;akt-1 strain that maintained fully penetrant 
dauer arrest.  Sequences of the two strains were compared, revealing only two non-
synonymous mutations that were present in the eak-7;akt-1;seak strain but absent in the 
eak-7;akt-1 control (Table 4.1).  Linkage analysis revealed the seak phenotype was not 
X-linked, instead showing linkage to LG I, implicating the missense allele dp17 in the 
gene gap-3 as the putative seak mutation.  dp17 is predicted to cause a leucine to 
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Table 4.1: Candidate seak mutations.   
SNVs identified by whole genome sequencing that are present in eak-7;akt-1;seak and 




Figure 4.1: gap-3 is a seak gene. 
Isolated gap-3(dp17) in animals harboring eak-7;akt-1 mutations recapitulates the dauer 
suppression phenotype  of the seak strain, as do loss-of-function alleles of gap-3, ga139 
and zh94. Data are from one representative experiment.  Error bars indicate SEM. 
 
  
Figure 4.2: Genetic structure of gap-1, gap-2, and gap-3, the three putative RasGAPs 
encoded in the C. elegans genome. 
Introns are represented by lines, exons by boxes.  Three alleles of gap-3 lie within the 
RasGAP domain.  
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gap-3 inactivation suppresses dauer arrest in eak-7;akt-1 double mutants 
We outcrossed eak-7;akt-1;seak to separate the two spontaneous mutations in the strain 
(Table 4.1), then tested the dauer arrest phenotype of gap-3(dp17);eak-7;akt-1.  We 
found that gap-3(dp17) recapitulates the suppression of eak-7;akt-1;seak (Figure 4.1), 
confirming that the mutation in gap-3 is responsible for the seak phenotype.  We tested 
the ability of known loss-of-function alleles of gap-3, ga139 and zh94 (Stetak et al., 
2008), to suppress eak-7;akt-1 dauer arrest.  We found that both alleles recapitulate the 
seak phenotype, indicating that the new dp17 allele is likely a loss-of-function mutation, 
and suggesting that activity of GAP-3 is required for dauer arrest in eak-7;akt-1 mutants.  
Suppression of dauer arrest is specific to gap-3  
gap-3 encodes the putative C. elegans p120 RasGAP, the ortholog of human RASA1 
(Stetak et al., 2008), which functions to turn off the activity of Ras.  Ras proteins play 
key roles in signal transduction from receptor tyrosine kinases; as a small G protein, Ras 
alternates between its active and inactive state by hydrolyzing bound GTP to GDP.  GTP-
bound Ras is active and stimulates the activation of downstream mitogen activated 
protein kinase (MAPK) signaling pathways, canonically the Raf/Mek/Erk MAPK 
pathway.  In contrast, GDP-bound Ras is inactive.  Ras possesses weak intrinsic GTP-
hydrolysis activity, but this activity is promoted by the action of GTPase-activating 
proteins (GAPs).  GAPs therefore promote the inactivation of the Ras small GTPase by 
accelerating the hydrolysis of GTP to GDP.   
Most eukaryotes have multiple RasGAPs whose domain structures define four 
subfamilies; the p120 subfamily, the Neurofibromin 1 (NF1) subfamily, the Gap1 
subfamily, and the synGAP subfamily.  The C. elegans genome encodes three putative 
RasGAPs, Gap1 subfamily member gap-1, synGAP member gap-2, and gap-3, the sole 
p120 RasGAP subfamily member.  No clear NF1 ortholog exists in C. elegans.   
The domain structure of gap-3, illustrated in Figure 4.2, is typical of all p120 RasGAPs.  
gap-3 contains a Src homology 3 (SH3) domain flanked by two SH2 domains, a 
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pleckstrin homology (PH) domain, and a C-terminal catalytic domain that is common to 
all RasGAP subfamilies (Stetak et al., 2008).  Notably, the dp17 allele we isolated resides 
within the C-terminal RasGAP domain of the protein, as do both ga139 and zh94.   
The C. elegans genome encodes one Ras protein, LET-60 (Beitel et al., 1990; Han et al., 
1990).  Analogous to mammals, a MAPkinase pathway defined by lin-45/Raf, mek-
2/Mek, and mpk-1/MAPK functions downstream of LET-60/Ras (Han et al., 1993; 
Lackner et al., 1994; Wu and Han, 1994; Kornfeld et al., 1995; Wu et al., 1995). LET-60 
was first discovered based on its role in regulating normal vulval development in the 
worm.  GAP-1 is the predominant inhibitor of LET-60/Ras in vulval development, 
whereas GAP-3 is the main LET-60/Ras inhibitor in meiotic progression of the germ 
cells (Stetak et al., 2008).  In some tissues, all three RasGAPs cooperate to regulate LET-
60/Ras.   
We asked whether seak activity was specific to gap-3 or a trait of all three RasGAPs.  We 
built loss-of-function mutations of gap-1 and gap-2 into the eak-7;akt-1 mutant 
background and tested their impact on dauer arrest.  We found that neither gap-1(ga133) 
nor gap-2(tm748) mutation recapitulates the dauer suppression conferred by gap-3 





Figure 4.3: seak activity is specific to gap-3. 
Mutation of neither gap-1 nor gap-2 does not suppress eak-7;akt-1 dauer arrest. Data are 





gap-3 inactivation suppresses life span in eak-7;akt-1 double mutants 
Because genes required for dauer arrest frequently also impinge on longevity regulation 
in C. elegans, we tested the impact of gap-3 mutation on the life span extension 
phenotype of eak-7;akt-1 mutants.  Consistent with its function as a suppressor of dauer 
arrest, gap-3 mutation partially suppressed life span extension eak-7;akt-1 (Figure 4.4).  
Importantly, gap-3 single mutant life span is not different from wild-type, suggesting 




Figure 4.4: gap-3 inactivation partially suppresses life span extension of eak-7;akt-1 
mutant animals. 
Data are from one representative experiment with approximately 100 animals assayed per 
genotype. 
 
gap-3 inactivation does not suppress dauer arrest of other dauer-constitutive 
mutants.   
To unravel how gap-3 functions to promote dauer arrest, we set out to determine if gap-3 
mutation confers general suppression of dauer arrest, or if it is specific to dauer arrest in 
the context of eak-7 and/or akt-1 mutation.  We found that gap-3(ga139) mutation 
suppresses arrest of eak-7 single mutants, but has no impact on akt-1 single mutants 
(Figure 4.5).  In contrast, gap-3(zh94) suppresses both eak-7 and akt-1 arrest with high 
penetrance, suggesting allelic differences between the two loss-of-function mutations (see 
Figure 4.2 for the nature of the alleles).  Interestingly gap-3 inactivation does not 
completely suppress either eak-7 or akt-1 single mutant, but suppresses the double mutant 
completely, suggesting that GAP-3 might play a role in regulating DAF-16 in the specific 
context of activation downstream of both eak-7 and akt-1 mutation.  We pursued this 




In addition to the EAK pathway and the ILS pathway, a TGFβ-like pathway regulates 
dauer arrest in a DAF-16-dependent manner.  In the TGF-like pathway, a TGF-like 
ligand, DAF-7 (Ren et al., 1996), and its receptors promote reproductive development by 
regulating the activity of three SMAD transcription factor-like molecules DAF-3, DAF-8, 
and DAF-14, and a Sno transcription factor homolog DAF-5 (Georgi et al., 1990; Estevez 
et al., 1993; Patterson et al., 1997; Inoue and Thomas, 2000; da Graca et al., 2004; 
Tewari et al., 2004; Park et al., 2010).  Animals with loss-of-function mutations in the 
SMAD-like transcription factors daf-8 and daf-14 have dauer-constitutive phenotypes at 
elevated temperatures.  We tested the ability of gap-3(ga139) mutation to suppress daf-8 
and daf-14 dauer arrest and found that gap-3(ga139) modestly suppresses arrest of both 
daf-8 and daf-14 mutants; however, the effect was not statistically significant in either 
case (Figure 4.5, p = 0.1523 for comparison of gap-3(ga139);daf-8 to daf-8; p = 0.0544 
for comparison of gap-3(ga139);daf-14 to daf-14).  Collectively, these data suggest that 
GAP-3 regulates dauer arrest predominately in the context of both eak-7 and akt-1 loss.   
 
 
Figure 4.5: gap-3(ga139) mutation suppresses dauer arrest of eak-7 single mutants 
but not of akt-1(null) nor TGFβ-like pathway mutants, daf-8 and daf-14.  
Data are from one representative experiment.  Error bars indicate SEM. 
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gap-3 inactivation does not change nuclear localization of DAF-16::GFP 
Insulin and TGFβ-like regulates dauer arrest by affecting the subcellular localization of 
DAF-16.  Signaling through ILS and TGFβ-like signaling results in nuclear exclusion of 
DAF-16, inhibiting its activity as a transcription factor.  A possible explanation for the 
suppression of dauer arrest when gap-3 activity is reduced is that GAP-3 might normally 
function to promote nuclear accumulation of DAF-16.  To test this hypothesis, we 
assayed the localization of a DAF-16a::GFP fusion protein in the context of gap-
3(ga139) and akt-1(null) mutations.  As expected, animals harboring the DAF-16a::GFP 
fusion construct and an akt-1(null) mutation have predominately nuclear DAF-16a::GFP.  
gap-3 mutation does not change the nucleocytoplasmic distribution of DAF-16a::GFP 
(Figure 4.6), suggesting that the mechanism of suppression of dauer arrest by gap-3 
mutation is not mediated by exclusion of DAF-16 from the nucleus.    
 
 
Figure 4.6: GAP-3 inactivation does not change DAF-16::GFP nuclear localization. 
Data are pooled from three experiments with approximately 30 animals scored per 




Suppression of dauer arrest by gap-3 inactivation is independent of LET-
60/Ras   
We asked whether GAP-3 activation of DAF-16 is mediated by LET-60/Ras, the 
canonical target of gap-3 GAP activity.  We reasoned that if dauer suppression due to 
gap-3 loss-of-function was mediated by activation of Ras, then an activating mutation in 
Ras should phenocopy gap-3 loss-of-function.  A gain-of-function allele of let-60/Ras 
exists which renders Ras insensitive to inactivation by GAP.  We built let-60(n1046) into 
the eak-7;akt-1 background and tested its dauer arrest phenotype.  We found that Ras 
activation does not fully recapitulate dauer suppression in the eak-7;akt-1 background, 
suggesting that, at least in part, GAP-3 function is LET-60/Ras-independent (Figure 4.7). 
 
Figure 4.7: An activating mutation in let-60/Ras that renders Ras insensitive to 
inactivation by GAP activity does not recapitulate gap-3 loss-of-function mutations. 





This Ras-independence spurred us to pursue identification of the causative small GTPase, 
as we hypothesized that gap-3 most likely impacts dauer arrest through its function as a 
GAP.  The C. elegans genome encodes fifty-two small GTPases, eleven of which are in 
the Ras/Rap/Ral superfamily.  We performed an RNAi screen of all small GTPases 
present in the genome-wide RNAi feeding libraries (36 out of 52 total small GTPases, 
including let-60, were screened) to identify potential causative small GTPases.  We 
reasoned that reducing the activity of the causative small GTPase by RNAi in the gap-
3;eak-7;akt-1 mutant should restore dauer arrest.  We tested all clones corresponding to 
small GTPases that were present in the library and found that none of the clones tested, 
including let-60, rescued dauer arrest after one or two generations of feeding RNAi.  In 
addition to the lack of complete coverage of all small GTPases, this experiment is subject 
to the caveat that not all tissues are responsive to RNAi.  Therefore, if GAP-3 exerts its 
function in a tissue refractory to RNAi, such as the nervous system or pharynx, this assay 
will likely be unable to detect a causative GTPase.  It is noteworthy that gap-3 RNAi has 
no effect on eak-7;akt-1 dauer arrest (Supplemental Figure 4.1), suggesting that indeed 
gap-3 might function in a RNAi refractory tissue.   
We took a second approach to identify the GTPase that might interact with GAP-3, 
pursuing a yeast-two hybrid screen of small GTPases.  Using full length gap-3 as well as 
RasGAP domain constructs of both mutant and wild-type gap-3, we screened the small 
GTPases present in the wORFeome (worm Open Reading Frame collection; 42 of 52 
small GTPases, including let-60, were screened).  gap-3 constructs were tested as both 
bait and prey.  This analysis failed to identify any interacting GTPases. In addition to 
having incomplete coverage of all small GTPases, this approach is typified by a high 
false-negative rate.  Despite the failure of these two approaches, we do not exclude the 
possibility that GAP-3 activity in the context of dauer arrest is mediated by its interaction 
with a small GTPase.    
Discussion 
The signaling pathways controlling the dauer decision in C. elegans are well described; 
they include the ILS pathway, TGFβ-like pathway, and the dafachronic acid/DAF-12 
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pathways.  Genetic screens to identify new components of these dauer regulatory 
pathways appear to be saturated, suggesting all known components of the pathways have 
been identified.  Despite this, here we describe the fortuitous identification of a novel 
regulator of dauer arrest, gap-3, whose mutation occurred spontaneously in a genetic 
background that promotes the activation of the DAF-16/FoxO transcription factor.   
We implicate the RASA1 ortholog gap-3 as a suppressor of the constitutive dauer arrest 
phenotype of eak-7;akt-1 double mutant animals (suppressor of eak-7;akt-1, seak 
mutant).  eak-7;akt-1 animals harbor activated DAF-16/FoxO; a spontaneous, loss-of-
function point mutation in the RasGAP domain of gap-3 abrogates dauer arrest in this 
context, suggestion that GAP-3 normally functions to promote dauer arrest, possibly by 
promoting the activation of DAF-16/FoxO.  Furthermore, we find that seak activity is 
specific to gap-3 (Figure 4.3) and likely does not require LET-60/Ras (Figure 4.7).    
Surprisingly, the gap-3 loss-of-function allele ga139 does not significantly impact dauer 
arrest of akt-1 single mutants (Figure 4.5), despite inhibiting eak-7;akt-1 double mutant 
arrest completely (Figure 4.2 and 4.3).  This, together with the observation that gap-3 
mutation does not change the subcellular localization of DAF-16/FoxO (Figure 4.6), 
suggests that gap-3 might mediate specifically the EAK pathway signal to DAF-
16/FoxO.  This hypothesis is consistent with the effect of gap-3 mutation on life span, as 
mutation shortens life span of eak-7;akt-1 mutant animals, but does not reduce life span 
back to wild-type levels (Figure 4.4), suggesting residual DAF-16 activity persists in the 
absence of GAP-3.  It is not yet known how gap-3 mutation affects the ability of DAF-16 
to activate gene expression.  Expression profiling experiments of DAF-16 target genes 
will be revealing in this regard.   
We hypothesize that gap-3 mutation suppresses dauer arrest independently of LET-
60/Ras activation based on our finding that the activating allele let-60(n1046) does not 
phenocopy dauer suppression of gap-3 loss-of-function mutations (Figure 4.7).  This 
prompted an attempt to identify the causative GTPase by two approaches, a yeast-two-
hybrid screen and a targeted RNAi screen.  Both approaches yielded no candidates.  
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Notably, LET-60/Ras was tested in each screen; let-60 knock-down by RNAi did not 
restore dauer arrest in gap-3;eak-7;akt-1 mutants, nor did a let-60 construct physically 
interact with any of the gap-3 constructs tested in the two-hybrid approach.  We do not 
rule out the possibility that gap-3 interacts with a small GTPase given these results.  
Instead, we continue to pursue this line of inquiry by other methodologies. 
A GAP-3 function that is independent of Ras/MAPK activity has not yet been described.  
Given the conservation of gap-3, this novel mechanism might have relevance to disease 
in humans.  Interestingly, patients with loss of function mutations in the RASA1, the 
human ortholog of gap-3, have clinical phenotypes distinct from patients with Ras 
activating mutations, supporting the hypothesis that p120 GAPs might function 
independently of Ras.   
In summary, this work identifies GAP-3 as a novel regulator of C. elegans dauer arrest 
and longevity, possibly via its interaction with the EAK pathway.  We hypothesize that 
activity of gap-3 in the EAK pathway might be the reason that, despite saturation of 
genetic screens in the context of canonical dauer regulatory pathways, gap-3 has never 
before emerged from a dauer suppressor screen.  In light of this discovery, we believe the 
eak-7;akt-1 mutant background in which gap-3 was discovered provides a uniquely 
sensitized background from which to uncover novel DAF-16 modulators.  Moving 
forward, we will pursue a forward genetic screen to identify more seak genes.  seak gene 
identity promises to shed light on the mechanism by which the EAK pathway regulates 







Supplemental Figure 4.1: gap-3 RNAi does not suppress eak-7;akt-1 dauer arrest. 
An RNAi construct corresponding to the RasGAP domain of gap-3 was constructed and 
used for feeding RNAi to animals harboring eak-7 and akt-1 mutations.  gap-3 RNAi did 
not suppress arrest of eak-7;akt-1 animals, in contrast to daf-12 RNAi control, which 
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Chapter 5: Post-embryonic control of 
Caenorhabditis elegans DAF-2 insulin-like 
signaling by the conserved dosage 
compensation protein DPY-214 
Abstract 
During embryogenesis, an essential process known as dosage compensation is initiated to 
equalize gene expression from sex chromosomes. Although much is known about how 
dosage compensation is established, the consequences of modulating the stability of 
dosage compensation post-embryonically are not known. Here we define a role for the 
Caenorhabditis elegans dosage compensation complex (DCC) in the regulation of DAF-2 
insulin-like signaling. In a screen for dauer regulatory genes that control the activity of 
the FoxO transcription factor DAF-16, we isolated three mutant alleles of dpy-21, which 
encodes a conserved DCC component. Knockdown of multiple DCC components in 
hermaphrodite and male animals indicates that the dauer suppression phenotype of dpy-
21 mutants is due to a defect in dosage compensation per se. In dpy-21 mutants, 
expression of several X-linked genes that promote dauer bypass is elevated, including 
four genes encoding components of the DAF-2 insulin-like pathway that antagonize 
DAF-16/FoxO activity. Accordingly, dpy-21 mutation reduced the expression of DAF-
16/FoxO target genes by promoting the exclusion of DAF-16/FoxO from nuclei. Thus, 
dosage compensation enhances dauer arrest by repressing X-linked genes that promote 
reproductive development through the inhibition of DAF-16/FoxO nuclear translocation. 
This work is the first to establish a specific post-embryonic function for dosage 
compensation in any organism. The influence of dosage compensation on dauer arrest, a 
larval developmental fate governed by the integration of multiple environmental inputs 
and signaling outputs, suggests that the dosage compensation machinery may respond to 
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external cues by modulating signaling pathways through chromosome-wide regulation of 
gene expression. 
Introduction 
In the nematode Caenorhabditis elegans, the DAF-2 insulin-like growth factor receptor 
(IGFR) ortholog promotes reproductive development and aging by inhibiting the FoxO 
transcription factor DAF-16 through the AGE-1 phosphoinositide 3-kinase (PI3K) and 
the conserved kinases PDK-1, AKT-1, and AKT-2 (Fielenbach and Antebi, 2008; 
Kenyon, 2010). daf-2 mutants were first isolated in genetic screens for dauer-constitutive 
mutants (Riddle et al., 1981). In replete environments, hatched embryos develop 
reproductively by traversing four larval stages (L1-L4) prior to adulthood. In conditions 
of increased population density, reduced food availability, or elevated temperature, L1 
larvae enter a distinct developmental pathway that culminates in arrest as an alternative, 
long-lived, morphologically distinct third larval stage known as dauer (Riddle, 1988). 
daf-2/IGFR, age-1/PI3K, pdk-1, and akt-1 loss-of-function mutants all have dauer-
constitutive phenotypes; i.e., they undergo dauer arrest in conditions in which wild-type 
animals develop reproductively(Riddle et al., 1981; Vowels and Thomas, 1992; Gottlieb 
and Ruvkun, 1994; Morris et al., 1996; Kimura et al., 1997; Paradis et al., 1999; Ailion 
and Thomas, 2003). The dauer-constitutive phenotype of these mutants requires DAF-
16/FoxO, as loss of daf-16/FoxO function fully suppresses dauer arrest in daf-2/IGFR, 
age-1/PI3K, pdk-1, and akt-1 mutants (Vowels and Thomas, 1992; Gottlieb and Ruvkun, 
1994; Larsen et al., 1995; Paradis et al., 1999; Ailion and Thomas, 2003). Taken together, 
these data indicate that the DAF-2/AGE-1/PDK-1/AKT-1 pathway promotes 
reproductive development by inhibiting DAF-16/FoxO.   
Two other conserved signaling pathways play important roles in dauer regulation. The 
transforming growth factor- (TGF)-like ligand DAF-7 inhibits dauer arrest in parallel 
to the DAF-2/IGFR pathway by signaling through the Type I TGF receptor homolog 
DAF-1 and the Type II receptor homolog DAF-4 to regulate the SnoN homolog DAF-5 
and the SMAD homologs DAF-3, DAF-8, and DAF-14 (Fielenbach and Antebi, 2008). 
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Downstream of the DAF-2/IGFR and DAF-7/TGF pathways, a hormone biosynthetic 
pathway consisting of DAF-36 (Rottiers et al., 2006), DHS-16 (Wollam et al., 2012), and 





steroid ligand that prevents dauer arrest by binding to the DAF-12 nuclear receptor 
(Motola et al., 2006). 
Although insulin- and insulin-like ligand-induced inhibition of FoxO transcription factors 
through nuclear export and cytoplasmic sequestration is a well-established mechanism of 
FoxO regulation, nuclear translocation is not sufficient to fully activate FoxO (Lin et al., 
2001; Tsai et al., 2003). In C. elegans, the EAK proteins comprise a conserved pathway 
that acts in parallel to AKT-1 to control the activity of nuclear DAF-16/FoxO (Williams 
et al., 2010).  eak mutations, while causing a weak dauer-constitutive phenotype in 
isolation, strongly enhance the dauer-constitutive phenotype caused by akt-1 mutations 
(Hu et al., 2006; Zhang et al., 2008; Alam et al., 2010; Dumas et al., 2010). EAK-7, 
which is likely the most downstream component of the known EAK pathway, is a 
conserved protein of unknown function that is expressed in the same tissues as DAF-
16/FoxO. Although EAK-7 likely regulates the nuclear pool of DAF-16/FoxO, it is 
situated at the plasma membrane (Alam et al., 2010), suggesting that it controls DAF-
16/FoxO activity via unknown intermediary molecules. 
We conducted a genetic screen to identify new FoxO regulators that may mediate EAK-7 
action. Herein we describe our initial findings, which reveal an unexpected role for 
dosage compensation in controlling dauer arrest, insulin-like signaling, and FoxO 
transcription factor activity. 
Materials and Methods 
C. elegans strains and maintenance 
The following strains were used in this study: N2 Bristol, CB4856 (Wicks et al., 2001), 
and TJ356 [DAF-16::GFP(zIs356)] (Henderson and Johnson, 2001).  The following 
mutant alleles were used: akt-1(mg306) (Hu et al., 2006), akt-1(ok525) (Hertweck et al., 
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2004), akt-2(ok393) (Hertweck et al., 2004), daf-1(m40) (Georgi et al., 1990), daf-
2(e1368) (Kimura et al., 1997), daf-8(e1393) (Park et al., 2010), daf-9(dh6) and daf-
9(k182) (Gerisch et al., 2001), daf-12(rh61rh411) (Antebi et al., 2000), daf-14(m77) 
(Inoue and Thomas, 2000), daf-16(mu86) (Lin et al., 1997), daf-36(k114) (Rottiers et al., 
2006), dpy-21(e428) (Yonker and Meyer, 2003), dpy-28(y1) (Meyer and Casson, 1986),  
eak-7(tm3188) (Alam et al., 2010), and sdc-2(y46) (Nusbaum and Meyer, 1989).  Double, 
triple, and quadruple mutant animals were constructed by conventional methods.  
Animals were maintained on nematode growth media (NGM) plates seeded with E. coli 
OP50.   
Suppressor of eak-7;akt-1 (seak) screen 
eak-7(tm3188);akt-1(ok525) double mutant animals were mutagenized using N-ethyl-N-
nitrosourea (ENU) at a concentration of 0.5 mM in M9 buffer for four hours at room 
temperature, with gentle agitation (De Stasio and Dorman, 2001). eak-7(tm3188) and akt-
1(ok525) both harbor deletion mutations that are likely to be null alleles (Hertweck et al., 
2004; Alam et al., 2010); these alleles were chosen to minimize the chances of isolating 
informational suppressors such as tRNA anticodon mutants or mutants defective in 
nonsense-mediated mRNA decay. After mutagenesis egg lays were performed with F1 
animals at 25°, and rare F2 dauer bypassors were isolated for further analysis. The dauer 
suppressor phenotype was verified for sixteen independent mutants, indicating that these 
are bonafide seak mutants. Approximately 1200 haploid genomes were screened. 
Whole genome sequencing 
Genomic DNA was isolated from each of the sixteen seak strains and the non-
mutagenized eak-7;akt-1 double mutant strain by phenol-chloroform extraction and 
subjected to whole genome sequencing using the Illumina HiSeq2000 platform. 





Sequence reads were mapped to the WormBase reference genome build WS220 using the 
short read aligner BWA (Li and Durbin, 2009). Single nucleotide variants (SNVs) were 
identified with the help of the SAMtools toolbox (LI et al. 2009). Each SNV was 
annotated with a custom-made Perl script and gene information available from 
WormBase version WS220. Sequences of the seak mutant strains were compared to that 
of the non-mutagenized eak-7;akt-1 parental strain.  All non-synonymous changes and 
predicted splice junction mutations were considered for subsequent analysis.  A total of 
664 such SNVs were identified among the sixteen seak strains. 
Mapping 
Single nucleotide polymorphism mapping was performed using the polymorphic 
Hawaiian CB4856 strain and a set of 48 primer pairs distributed throughout the genome 
(eight per chromosome) that flank DraI restriction site polymorphisms (Davis et al., 
2005). Since the mutagenesis was performed on eak-7;akt-1 double mutant animals, we 
constructed a “Hawaiianized” eak-7(tm3188);akt-1(ok525) double mutant strain for 
mapping. This was generated by outcrossing the original eak-7;akt-1 double mutant ten 
times with CB4856 and identifying eak-7;akt-1 double mutant recombinants harboring 
CB4856 polymorphisms at sites flanking eak-7 and akt-1. Hawaiianized eak-
7(tm3188);akt-1(ok525) double mutants arrested as dauers to the same extent as eak-
7(tm3188);akt-1(ok525) double mutants in the Bristol background, indicating that the 
CB4856 background does not strongly influence dauer arrest in eak-7;akt-1 double 
mutant animals. 
Mapping was performed by crossing seak mutant hermaphrodites (eak-7;akt-1;seak) with 
Hawaiianized eak-7;akt-1 males and isolating F2 dauers and bypassors. After confirming 
the dauer-constitutive and suppressor phenotypes in the following generation, F2 dauers 
and bypassors were pooled and assayed for all 48 DraI SNPs (Davis et al., 2005). 
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Dauer arrest assays 
Dauer arrest assays were performed at the indicated temperatures in Percival I-36NL 
incubators (Percival Scientific, Inc., Perry, IA) as described (Hu et al., 2006). In assays 
involving daf-9(k182) and daf-36(k114) mutants, supplemental cholesterol was not added 
to the NGM assay plates (Gerisch et al., 2001; Rottiers et al., 2006).  In assays involving 
daf-9(dh6) mutants, animals were propagated on NGM plates supplemented with 10 nM 
Δ
7
-DA to rescue the constitutive dauer phenotype of daf-9(dh6) (Sharma et al., 2009). 
Gravid animals raised on Δ
7
-DA were transferred to NGM plates without Δ
7
-DA and 
allowed to lay eggs for the dauer assay.   Raw data and statistical analysis of all dauer 
assays are presented in Table S1. 
RNAi 
Feeding RNAi was performed using variations of standard procedures (Kamath et al., 
2001).  For dauer assays, NGM plates containing 5 mM IPTG and 25 μg/ml carbenicillin 
were seeded with 500 μl of overnight culture of E. coli HT115 harboring either control 
L4440 vector or indicated RNAi plasmid. Gravid animals cultured on NGM plates seeded 
with E. coli OP50 were picked to assay plates for six-hour egg lays at 20°. Dauers were 
scored after progeny had been incubated at the assay temperature for 48–60 hours.   
Male dauer assay 
eak-7;akt-1 males were crossed with eak-7;akt-1 hermaphrodites. Mated hermaphrodites 
were picked for egg lays on RNAi plates. The dauer arrest phenotype of male and 
hermaphrodite cross progeny was scored. The sex of dauers was determined by allowing 
the animals to recover to adulthood.    
RNA preparation and real-time quantitative PCR 
100-200 adult animals were allowed to lay eggs for 6 hours at 20° on NGM plates seeded 
with E. coli OP50.  After egg lay, adults were removed and eggs were shifted to 25°.  L2 
larvae were harvested 24 hours later, washed twice in M9 buffer, then frozen in TRIzol 
reagent (Invitrogen, catalog #15596-026). RNA was extracted using TRIzol, cleaned 
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using the RNeasy Mini Kit (Qiagen, catalog #74104), and treated with DNAse (Qiagen, 
RNase-Free DNase Set, catalog #79254). mRNA was reverse transcribed using the 
SuperScript First-Strand Synthesis System for RT-PCR and oligo-dT primers (Invitrogen, 
catalog #11904-018). 10 ng of cDNA was used as template for real-time quantitative 
PCR amplification using the Absolute Blue QPCR SYBR Green Mix (Thermo Scientific, 
catalog #AB-4166/B) in a 15 μl reaction volume. Reactions were run on an Eppendorf  
realplex Mastercycler. Primer sequences are presented in Table S2.  Relative 
expression levels of each gene were determined using the ΔΔ2Ct method (Nolan et al., 
2006). Gene expression levels were normalized relative to actin (act-1) in the same 
sample, and then relative to the levels of the same gene in the control sample (wild-
type/N2 Bristol or eak-7;akt-1 siblings, as indicated).  Measurements were performed in 
triplicate, with three or four biological replicates for each condition. 
DAF-16A:GFP localization 
daf-16(mu86);zIs356;akt-1(mg306) animals (akt-1 mutants harboring a DAF-16A::GFP 
transgene as the only source of DAF-16) were cultured for two generations on dpy-21 
RNAi or vector control at 20°. L2 or L3 larvae were mounted on glass slides using a thin 
pad of 2% agarose and 10 mM sodium azide to paralyze the animals.  Images were 
captured using an Olympus BX61 epifluorescence compound microscope equipped with 
a Hamamatsu ORCA ER camera and Slidebook 4.0.1 digital microscopy software 
(Intelligent Imaging Innovations) and processed using ImageJ software. Images were 
captured within twenty minutes of mounting animals on slides to prevent variations in 
DAF-16A::GFP localization due to prolonged stress induced by mounting.  Images were 
then blinded and animals sorted into categories 1 through 5 (Supplemental Figure 5.2) 
based on the extent of nuclear localization of DAF-16A::GFP. 1 indicates that all cells 




A genetic screen for novel DAF-16/FoxO regulators 
We pursued a genetic approach to identify molecules that mediate EAK-7 regulation of 
DAF-16/FoxO. The strong dauer-constitutive phenotype of eak-7;akt-1 double mutants is 
fully suppressed by daf-16/FoxO loss-of-function mutations (Alam et al., 2010). We 
reasoned that screening for loss-of-function mutations that suppress the dauer-
constitutive phenotype of eak-7;akt-1 double mutants might identify genes encoding 
novel DAF-16/FoxO activators.  Therefore, we mutagenized eak-7(null);akt-1(null) 
double mutant animals with N-ethyl-N-nitrosourea (ENU) and screened for rare F2 
suppressors of the eak-7;akt-1 dauer-constitutive phenotype (seak mutants). Sixteen 
independent mutant strains were validated as bonafide seak mutants based on consistent 
high penetrance of the seak phenotype in subsequent generations.  
To identify molecular lesions in these mutant strains, we isolated and sequenced genomic 
DNA isolated from non-outcrossed seak mutants and the original non-mutagenized eak-
7;akt-1 double mutant. Subsequently, each seak mutant was subjected to low-resolution 
single nucleotide polymorphism (SNP) mapping with the polymorphic CB4856 strain 
(Wicks et al., 2001; Davis et al., 2005). 
dpy-21 inactivation suppresses dauer arrest in eak-7;akt-1 double mutants 
Three independent seak strains harbored distinct non-synonymous mutations in the 
conserved gene dpy-21 (alleles dp253, dp579 and dp381; Figure 5.1A). Each allele is 
predicted to be a missense mutation affecting a conserved residue in the conserved C-
terminal region of DPY-21 (Figure 5.1A; (Yonker and Meyer, 2003)).  Low-resolution 
SNP mapping indicated that the genomic region containing dpy-21 is linked to the dauer 
suppression phenotype in each of these three strains. dpy-21 RNAi also suppressed the 
dauer-constitutive phenotype of eak-7;akt-1 double mutants (Figure 5.1B). Moreover, the 
dpy-21(e428) null allele [hereafter referred to as “dpy-21(null)”] (Yonker and Meyer, 
2003), as well as dpy-21(dp253), isolated from other mutagenesis-induced SNVs present 
in the original seak strain, also strongly suppressed the dauer-constitutive phenotype of 
114 
 
eak-7;akt-1 double mutants (Figure 5.1C). Taken together, these data indicate that dpy-21 
inactivation suppresses the dauer-constitutive phenotype of eak-7;akt-1 double mutants. 
Therefore, the three mutant alleles that emerged from our screen (Figure 5.1A) are likely 





Figure 5.1: dpy-21 inactivation suppresses the dauer phenotype of eak-7;akt-1 
mutants. 
(A) Genomic structure of the dpy-21 locus and locations of the e428 null allele and three 
alleles isolated in this study. Exons are denoted by boxes and introns by lines. (B-C) 
Effect of reduction of dpy-21activity on the dauer-constitutive phenotype of eak-7;akt-1 
double mutants at 25°C. (B) dpy-21 RNAi suppresses dauer arrest of eak-7;akt-1 mutants 
(13.4% mean dauer arrest in animals exposed to dpy-21 RNAi compared to 75.6% in 
animals exposed to control vector, p = 0.0004 by two-sided t-test). Data are from one 
representative experiment with greater than 250 animals assayed per condition. (C) dpy-
21(null) and dpy-21(dp253) suppress dauer arrest of eak-7;akt-1 mutants (0% mean dauer 
arrest in eak-7;akt-1 dpy-21(e428) triple mutants compared to 94.2% in eak-7;akt-1 
double mutants, p < 0.0001; 0% mean dauer arrest in eak-7;akt-1 dpy-21(dp253) triple 
mutants, p < 0.0001).  Data are pooled from three replicate experiments with at least 1000 
animals assayed per genotype. (B-C) Error bars indicate SEM.  Raw data and statistics 




DPY-21 is a general regulator of dauer arrest 
To determine whether DPY-21 influences dauer arrest generally as opposed to 
specifically in the context of eak-7 and akt-1 mutation, we determined the effect of 
reducing DPY-21 activity on dauer arrest in the background of other dauer-constitutive 
mutations using both dpy-21 RNAi and dpy-21(null) genetic mutation. Dauer arrest is 
controlled by three major signal transduction pathways; in addition to the DAF-2/IGFR 
pathway, the DAF-7 TGF-like pathway and the DAF-9 DA pathway also promote 
reproductive development by inhibiting dauer arrest (Fielenbach and Antebi, 2008). We 
tested the effect of dpy-21 inactivation on dauer arrest in animals harboring mutations in 
each of these three pathways that confer a dauer-constitutive phenotype. 
Reducing the activity of dpy-21 suppressed dauer arrest in animals with reduced DAF-
2/IGFR signaling.  dpy-21 RNAi modestly but significantly suppressed the 25° dauer-
constitutive phenotype of animals harboring daf-2(e1368), which contains a missense 
mutation in the ligand-binding domain of DAF-2/IGFR (Kimura et al., 1997) (Figure 
5.2A), and dpy-21(null) strongly suppressed daf-2(e1368) dauer arrest (Figure 5.2B).  
Additionally, dpy-21(null) suppressed the 27° dauer arrest phenotype of akt-1(ok525), a 
likely null allele harboring a 1251-base-pair deletion eliminating the kinase domain 
(Hertweck et al., 2004) (Supplemental Figure 5.1A). These data indicate that DPY-21 
promotes dauer arrest in the context of reduced DAF-2/IGFR signaling.   
In the TGF-like pathway, a ligand (DAF-7 (Ren et al., 1996)) and its receptors (the 
Type I- and Type II- TGF receptor-like molecules DAF-1 (Georgi et al., 1990) and 
DAF-4 (Estevez et al., 1993), respectively) promote reproductive development by 
regulating the activity of three SMAD-like molecules (DAF-3 (Patterson et al., 1997), 
DAF-8 (Park et al., 2010), and DAF-14 (Inoue and Thomas, 2000)) and a Sno 
transcription factor homolog (DAF-5 (Da Graca et al., 2004; Tewari et al., 2004)). dpy-21 
inactivation also suppresses the dauer-constitutive phenotypes of mutants in the DAF-
7/TGF-like pathway. Reducing dpy-21 activity either by RNAi or via dpy-21(null) 
mutation modestly suppresses dauer arrest caused by the daf-1(m40) and daf-14(m77) 
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nonsense mutations (Georgi et al., 1990; Inoue and Thomas, 2000) (Figures 5.2C-D), 
indicating that DPY-21 also promotes dauer arrest in the context of reduced DAF-7 
TGF-like signaling. The effect of dpy-21 knockdown on the dauer-constitutive 
phenotype caused by the daf-8(e1393) missense allele is unclear; dpy-21 RNAi 
suppresses daf-8(e1393) dauer arrest, but dpy-21(null) slightly enhances daf-8(e1393) 
dauer arrest (Supplemental Figure 5.1B). 
In the dafachronic acid (DA) pathway, multiple biosynthetic enzymes [DAF-36 (Rottiers 
et al., 2006), DHS-16 (Wollam et al., 2012), and DAF-9 (Gerisch et al., 2001; Jia et al., 




-DA), a steroid ligand 
that promotes reproductive development by binding to and inactivating the DAF-12 
nuclear receptor (Motola et al., 2006).  DAF-9 and DAF-12 act downstream of the DAF-
2/IGFR and DAF-7/ TGF-like pathways to control dauer arrest (Gerisch et al., 2001, 
2007; Jia et al., 2002; Mak and Ruvkun, 2004). We tested the effect of dpy-21 
inactivation on the dauer-constitutive phenotype of daf-9(dh6) animals, which harbor a 
null mutation in daf-9 that completely abrogates DA biosynthesis (Gerisch et al., 2001; 
Motola et al., 2006) (hereafter referred to as “daf-9(null)”).  Neither dpy-21 RNAi 
(Figure 5.2E) nor dpy-21(null) (Figure 5.2F) influenced the dauer-constitutive phenotype 
of daf-9(null) mutants at 25°. In contrast, dpy-21(null) modestly suppressed the 27° 
dauer-constitutive phenotypes caused by the hypomorphic daf-9(k182) mutation (Gerisch 
et al., 2001) and the daf-36(k114) null mutation (Rottiers et al., 2006), which reduces the 
biosynthesis of dafachronic acids (Wollam et al., 2011) (Supplemental Figure 5.1C). 
Overall, these data indicate that DPY-21 is required for dauer arrest in the context of 
reduced DAF-2/IGFR signaling and plays a modest role in controlling DAF-7/TGF-like 
and DA hormonal signaling. 
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Figure 5.2: DPY-21 is a 
general regulator of dauer 
arrest. 
Effect of reduction of dpy-
21activity on the dauer-
constitutive phenotypes of 
DAF-2/IGFR pathway, DAF-
7/TGF-like pathway, and 
dafachronic acid pathway 
mutants. (A) dpy-21 RNAi 
suppresses dauer arrest of 
daf-2(e1368)  mutants 
(91.7% mean dauer arrest in 
animals exposed to dpy-21 
RNAi compared to 95.2% in 
animals exposed to control 
vector, p = 0.0275 by two-
sided t-test).  Data are pooled 
from three replicate 
experiments with at least 
1000 animals assayed per 
genotype.  (B) dpy-21(null) 
suppresses dauer arrest of 
daf-2(e1368) (17.2% mean 
dauer arrest in daf-2;dpy-21 
compared to 96.5% in daf-2, 
p < 0.0001). Data are pooled 
from three replicate 
experiments with at least 
1300 animals assayed per genotype. (C) dpy-21 RNAi does not influence or suppresses 
modestly dauer arrest of mutants with reduced DAF-7/TGF-like pathway signaling 
(91.0% mean dauer arrest in daf-1 mutant animals exposed to dpy-21 RNAi compared to 
89.3% in animals exposed to control vector, p = 0.7064; 16.0% mean dauer arrest in daf-
14 mutant animals exposed to dpy-21 RNAi compared to 33.8% in animals exposed to 
control vector, p = 0.0321).  Data are pooled from two replicate experiments with at least 
550 animals assayed per condition.  (D) dpy-21(null) suppresses dauer arrest of daf-1 and 
daf-14 mutants (74.5% mean dauer arrest in daf-1;dpy-21 compared to 94.3% in daf-1, p 
= 0.01; 20.0% mean dauer arrest in daf-14;dpy-21 compared to 42.5% in daf-14, p = 
0.0037). Data are pooled from three replicate experiments with at least 750 animals 
assayed per genotype.  (E and F) Neither dpy-21 RNAi nor dpy-21(null) influence dauer 
arrest in daf-9(null) mutant animals (E) p = 0.2153 for dpy-21 RNAi v. vector control.  
Data are pooled from three replicate experiments with at least 800 animals per condition 
(F) p = 0.9503 for dpy-21(null);daf-9(null) v. daf-9(null). Data are from one 
representative experiment with at least 250 animals per genotype.  (A-F) Error bars 
indicate SEM. Raw data and statistics are presented in Supplemental Table 5.1.  
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Dosage compensation influences dauer arrest 
DPY-21 was originally identified as one of ten components of the C. elegans dosage 
compensation complex (DCC) (Yonker and Meyer, 2003).  This multi-protein complex 
mediates dosage compensation by assembling on both hermaphrodite X chromosomes to 
reduce X-linked gene expression by approximately 50%, thereby equating X-linked gene 
expression between XX hermaphrodites and XO males (Meyer, 2010). Based on its 
established role in dosage compensation, we sought to determine whether the suppression 
of dauer arrest by DPY-21 inactivation was a consequence of reduced dosage 
compensation per se as opposed to impairment of a DPY-21 activity that is independent 
of dosage compensation. To test this, we determined the effect of RNAi inactivation of 
each of the nine other DCC components on the dauer-constitutive phenotype of eak-
7;akt-1 double mutants. Strikingly, we found that reducing the activity of most DCC 
components by RNAi suppresses the dauer-constitutive phenotype of eak-7;akt-1 double 
mutants (Figure 5.3A). It is noteworthy that, whereas loss-of-function mutations in most 
DCC components results in lethality (Riddle DL, 1997), RNAi-based inactivation of 
individual DCC components RNAi for multiple generations is not lethal (data not 
shown), suggesting that RNAi directed against these genes does not completely abrogate 
their function.  Thus, the differential penetrance of dauer suppression observed after 
RNAi-based knockdown of DCC components could be a consequence of variable 
efficacy of RNAi against each targeted gene. 
To further evaluate the role of other DCC components in dauer regulation, we reduced 
the activity of two DCC components via genetic mutation. y1 is a temperature-sensitive 
missense allele of dpy-28 (Plenefisch et al., 1989), which encodes a core DCC subunit 
(Tsai et al., 2008), and y46 is a weak allele of sdc-2 (Nusbaum and Meyer, 1989), which 
encodes a hermaphrodite-specific protein that targets the DCC to X chromosomes 
(Dawes et al., 1999). In accordance with our RNAi-based findings, both dpy-28(y1) and 
sdc-2(y46) completely suppress the dauer-constitutive phenotype of eak-7;akt-1 double 
mutant animals (Figures 5.3B and 5.3C, respectively). Together, these results implicate 
the DCC itself in the control of dauer arrest.  
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Reducing DCC activity could suppress dauer arrest due to a reduction in dosage 
compensation. Alternatively, the dauer suppression phenotype could be a consequence of 
perturbing a novel, dosage-compensation-independent function of the DCC. To 
distinguish between these two possibilities, we took advantage of the observation that 
mutations that disrupt dosage compensation, while causing severe phenotypes in XX 
hermaphrodite animals, are phenotypically silent in XO male animals owing to the fact 
that the DCC does not repress X-linked gene expression in males (Meyer, 2010). 
Therefore, we compared the effect of DCC component RNAi on the dauer-constitutive 
phenotype of eak-7;akt-1 hermaphrodites and males. In contrast to what was observed in 
eak-7;akt-1 hermaphrodites, DCC component RNAi had no effect on the dauer-
constitutive phenotype of eak-7;akt-1 male siblings. In comparison, daf-16/FoxO and 
daf-12 RNAi fully suppressed dauer arrest in eak-7;akt-1 hermaphrodites and males 
(Figure 5.3A). Because DCC-mediated repression does not occur in males, these data 





Figure 5.3: Dosage compensation influences dauer arrest. 
Effect of RNAi of individual dosage compensation complex components on the dauer-
constitutive phenotype of eak-7;akt-1 hermaphrodites (black bars) and males (red bars). 
Reducing expression of most dosage compensation complex components by RNAi 
mediated knock-down suppresses arrest of eak-akt-1 hermaphrodites (p <0.05 for all 
DCC components except for sdc-1 and dpy-30, which were not significantly different 
from vector, as calculated  by a one-way ANOVA).  Dauer arrest in male animals 
subjected to DCC component RNAi clone was not statistically different from vector 
control for any RNAi clone tested.  In contrast, daf-16 and daf-12 RNAi caused 
significant suppression of dauer arrest in both hermaphrodite and male animals (p < 0.001 
for comparison between daf-16 or daf-12 RNAi and vector control).  Data are from a 
single experiment, representative of three replicates, with 100-800 animals scored per 
RNAi condition, per sex. Error bars indicate SEM.  Raw data and statistics are presented 
in Supplemental Table 5.1. 
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Dauer inhibitory genes are upregulated in dpy-21 mutants 
Dosage compensation could potentially influence dauer arrest by controlling the 
expression of X-linked genes that normally function to inhibit dauer arrest. C. elegans 
has nine known X-linked dauer regulatory genes, most of which encode proteins that 
inhibit dauer arrest: mrp-1 (Yabe et al., 2005), daf-3 (Patterson et al., 1997), pdk-1 
(Paradis et al., 1999), ncr-1 (Li et al., 2004), daf-9 (Gerisch et al., 2001; Jia et al., 2002), 
ist-1(Wolkow et al., 2002), daf-12 (Antebi et al., 2000), ftt-2 (Li et al., 2007), and akt-2 
(Paradis and Ruvkun, 1998). Six of these genes have previously been shown to be 
upregulated approximately 2-fold in embryos defective in dosage compensation (Jans et 
al., 2009) (Supplemental Table 5.2). Notably, four of these genes, ist-1, pdk-1, akt-2, and 
ftt-2, encode components of the DAF-2/IGFR pathway, and the products of all four genes 
inhibit DAF-16/FoxO activity (Paradis and Ruvkun, 1998; Paradis et al., 1999; Wolkow 
et al., 2002; Li et al., 2007). 
We quantified expression of these nine dauer regulatory genes in eak-7;akt-1 dpy-21 
triple mutant animals and their eak-7;akt-1 double mutant siblings in animals raised at 
25° for 24 hours after hatching (this time point corresponds to the L2 transition, 
following which animals commit developmentally to either dauer arrest or reproductive 
development).  Expression of most of the X-linked dauer regulatory genes was increased 
approximately 2-fold in eak-7;akt-1 dpy-21 triple mutants compared to eak-7;akt-1 
double mutant siblings, consistent with their modulation by dosage compensation [Figure 
5.4A, left panel, and Supplemental Figure 5.3; (Jans et al., 2009)]. All four genes 
encoding DAF-2/IGFR pathway components that inhibit DAF-16/FoxO were upregulated 
in the context of dpy-21 mutation (ist-1: 2.87-fold increase in eak-7;akt-1 dpy-21 
compared to eak-7;akt-1; pdk-1: increased 1.77-fold; akt-2: increased 3.46-fold; ftt-2: 
increased 1.57-fold). An increase in expression of these proteins would be predicted to 
inhibit DAF-16/FoxO activity by promoting its phosphorylation, nuclear export, and/or 
retention in the cytoplasm. 
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Strikingly, the expression of daf-9, the cytochrome P450 family member that catalyzes 
the final step in DA biosynthesis (Motola et al., 2006), was increased in the context of 
dpy-21 mutation to a much greater extent than would be expected based on a reduction in 
dosage compensation. In four independent biological replicates, daf-9 expression 
increased approximately 8- to 30-fold in eak-7;akt-1 dpy-21 triple mutants compared to 
eak-7;akt-1 siblings. This may be a consequence of suppression of the eak-7;akt-1 dauer-
constitutive phenotype by dpy-21(null), as hypodermal daf-9 expression is induced in 
reproductively growing daf-2 mutant larvae but repressed in daf-2 mutant dauers 
(Gerisch and Antebi, 2004). Notably, although many X-linked genes are upregulated 
approximately two-fold in mutants defective in dosage compensation, the influence of the 
DCC on the expression of individual X-linked genes is highly variable (Jans et al., 2009). 
To determine whether changes in the expression of autosomal dauer inhibitory genes 
contribute to suppression of eak-7;akt-1 dauer arrest by dpy-21 inactivation, we 
quantified the expression of eleven autosomal dauer inhibitory genes in eak-7;akt-1 dpy-
21 triple mutants and their eak-7;akt-1 double mutant siblings (Figure 5.4A, right panel, 
and Supplemental Figure 5.3). In contrast to X-linked dauer regulatory genes, expression 
of autosomal dauer inhibitory genes either did not change or increased only modestly in 
eak-7;akt-1 dpy-21 triple mutants compared to eak-7;akt-1 sibling controls (Figure 5.4A, 
compare left and right panels). This finding is consistent with a model whereby dpy-21 
mutation suppresses dauer arrest via the perturbation of dosage compensation.   
DPY-21 promotes DAF-16/FoxO nuclear localization 
Our genetic analysis suggests that DPY-21 controls dauer arrest primarily by influencing 
DAF-2/IGFR signaling (Figure 5.2). The upregulation of four X-linked genes encoding 
DAF-2/IGFR pathway components that inhibit DAF-16/FoxO activity in the context of 
dpy-21 mutation (Figure 5.4A) is predicted to result in DAF-16/FoxO inhibition due to 
increased nuclear export and cytoplasmic sequestration of DAF-16/FoxO. If this is the 
major mechanism through which DPY-21 controls dauer arrest, then dpy-21 inactivation 
should promote the nuclear export of DAF-16/FoxO. To test this model, we determined 
the effect of dpy-21 RNAi on the subcellular localization of a functional DAF-16A::GFP 
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fusion protein (Henderson and Johnson, 2001) in daf-16(null);akt-1(null) double mutant 
animals (Figures 5.4B and Supplemental Figure 5.2). As previously shown (Zhang et al., 
2008; Alam et al., 2010; Dumas et al., 2010), DAF-16A::GFP was nuclear in many akt-
1(null) animals cultured on E. coli containing a control RNAi construct. Exposure of 
animals of the same genotype to dpy-21 RNAi promoted the nuclear export and 
cytoplasmic retention of DAF-16A::GFP. Therefore, DPY-21 promotes the nuclear 
localization of DAF-16A::GFP. 
DPY-21 activates DAF-16/FoxO 
To determine the impact of dpy-21 inactivation on DAF-16/FoxO activity in dauer 
regulation, we quantified the expression of the DAF-16/FoxO target genes sod-3, mtl-1, 
and dod-3 (Murphy et al., 2003; Oh et al., 2006) in eak-7;akt-1 dpy-21 triple mutants and 
their eak-7;akt-1 double mutant siblings grown at 25° for 24 hours after hatching. As 
previously shown (Alam et al., 2010), the expression of all three genes is increased in a 
daf-16/FoxO-dependent manner in eak-7;akt-1 double mutants (Figure 5.4C). dpy-21 null 
mutation strongly reduced the expression of at least two of the three genes in the eak-
7;akt-1 double mutant background, though not to the same extent as a daf-16 null 
mutation. These results are consistent with a model whereby DPY-21 activates DAF-
16/FoxO, as dpy-21 mutation results in significant but incomplete inhibition of DAF-
16/FoxO activity.   
If suppression of the dauer-constitutive phenotype of eak-7;akt-1 double mutants by dpy-
21 mutation (Figure 5.1C) is due to DAF-16/FoxO inhibition secondary to increases in 
the expression of ist-1, ftt-2, pdk-1, and akt-2 (Figure 5.4), then reducing the expression 
of ist-1, ftt-2, pdk-1, and akt-2 expression by approximately two-fold in eak-7;akt-1 dpy-
21 triple mutants should restore the dauer-constitutive phenotype. As a first step toward 
testing this hypothesis, we determined the dauer-constitutive phenotype of eak-7;akt-1 
dpy-21 triple mutants that were heterozygous for the akt-2(ok393) null mutation. To test 
this model, we sought to reduce the expression of one of the X-linked DAF-2/IGFR 
pathway genes, akt-2, to see if abrogating the dpy-21(null)-induced expression increase 
was sufficient to rescue dauer arrest in eak-7;akt-1 dpy-21(null) animals.   We used akt-
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2(ok393) null heterozygousity to reduce expression of akt-2 by approximately half, and 
then asked whether dauer arrest was restored in the progeny of eak-7;akt-1 dpy-21;akt-
2/+ parents compared to controls with wild-type akt-2.  akt-2(ok393)  null mutation is 
known to synergize with akt-1 mutation to promote dauer arrest, such that akt-1;akt-2 
double homozygous mutant animals arrest constitutively as dauers and do not recover 
(Alam et al., 2010).  We found that eak-7;akt-1 dpy-21(null) mutants heterozygous for 
akt-2(ok393) threw less than 25% dauer progeny, indicating that there was not rescue of 
dauer arrest beyond that expected from normal Mendelian segregation of the mutant akt-
2(ok393) allele in the progeny (Figure 5.4D).  Supporting this inference, all dauer 
progeny from eak-7;akt-1 dpy-21;akt-2/+ parents never recovered from dauer after 
several days at permissive temperature (data not shown), suggesting their genotype was 





Figure 5.4: DPY-21 activates DAF-16/FoxO. 
(A) Effect of dpy-21(null) on the expression of X-linked and autosomal dauer inhibitory 
genes (blue bars) at the L2 stage in dauer-inducing conditions.  Data are normalized to 
expression levels of actin (act-1, orange bars), which is not X-linked. Expression in eak-
7;akt-1 dpy-21 relative to expression in eak-7;akt-1 is shown. The dashed line indicates 
relative expression of one. Data are from a single representative experiment.  Error bars 
indicate 95% confidence interval.  Replicate data are presented in Supplemental Figure 
5.3. (B) DPY-21 promotes DAF-16/FoxO nuclear localization in an akt-1(null) 
background. Localization of DAF-16A::GFP was assessed in L2 or L3 daf-16(null);akt-
1(null) double mutant animals after growth on E. coli harboring either control plasmid or 
dpy-21 RNAi plasmid for two generations.  DAF-16A::GFP localization was scored on 1 
to 5 cytoplasmic/nuclear scale. 1 (blue) = all cells in the animal have completely 
cytoplasmic localization; 2 (green) = most cells in the animal have completely 
cytoplasmic localization; 3 (yellow) = cells have both nuclear and cytoplasmic 
localization; 4 (orange) = most cells in the animal have completely nuclear localization; 5 
(red) = all cells in the animal have completely nuclear localization. See Supplemental 
Figure 5.2 for representative images. Data represent three replicate experiments of 
approximately 30 animals per condition. Error bars indicate SEM. (C) DPY-21 promotes 
DAF-16/FoxO target gene expression. sod-3, mtl-1, and dod-3 expression were quantified 
in L2 larvae under dauer inducing-conditions.  Data are normalized to expression levels 
of actin (act-1) and expressed relative to wild-type N2 Bristol expression. eak-7;akt-
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1(ok525) animals are siblings of eak-7;akt-1 dpy-21 animals. Data are from a single 
experiment.  Error bars indicate 95% confidence interval.  Replicate data are presented in 
Supplemental Figure 5.4. (D)  Reducing akt-2 expression does not rescue dauer arrest of 
eak-7;akt-1 dpy-21(null) triple mutants.  Dauer arrest was assayed in the progeny of eak-
7;akt-1 dpy-21(null);akt-2/+ parents compared to eak-7;akt-1 dpy-21(null) sibling 
controls.  akt-2 heterozygousity did not rescue dauer arrest beyond the 25% predicted 
from segregation of the akt-2 mutant allele in the assayed generation (14.72% dauer 
arrest in progeny of eak-7;akt-1 dpy-21(null);akt-2/+  parents, p = 0.0002 for comparison 
v. theoretical mean value of 25% arrest, by one-sample t-test).  Data are pooled from two 
replicate experiments with at least 500 animals assayed per parental genotype.  Error bars 




Although much is known about the molecular components of the dosage compensation 
machinery and its influence on X-linked gene expression in C. elegans and other 
organisms, the physiologic consequences of dosage compensation are poorly understood. 
We have discovered a new function for dosage compensation in the control of DAF-
2/IGFR signaling and dauer arrest. To our knowledge, this represents the first report of a 
specific post-embryonic function for dosage compensation in any organism. 
We have shown that dpy-21 mutation suppresses dauer arrest due to a defect in dosage 
compensation (Figures 5.1, 5.2, and 5.3). Impaired compensation of X-linked gene 
expression results in the increased expression of dauer inhibitory genes, including four 
genes encoding DAF-2/IGFR signaling components that inhibit DAF-16/FoxO activity 
by promoting its nuclear export and cytoplasmic retention (Figure 5.4A). Accordingly, 
dpy-21 inactivation induces the relocalization of DAF-16/FoxO from nuclei to cytoplasm 
(Figure 5.4B) and inhibits the expression of DAF-16/FoxO target genes (Figure 5.4C). 
Our results support a model in which DPY-21 (and presumably the DCC) controls dauer 
arrest and DAF-16/FoxO activity by modulating the expression of DAF-2/IGFR pathway 





Figure 5.5: Model of DAF-2/IGFR pathway regulation by DPY-21. 
In eak-7;akt-1 double mutant animals, activated DAF-16/FoxO promotes dauer arrest 
(left panel). In eak-7;akt-1 dpy-21 triple mutant animals, increased expression of ist-1, 
pdk-1, akt-2, and ftt-2 contributes to suppression of dauer arrest by promoting the 
inhibition of DAF-16/FoxO (right panel). 
 
 
While our data support a model whereby dpy-21 mutation results in dauer suppression via 
DAF-16/FoxO inhibition as a result of DAF-2/IGFR pathway activation, we cannot rule 
out the contribution of the expression level increases of the multiple X-linked and 
autosomally encoded dauer inhibitory genes, as well as the potential contribution of other 
genes that we did not test that may change in response to dpy-21 mutation.  It is 
noteworthy that all genes tested have dauer constitutive phenotype when mutated, 
indicating that the normal function of the molecules encoded by these genes is to 
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suppress dauer.  All targets assayed either increased or did not change; given the impact 
of these targets on dauer arrest, any increases would be predicted to contribute to 
suppression of dauer.  Because of this, the dauer suppression phenotype we observe in 
dpy-21 mutant animals might be a consequence of expression changes of many genes 
simultaneously.  Consistent with this, reducing akt-2 expression via heterozygous 
deletion of akt-2 (via akt-2(ok393) null allele), did not rescue dauer arrest in the eak-
7;akt-1 dpy-21(null) mutant population (Figure 5.4D), suggesting that expression level 
changes in just one gene are insufficient to cause the observed seak phenotype.  Thus, 
dauer suppression in dpy-21(null) mutant animals may be a result of the concurrent 
increase in expression of akt-2, ist-1, pdk-1 and ftt-2, but we cannot exclude the 
contribution of molecules in other dauer regulatory pathways acting either upstream or 
downstream of DAF-16/FoxO to control dauer arrest.  
The observation that dpy-21(null) suppresses the dauer-constitutive phenotypes of DAF-
2/IGFR pathway mutants to a greater extent that it suppresses DAF-7/TGF-like pathway 
mutants (Figure 5.2) supports the model that the major impact of DPY-21 on dauer 
regulation occurs through the modulation of DAF-16/FoxO subcellular localization.  In 
addition to regulation of localization by the DAF-2/IGFR pathway, the DAF-7/TGF-like 
pathway can also influence DAF-16/FoxO nuclear localization, as daf-7 mutation 
promotes nuclear accumulation of DAF-16/FoxO (Lee et al., 2001; Shaw et al., 2007); 
whether the TGF-like pathway regulates nuclear localization of DAF-16/FoxO 
independently or via regulation of the DAF-2/IGFR pathway is unclear.  The key role of 
the DAF-2/IGFR pathway in the regulation of DAF-16/FoxO nuclear localization thus 
correlates with the strength of dauer suppression we observe in the context of dpy-21 
mutation; dauer arrest of DAF-2/IGFR pathway mutants was strongly suppressed, in 
contrast to modest suppression of arrest in TGF-like pathway mutants and dafachronic 
acid/DAF-12 pathway mutants (Figure 5.2, Supplemental Figure 5.1).    
The establishment of a role for dosage compensation in the control of dauer arrest and 
insulin-like signaling may serve as a platform for investigations into other post-
embryonic processes that might be influenced by dosage compensation, whether dosage 
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compensation is physiologically regulated, and whether it is dysregulated in human 
disease. Indeed, a recent study in mice suggests that sex chromosome dosage per se can 
influence metabolic phenotypes independently of gonadal sex (Chen et al., 2012). 
Furthermore, skewing of X chromosome inactivation increases with age in human 
females and is attenuated in cohorts of female centenarians (Gentilini et al., 2012), 
suggesting a correlation between dysregulation of dosage compensation and the aging 
process. To date, studies on dosage compensation have largely focused on the 
establishment of dosage compensation during embryogenesis; mechanisms governing the 
post-embryonic stability of dosage compensation remain poorly understood. Further 
inquiry into the function and regulation of dosage compensation in post-embryonic 
contexts has the potential to illuminate new functions for dosage compensation and 






Supplemental Figure 5.1: DPY-21 regulates dauer arrest. 
(A) dpy-21(null) suppresses 27°C dauer arrest of akt-1 mutant animals (6.3% dauer arrest 
in akt-1 dpy-21 mutants compared to 92.5% arrest in akt-1, P <0.0001). Data are pooled 
from four replicate experiments with at least 700 animals scored per genotype.  (B) dpy-
21 RNAi suppresses the dauer-constitutive phenotype of the TGF-like pathway mutant 
daf-8(e1393) (11.9% dauer arrest in daf-8 mutants exposed to dpy-21 RNAi compared to 
33.7% arrest in animals exposed to control vector, p = 0.0289). Data are from a single 
representative experiment with at least 450 animals scored per condition.  In contrast, 
dpy-21(null) enhances dauer arrest of daf-8 mutant animals (49.6% dauer arrest in daf-8; 
dpy-21 mutants compared to 24.5% arrest in daf-8, p = 0.0004). Data are pooled from 
three replicate experiments with at least 950 animals scored per genotype. (C) dpy-
21(null) suppresses 27°C, dauer arrest of daf-9(k182) and daf-36(k114) mutants raised on 
plates without supplemental cholesterol (60.7% dauer arrest in dpy-21;daf-9 mutants 
compared to 79.9% arrest in daf-9, p = 0.0269; 82.6% dauer arrest in daf-36 dpy-21 
mutants compared to 98.4% arrest in daf-36, p = 0.0004). Data are pooled from four 
replicate experiments with at least 450 animals scored per genotype. (A-C) Error bars 





Supplemental Figure 5.2: Representative images of animals exhibiting cytoplasmic 
and nuclear DAF-16A::GFP localization. 
The scale ranges from “1” (all cells have completely cytoplasmic localization) to “5” (all 












Supplemental Figure 5.3: X-linked and autosomal gene expression replicate data. 
Data are normalized to actin (act-1, orange bar) and expressed relative to eak-7;akt-1 
dpy-21(wt) expression.  Dashed line indicates relative expression of one.  Each row 
corresponds to one biological replicate, with X-linked and autosomally encoded dauer 





Supplemental Figure 5.4: DAF-16/FoxO target gene expression replicate data. 
Data are normalized to actin (act-1) and expressed relative to wild-type N2 Bristol 
expression.  eak-7;akt-1(ok525) animals are siblings of eak-7;akt-1 dpy-21 animals. Data 



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Std. Deviation 0.22 10.75






eak-7;akt-1 dpy-21;akt-2/+ v. 25%
0.0002
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Mean 0.00 92.46 6.28 Mean 0.00 24.53 49.66
Std. Deviation 0.00 7.08 5.59 Std. Deviation 0.00 13.98 9.18
Std. Error 0.00 2.04 1.61 Std. Error 0.00 4.66 3.06
n 430 827 744 n 430 1665 970
# experiments 1 # experiments 1
comparison comparison
p value p value
sig level sig level
Figure S1B
daf-8(e1393) vector daf-12 dpy-21
Mean 33.73 0.00 11.94
Std. Deviation 10.77 0.00 3.46
Std. Error 6.22 0.00 2.00
n 483 503 491
# experiments
comparison v. vector RNAi v. vector RNAi
p value < 0.0001 0.0289



































Mean 0.00 79.93 60.70 98.39 82.62
Std. Deviation 0.00 11.53 20.68 2.77 9.56
Std. Error 0.00 3.84 6.89 0.92 3.90




sig level * ***
4 4




Supplemental Table 5.2: Primers used for real-time quantitative PCR. 
  
Target Forward Primer (5’ to 3’) Reverse Primer (5’ to 3’) 
sod-3 TATTAAGCGCGACTTCGGTTCCCT  CGTGCTCCCAAACGTCAATTCCAA 
mtl-1 ATGGCTTGCAAGTGTGACTG CACATTTGTCTCCGCACTTG 
dod-3 AAAAAGCCATGTTCCCGAAT GCTGCGAAAAGCAAGAAAAT 
akt-2 TCGTGATATGAAACTCGAAAATTTGC ATTCTGGTGTTCCGCAAAAGGTG 
daf-12 AATGTTTAGAGTTCTTCGGTTTCTTC T TCGTTCATCGGAGGATCAGAG 
daf-3 AGCTGCGAAGGGAAGCAACA CTCAATCCAAACTGGACAATCATG 
daf-9 ATTCCCCACAAAACAATCGAAGAAT GAGATTCAAACACGTTTGGATCG 
ftt-2 ACAGAAACTCGGTTGTCGAGAAG ATAGAAGAAGACAGAGAAGTTGAGAG 
ist-1 ATTGAAGATAACAAAGTGACCAGAAG TGCATGCTGAAGATCTTCTATTCG 
mrp-1 CGACTGAATACGGTTATGGATAGT CACAACATTTGCATCTTTTGCCATTG 
ncr-1 GCGTGCGTTTTGTCGCCAAC C AATCCCACCTTCCGCTTTAAG 
pdk-1 TTTATACATACGCCCAACCGCGT T TTCGATAGTCACCGAGTACCG 
age-1 GGATCATTTGAAGAAAACCCTCTTC TTTGGTAGACCATGATCCATTGAAG 
daf-1 GTACTGTTAGATACCTTGCACC CGGCAGAACATCTCCATCTTC 
daf-11 TTGTTTCGGAGAAGCTGTTATATTAG ACGACCAATTCCTTCAATAGTACG 
daf-14 TTCAAATATCTCAAGCCAATCTTCTT AGCTCGTAGTAAAATATGGTACAC 
daf-2 CCGGTGCGAAGAACGGTG CCCACGTAATATGAATAGCGTCC 
daf-36 GGATGGAAAATGGGAAGTGAAATC ACCATGCTGCTCTGCAACAAG 
daf-4 AATCTCTAGACAAGTTCCCATTCT CTCCTCCTTCTTATTCTGCTGA 
daf-7 GCACACCACTTCAACTTGGC GATCAGCTTGATGTAGTCGTAC 
daf-8 ACATATCAAGACGTCTACTGTCTC CATCGGATTATTCAAATGAGCCTG 
ncr-2 CAATATGGCAATGTCTCTTGGAATC TAGATCCATTACTGACAAGTGCAG 
par-5 GGCTTACCAGGAGGCTCTTG CAAGCGTGCTCTGGAGTGTTC 
scd-2 ATAGAATCCAACTGCACGAACTG CATATTGGACTCTTGCGAGATCT 





Supplemental Table 5.3: Dosage compensation of X-linked dauer regulatory genes. 
Adapted from Jans et al. 2009, Supplemental Table 4, Dosage-Compensated Genes and 
Supplemental Table 5, Non-Compensated Genes. “Not listed” indicates a gene that was 











Increase (fold) in sdc-2 
mutant 
Increase (fold) in dpy-
27 mutant 
 mrp-1 Yes 1.5 1.8 
 daf-3 Yes 1.8 1.7 
 ncr-1 Yes 2.0 1.7 
 ist-1 Yes 2.1 1.8 
 daf-12 Yes 2.6 2.1 
 akt-2 Yes 2.8 3.1 
 pdk-1 Not listed   
 daf-9 Not listed   
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Chapter 6: Conclusions  
This dissertation was motivated by the desire to understand novel paradigms of FoxO 
transcription factor regulation, based on the discovery that the EAK pathway inhibits the 
function of DAF-16/FoxO in parallel to PI3kinase/Akt signaling (Hu et al., 2006; Zhang 
et al., 2008; Alam et al., 2010).   In each chapter, the function of a different protein 
involved in the regulation of DAF-16/FoxO was interrogated; collectively, these 
investigations expand the repertoire of known FoxO regulators and provide potential 
avenues to pursue to modulate the activity of this important transcription factor.  
HSD-1 and dafachronic acids 
In characterizing eak-2/hsd-1, we found that the 3HSD family member acts in the EAK 
pathway, in parallel to AKT-1, to regulate dauer arrest via DAF-16/FoxO and DAF-12. 
Deletion of both hsd-1 and akt-1 synergize to increase expression of DAF-16 target 
genes; we discovered that this expression increase requires DAF-12, suggesting 
cooperativity between DAF-16 and DAF-12 at the level of transcriptional control.   
Phenotypic observations of hsd-1 mutants were consistent with the proposed role of 
HSD-1 in one arm of the bifurcated dafachronic acid biosynthesis pathway; synthesizing 
the 
4
-dafachronic acid precursor, 4-cholesten-3-one (Patel et al., 2008). Collectively, 
this work suggested that DAs made by HSD-1 act in parallel to AKT-1 to promote 
reproductive development via inhibition of the activity of DAF-16/FoxO and the dauer-
promoting function of unliganded DAF-12.  Moreover, it suggested that the HSD-1 
derived DAs promote life span in the context of daf-2/InsR mutation, but do not influence 
life span in the context of germline removal.  This finding differentiated HSD-1-derived 
DA activity with that of DAs made by DAF-36, which are required for life span 
extension in the absence of the germline (Rottiers et al., 2006).   
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At the time of this study, the biochemical activities of HSD-1 and DAF-36 had not been 
characterized.  Additionally, the steroid hormone profiles of hsd-1 and daf-36 mutants 
were unknown.  Since this work, investigation of the hsd-1 and other proposed DA 
biosynthetic enzyme mutants revealed that HSD-1 is not in fact required for 4-cholesten-
3-one production as previously thought (Wollam et al., 2012), suggesting HSD-1 may act 
in an alternative parallel pathway to synthesize DA. This led to the revision of the model 
of DA biosynthesis (Figure 6.1), in which HSD-1 is no longer implicated in the synthesis 
of 
4
-dafachronic acid.  
 
Figure 6.1: Revised model of dafachronic acid biosynthesis. 
Adapted from Wollam et al., 2012. 
In an additional line of inquiry, we collaborated with the Schroeder group to profile the 
metabolome of hsd-1 mutants and controls (Mahanti et al. in revision.).  Interestingly, 
this study failed to detect 
4





-DA is not physiologically relevant. However, given that hsd-1 is only 
expressed in the two XXX cells, failure to find 
4
-DA could simply be indicative of a 
lack of sensitivity to detect the likely low-abundance DA.  Surprisingly, metabolome 
profiling revealed two novel DAs that were differentially present in hsd-1 mutants and 
controls.  The first novel DA, dafa A, is not present in wild-type animals but is found in 
animals lacking functional HSD-1.  The second, dafa-B, is detectable in wild-type 
animals, but is present at elevated levels in hsd-1 mutants.  This suggests that HSD-1 
might normally act on dafa-A and dafa-B, potentially converting them into other DAs.  
We tested dafa-B and found that exogenous administration of it was able to rescue 
phenotypes associated with DA absence, including full rescue of enhanced life span in 
the context of germline ablation.  This finding suggests that the presence of dafa-B, 
abundance of which is elevated in hsd-1 mutants, might be responsible for the failure of 
hsd-1 mutation to reduce germline longevity (Chapter 2; Dumas et al., 2010).   
Our findings with hsd-1 revealed a complex relationship between DAs, DAF-12 and 
DAF-16/FoxO-dependent life span regulation and supported the hypothesis that EAKs 
might exert their function via regulation of dafachronic acid synthesis or secretion.  To 
investigate this further, we analyzed the role of DAs and DAF-12 in the control of DAF-
16/FoxO-dependent life span, as described in Chapter 3.  For these studies, we principally 
used daf-36(null) animals to infer the impact of DAs and DAF-12 in the regulation of life 




-DA (Wollam et 
al., 2011).  Although not included in the publication due to the unclear biochemistry of 
HSD-1, we found that hsd-1(null) animals behaved similarly to daf-36 mutants in the 
context of daf-2/InsR mutant longevity.   Collectively, this study revealed that unliganded 
DAF-12 is detrimental to life span in the context of strong reduction of DAF-2/InsR 
activity; however DAF-12 itself is dispensable for longevity in this context.  In other 
words, as long as DAF-12 does not interact with its co-regulator DIN-1, as is the case 
when DA is present, DAF-12 activity is not required for longevity when DAF-2/InsR 
signaling is reduced.  This suggests that unliganded DAF-12 works to oppose the activity 
of DAF-16/FoxO in the control of life span when ILS is strongly reduced; in contrast, in 
the presence of DA, DAF-12 does not play a significant role.  If the EAK pathway 
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functions to promote DA biosynthesis or otherwise promote DA activity, but is not 
absolutely required for DA synthesis, this finding might explain why the majority of the 
EAKs (namely, eak-3, eak-4, eak-5/sdf-9 and eak-6) appear to play no role in life span 
regulation while strongly regulating dauer arrest (Hu et al., 2006; Zhang et al., 2008).   
seak gene identification 
Shifting focus away from the complexities of DAs and DAF-12 in DAF-16 regulation, 
we pursued a strategy to uncover suppressors of EAK activity (seak genes) in hopes that 
they would shed light on the mechanism of DAF-16/FoxO inhibition by the EAK 
pathway.  We did this by identifying molecules which suppress dauer arrest of eak-7;akt-
1 animals when mutated.  We postulated that SEAK proteins will normally function to 
promote DAF-16/FoxO activity, doing so by acting downstream of eak-7, downstream of 
PI3kinase/Akt, in parallel to both pathways, or, by potentially regulating a key 
downstream target of DAF-16/FoxO (Figure 6.2).   
 
Figure 6.2: Hypothetical role of SEAK protein, suppressors of eak-7;akt-1. 
SEAKs are predicted to activate FoxO by acting in position A, B, or C.  It is also possible 













To date, two seak genes have been characterized, gap-3 (Chapter 4, identified as a 
spontaneous mutation in eak-7;akt-1) and dpy-21 (Chapter 5, identified in our genetic 
screen).  GAP-3 is potentially representative of the very molecules we sought to find; 
those that are required to relay the EAK-7 inhibitory signal to DAF-16/FoxO.  We found 
that gap-3 mutation abrogates dauer arrest of eak-7;akt-1 mutants and eak-7 single 
mutants, but does not substantially impact akt-1 single mutant phenotypes.  This suggests 
that GAP-3 might normally promote DAF-16/FoxO activity downstream of the EAK 
pathway.  Furthermore, consistent with the mechanism of EAK pathway action, gap-3 
mutation does not alter DAF-16 nuclear-cytoplasmic shuttling.  Future studies will 
address the effect of gap-3 mutation on DAF-16 target gene expression and will further 
test the hypothesis that GAP-3 inhibits dauer arrest independently of LET-60/Ras.   
DPY-21 
In contrast to GAP-3, investigation of DPY-21 did not shed any new light onto the 
mechanism of EAK pathway action, but instead revealed a novel mechanism of DAF-
16/FoxO activation by dosage compensation.  DPY-21 appears to regulate DAF-16 via its 
function in the dosage compensation complex (DCC).  The DCC binds to both X 
chromosomes in hermaphrodite animals and turns down gene expression from each by 
one half, thereby equilibrating expression levels to that of males with only one X 
chromosome.  We discovered that deleting dpy-21 was sufficient to increase expression 
of X-linked ILS pathway components, resulting in the inhibition of DAF-16/FoxO 
nuclear translocation and bypass of dauer arrest in dauer inducing conditions.   
To our knowledge, this represents the first post-embryonic function for dosage 
compensation in any organism.  Because dosage compensation can regulate dauer arrest, 
a transition that requires the complex integration of environmental sensing and signal 
transduction, we hypothesize that the activity of DCC may itself be controlled by external 
cues.  Analogous to our observations with the ILS pathway, adjusting DCC activity could 
modulate other signaling pathways through chromosome-wide regulation of gene 
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expression, and therefore could impact diverse physiological processes.  Future work will 
pick up this line of inquiry and will address whether DCC formation or activity is 
responsive to various environmental stimuli, and if so, what impact this has on 
physiology.   
SEAK screen methodology and findings  
Our forward genetic screen resulted in the isolation of sixteen independent seak mutant 
strains, three of which harbor mutant alleles of dpy-21.  Thus, thirteen strains await 
identification of the causative seak mutation.  We currently have hints as to the identity of 
seak candidate genes within several of the remaining strains.  Namely, egl-8, orthologous 
to mammalian phospholipase C-β, has been confirmed as a bona fide seak gene.  
Investigation of egl-8 as a DAF-16/FoxO regulator is underway.  We isolated three 
independent alleles of egl-8 in the seak screen, as was the case for dpy-21.  We 
hypothesized that isolating three alleles of any given gene within a screen of our size 
(664 total SNVs) was highly significant; the confirmation of both dpy-21 and egl-8 (our 
only two triply-mutated genes) as seak genes supports this hypothesis.    
Interestingly, one of our seak strains actually harbors a mutation in both dpy-21 and egl-
8.  Finding one genome that simultaneously harbored mutations in two independent 
genes, both of which cause the same phenotype in isolation, was quite surprising to us.  
That said, we have not yet tested the ability of each mutation, in isolation, to suppress 
dauer arrest; it is possible that one of the two is non-functional and simply a coincidence.  
Moreover, our surprise might simply be illustrative of the novelty of the ‘genome-
sequence first, map later’ approach that we took in this screen.  It is likely that one of 
these two mutations would have been lost had we undertaken the traditional approach to 
mapping the causative mutation in this strain.  It is therefore possible that this type of 
double-hit is common during mutagenesis and selection, but the traditional approach to 
identifying causative mutations has prevented us from detecting it until now.  Looking 
forward, we foresee that the methodology we employed in the seak screen (i.e. pursuing 
genetic screens in conjunction with whole genome sequencing, prior to mapping) will 
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greatly accelerate genetic discovery, as its power is limited only by the cost of 
sequencing.   
Moving forward, seak gene identification and characterization promises to be a fruitful 
strategy to inform our understanding of the biology of DAF-16/FoxO regulation.   With 
luck, EAK proteins, together with SEAK proteins, might inform new avenues for 
therapeutic intervention for the many age-related diseases in which FoxO transcription 
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